

THE LANCET Infectious Diseases

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Cornely OA, Alastruey-Izquierdo A, Arenz D, et al, for the Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infect Dis* 2019; published online Nov 4. [https://doi.org/10.1016/S1473-3099\(19\)30312-3](https://doi.org/10.1016/S1473-3099(19)30312-3).

Appendix to Global guideline for the diagnosis and management of mucormycosis: An initiative of the ECMM in cooperation with the MSG ERC

Introduction


(continued)

Each of the over 150 recommendations tabulated can easily be traced back to the source references for maximum transparency. Any new relevant information, published after this document, can easily be placed in context, and any future updates can straightforwardly build on the tables. For consistency, the same methodology was used as in previous guidance documents.¹⁻³ As with any other guidance document, this guideline intends to assist management decisions. Whether specific recommendations are appropriate when managing individual patients needs to be carefully assessed by the treating physicians. Recommendations cannot and should not replace clinical judgment, and management of a patient with mucormycosis will always need to be individualised. Moreover, recommendations do not guarantee the availability of specific diagnostics or treatments, or reimbursement by healthcare systems. The recommendations do however reflect the current best available management for mucormycosis.

Guideline development

The general approach applied in the ECMM guideline programme has recently been described.⁴ We invited experts to participate in this specific guideline in January 2018. Our selection of experts was determined by their publication activity in the field of mucormycosis, their personal involvement in patient management, and their distribution over the world regions defined by the United Nations <https://unstats.un.org/unsd/methodology/m49/> (Figure S 1).

Figure S 1. Global distribution of authors of the mucormycosis guideline



Systematic approach

The guideline follows the structure and definitions of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines on Candidiasis and the ESCMID/ECMM guidelines on rare invasive fungal infections,^{2,5} which are in accordance with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) and Appraisal of Guidelines for Research & Evaluation (AGREE) systems.^{6,7} Mucormycosis is a rare disease for which only one small randomised trial has been conducted,⁸ and meta-analyses are therefore not applicable. The PICO (population, intervention, comparison, outcome) approach is applied, but in this set of guidelines, PICO is displayed within the tables. Both treatment strategies and diagnostic assays may alter patient course, and are thus regarded as interventions. The fixed sequence of seven columns in the tables is pre-defined, and increases transparency. First, a population is defined; then the intention or objective is stated, followed by the intervention. For that logical sequence, strength of recommendation (SoR) and quality of evidence (QoE) are provided, followed by the references on which the recommendation is based, and an index describing the source of level II evidence. In the last column, a comment may be added as appropriate. SoR and QoE are results of two independent evaluations, thus allowing a strong recommendation even in the absence of the highest quality evidence (**Table 1**). Empty tables covering prerequisite relevant topics were provided at the beginning of

the review exercise for population by the panel, and new tables were created by the authors to meet outstanding need as appropriate.

Authors and contributors

Authors fulfilled the criteria set forth by the International Committee of Medical Journal Editors (ICMJE). For the purposes of this guideline, further requirements reflecting sufficient author contribution were responsiveness throughout the guideline process, receipt of training on the guideline process, and disclosure of conflicts of interest. Contributors are individuals who do not meet all original ICMJE authorship criteria, but have contributed significantly to the guideline work.

Literature search terms


Authors used the following search strings: 'mucormycos* OR zygomycos*', 'ped mucormycos* AND child mucormycos* AND neonate', 'cavernous sinus syndrome or orbital apex syndrome* AND etiology*', 'epidemiology mucormycos* AND etiology*', 'mucormyc* AND susceptibility testing', 'conidiobolomyco*' rhinoconidiobolomyco*' basidiobolomyco*'. For the epidemiology section the following string was used 'mucormyc*[All Fields] OR zygomyc*[All Fields]) AND (case[Title/Abstract] OR cases[Title/Abstract] OR patient[Title/Abstract] OR patients[Title/Abstract] OR report[Title/Abstract]) AND ("2013/01/01"[PDat] : "2017/12/31"[PDat])'. With approximately 200 publications on mucormycosis cases per year, a five-year period was chosen to represent the current distribution of worldwide reports.

Work flow

Having members on the guideline group from 17 time zones is a challenge that we addressed by repeated video conferences on the methodology applied, as well as a video tutorial <https://www.youtube.com/watch?v=1silWTWHwdg>. Assistance to the group was provided by the coordinators (OAC, AC), who supervised and reminded contributors of timelines. Documents were shared among the authors on a password-protected OneDrive repository, and were updated several times per day. Updates on PICO tables were written in red font; after coordinators spell-checked and formatted, *e.g.* for consistent abbreviation use, the font colour was changed to blue for consideration by the group. Once the group discussed and agreed on contents, the font colour was changed to black. When all information on a slide had been agreed upon, the slide was flagged 'final'. Once all slides were final, a writing group (OAC, AAI, DA, SCAC, ED, BH, MH, HEJ, KL, REL, SCM, MMe, ZP, DS., DCS, RW, AC) volunteered to contribute the first draft, which was circulated to all authors and contributors.

At that time, any discrepancies in recommendations were resolved by majority vote. Additional aspects or publications missing in the manuscript could be contributed via a survey sent out to all authors. Once the authors and contributors agreed on a final draft, a 4-week public consultation phase followed. Comments received were evaluated, and either dismissed or led to changes in the manuscript. 51 societies from 33 countries worldwide have reviewed the manuscript and endorsed the guideline (**Figure S 2**).

Figure S 2. National societies endorsing the guideline



The following societies have endorsed this guideline:

International

- International Immunocompromised Host Society

Africa

- Medical Mycology Society of Nigeria
- Federation of Infectious Diseases Societies of Southern Africa

Americas, Latin America/Caribbean

- Brazilian Association of Hematology, Hemotherapy and Cell Therapy
- Mexican Academy of Dermatology
- Sociedad Mexicana de Dermatología (Mexico)

Americas, United States

- Mycoses Study Group Education and Research Consortium (USA)

Americas, Canada

- Association of Medical Microbiology and Infectious Disease (Canada)

Asia

- Asia Fungal Working Group

Asia, Central/Southern

- Clinical Infectious Disease Society (India)
- Society for Indian Human and Animal Mycology
- Iranian Society of Infectious Diseases and Tropical Medicine
- Iranian Society of Medical Mycology

Asia, Eastern/South-Eastern

- Infectious Diseases Society of Taiwan
- Infectious Diseases Society of Thailand with the Thai Medical Mycology Forum

Asia, Western

- Israel Society for Medical Mycology
- Israeli Society of Infectious Diseases
- Lebanese Society of Infectious Diseases and Clinical Microbiology
- Infectious Diseases and Clinical Microbiology Speciality Society of Turkey
- Society for Clinical Microbiologists of Turkey
- Turkish Febrile Neutropenia Society
- Turkish Society for Clinical Microbiology and Infectious Diseases

- Turkish Society of Hospital Infection and Control
 - Turkish Society of Medical Mycology
- Europe
- European Confederation of Medical Mycology
 - European Pediatric Mycology Network
- Europe, Eastern
- Hungarian Society for Infectology and Clinical Microbiology
 - Romanian Society of Medical Mycology and Mycotoxicology
 - Russian Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
 - Serbian Society of Medical Mycology
 - Slovak Society of Chemotherapy
 - Slovak Society of Infectious Diseases
- Europe, Northern
- Irish Fungal Society
 - Nordic Society for Medical Mycology
 - British Infection Association
 - British Society for Medical Mycology
- Europe, Southern
- Hellenic Society of Medical Mycology (Greece)
 - Federazione Italiana di Micopatologia Umana e Animale (Italy)
 - Sorveglianza Epidemiologica Infezioni nelle Emopatie (Italy)
 - Portuguese Association of Medical Mycology
 - Asociación Española de Micología (Spain)
 - Spanish Society of Medical Microbiology and Infectious Diseases
- Europe, Western
- Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (Austria)
 - Austrian Society for Medical Mycology
 - Belgian Society of Human and Animal Mycology
 - French Society for Medical Mycology
 - Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (Germany)
 - Deutsche Gesellschaft für Infektiologie (Germany)
 - German Center for Infection Research
 - German-Speaking Mycological Society
 - Paul-Ehrlich-Society for Chemotherapy (Germany)
 - Dutch Society for Medical Mycology
 - Swiss Society of Microbiology


Epidemiology of mucormycosis

Patient populations

(continued)

Our approach characterises mucormycosis as a global disease and identifies areas from where the epidemiology of mucormycosis may be underreported. It should also be noted that given the difficulty in diagnosing mucormycosis the incidence of disease will likely be underestimated. **Figure S 3** represents cases per million population reported in the medical literature between 2013 and 2017.

Figure S 3. Worldwide distribution of mucormycosis (reported cases per million population)



In a literature search, 505 publications with at least one case of severe infection caused by fungi of the order Mucorales reported between 2013 and 2017 were selected from initially 955 search results. In case the study period began before 2013, reported cases were calculated proportionally. In addition, seven epidemiological studies reporting on mucormycosis cases diagnosed before December 31st, 2017 and published in 2018 were included.^{9,10-520} Incidence estimations and non-severe infections were not included. High rates (> 1 per million) were calculated for Bahrain, Brunei, Lithuania, and Oman, although only three cases or fewer were reported in the past 5 years. Other countries with high rates may just reflect an actively publishing scientific community. The resident population per country was obtained from www.worldometers.info.⁵²¹

Incidence and prevalence of mucormycosis

Incidence and prevalence rates of mucormycosis are difficult to determine for several reasons. Key limitations are the lack of standardised diagnostic strategies, centralised surveillance systems, as well as the limited awareness of this uncommon mould disease in many regions. One major problem regarding varying diagnostic strategies is the common approach of relying only on histopathological findings with lack of growth and identification of the fungus in culture. Apart from many missed or unreported diagnoses, a major obstacle for defining and comparing rates of mucormycosis globally is the lack of harmonised denominators (*e.g.* cases per 1,000 patient days, cases per specific patient population, cases per million population).^{286,522-524}

In Italy, the incidence of mucormycosis was estimated at 0.35 cases per 1 million population per year.⁵²⁵ An older surveillance study performed during 1992-1993 in the San Francisco Bay area that was comprising mostly HIV and non-haematological patients, estimated 1.7 cases per 1 million population per year.⁵²⁶ In general, increasing incidence has been noted in several centres worldwide, especially in developing countries.^{9,179,527-533} Increases have been associated with an ever-growing at-risk population, in particular in patients undergoing haematopoietic stem cell or solid organ transplantation in Europe and the United States and in patients with uncontrolled diabetes mellitus throughout the world.^{365,528,533,534} An increase from 0.7 in 1997 to 1.2 per million population in 2006 was reported in a French surveillance study.⁵²⁷ A similar increase from 2000 to 2009 has been noted in a single centre in Belgium.⁵³¹ A multicentre study in Iran showed a 2.5-fold increase in newly diagnosed cases in 2013 as compared to 2008.⁵²⁹ A similar increase was noted in Lebanon from 2008 to 2017.⁹ In Spain, cases of mucormycosis were reported to increase from 1.2 cases/100,000 hospital admissions in a single centre before 2007 to 3.3 cases since 2007.¹⁷⁹ A similar rise in numbers has been observed in a Swiss study.⁵³⁵ The use of voriconazole for treatment of aspergillosis has also been linked to breakthrough mucormycosis in many centres.^{522,536-538}

Varying rates of mucormycosis have been reported for specific at-risk populations, and for different institutions. A multicentre study in France reported a prevalence of one mucormycosis case per 1,000 acute lymphocytic leukaemia (ALL) patients.⁷⁶ In a single-centre study in France, 25 cases of pulmonary mucormycosis were diagnosed in 2,099 episodes of neutropenia in patients with acute leukaemia.^{76,524} Incidence rates in transplant recipients was reported between 0.2 % and 3.5 % in American and European centres, whereas higher rates have been observed in Indian and Iranian centres.⁵³⁹⁻⁵⁴³ For example, mucormycosis was reported in 12 per 1,000 kidney transplant recipients in an Indian centre but in only 1.1 per 1,000 kidney transplant recipients in a transplant centre

in Brazil.^{540,544} Similar incidences of mucormycosis was reported in burn units in France, Greece, and the USA ranging from 4.9 to 6.3 per 1,000 admissions.^{268,545,546}

Mucormycosis incidence rates compared to other mould infections

Mucormycosis has been known to be the second- or third-most common mould infection after aspergillosis in most countries. Mucormycetes account for up to 10% of moulds isolated from solid organ and HSCT recipients with invasive mould disease.⁵⁴⁷⁻⁵⁵¹ However, the frequency of Mucorales recovery from clinical specimen varies widely across geographic locations, as shown in one Iranian centre, where mucormycetes caused 52.3% of the mould infections in kidney transplant recipients.⁵⁵² In an Iranian multicentre study, an increasing rate compared to other mould infections has been noted from 9.7% in 2008 to 23.7% in 2014.⁵²⁹

Clinical manifestations of mucormycosis

Mucorales cause opportunistic infections in a heterogeneous population, mostly in patients with impaired immune status. This includes patients with uncontrolled diabetes mellitus, haematological malignancy, transplant recipients, patients with CARD9 deficiency, chronic granulomatous diseases, HIV, and neutropenic patients in particular.^{199,250,524,550,553-560} Immunocompetent hosts can also develop mucormycosis, often via direct inoculation of organisms into disrupted skin or mucosa, for example following extensive burn, insect bite or traumatic injury.⁵⁶¹⁻⁵⁶⁷ Additionally, outbreaks of mucormycosis are associated with natural disasters, e.g. Joplin tornado of 2011 and Indian Ocean tsunami of 2004,^{561,567,568} and combat related injuries.^{562,569} Healthcare associated mucormycosis includes catheters, adhesive tapes and tongue depressors; few epidemics are also described.⁵⁷⁰⁻⁵⁷⁸ Patients who inject illicit substances parenterally may develop isolated renal mucormycosis.⁵⁷⁹ Rarely, patients with apparently normal immune system can also develop rhino-orbito-cerebral disease for unclear reasons.⁵⁸⁰⁻⁵⁸³ The clinical presentation of mucormycosis is highly variable, likely due to underlying host immune status,⁹ wide variety of fungal species and strains causing infection, and sites of infection.^{408,559,584} The spectrum ranges from cutaneous and soft tissue, to rhino-orbito-cerebral, sino-pulmonary, and gastrointestinal, to disseminated mucormycosis, whereas, blood stream infections are rarely proven, they likely have occurred in cases of disseminated disease.^{131,408,522,557} Indeed any organ system can be affected, and cases involving the pleura, mediastinum, bones, and oral tissue before or after dental extraction are described.^{379,585,586} Infections are characterised by rapid progression and angioinvasion, one hallmark of mucormycosis, resulting in extensive tissue necrosis and the invasion of adjacent organs and blood vessels.^{203,587-589} However, the clinical presentation can be protean, and the rate of progression of infection can vary from extremely rapid (from symptoms to death in days) to more indolent (from symptoms to death in months).^{132,185,298,499,590-592} Overall, sinusitis, pulmonary and cutaneous disease are the most frequent clinical presentations of mucormycosis.^{408,534,559} The nature of the immune defect bears a close relationship to the site of infection.

Cutaneous and soft tissue mucormycosis

(continued)

Infection can progress into deeper tissue affecting muscles or bone.^{593,594} Cutaneous mucormycosis may also develop in immunocompromised patients, where early recognition and treatment may prevent dissemination.^{595,596} Chronic cutaneous mucormycosis has also been described.⁵⁹⁷

Rhino-orbito-cerebral mucormycosis

(continued)

This form of mucormycosis may sometimes be related to surgical intervention and thus occurs through direct inoculation.⁵¹³ Typical syndromes are cavernous sinus syndrome, acute orbital apex syndrome, and extraocular muscle dysfunction.

Gastrointestinal mucormycosis

(continued)

These infections are characterised by rapid progression with the risk of gastrointestinal perforation. Dissemination has been described to involve the liver, intestines, abdominal wall, kidney, and lung in immunocompetent patients.^{598,599} Due to lack of clinical suspicion, diagnosis of gastrointestinal mucormycosis is often delayed or established post-mortem.⁶⁰⁰⁻⁶⁰² *Mucor indicus* has been found associated with gastrointestinal mucormycosis.⁶⁰³ In children, especially premature neonates the combination of broad-spectrum antibiotics, formula feeding and abdominal mass, specifically in the presence of shock and metabolic acidosis may be suggestive of mucormycosis.^{598,604} In adults with underlying risk factors for mucormycosis abdominal distension and fever accompanied by gastrointestinal bleeding may indicate mucormycosis.⁵⁹⁸

Renal and abdominal mucormycosis

(continued)

Apophysomyces elegans was identified as a cause of isolated renal mucormycosis in two cases.^{605,606} The mechanism for infection of the kidney in immunocompromised hosts may arise from haematogenous dissemination from an infected vascular catheter.⁶⁰⁷

Mucormycosis of bones and joints

Mucormycosis of extracranial bones and joints most commonly occurs by direct inoculation in immunocompetent hosts, especially in patients subjected to prior trauma/accident or previous surgery, followed by haematogenous dissemination.⁵⁸⁶ Infections of the cranial bones also may occur in the process of rhino-orbito-cerebral mucormycosis.⁶⁰⁸

Diagnosing mucormycosis

(continued)

Tests that may not be available, for example BDG, galactomannan, or certain nuclear amplification assays, are not strongly recommended at this time.

Imaging

Evidence – In some case series, a diagnosis of mucormycosis was more likely than aspergillosis if a neutropenic patient exhibited more than ten distinct nodular infiltrates on CT scan, pleural effusion, concomitant sinus disease, or vessel occlusion sign and negative serum and bronchoalveolar lavage (BAL) galactomannan assay results.⁶⁰⁹⁻⁶¹⁴ However, it should be emphasised that no radiographic finding alone has been shown to have adequate specificity or sensitivity to rule in or out pulmonary mucormycosis. Because a wide range of infectious and non-infectious diseases may present with these signs on CT, the diagnostic value of these findings depend on the pre-test probability.^{610,615,616} Vessel occlusion detected by CT pulmonary angiography is a more sensitive and possibly more specific radiographic sign than other common CT findings of invasive mould disease in patients with haematological malignancies.⁶¹⁷

In the sinus, the most common radiographic finding is sinusitis not distinguishable from bacterial infection. While mucosal thickening and partial or complete sinus opacification are frequent, bony erosion is a rare and very late finding.⁶¹⁸⁻⁶²¹ Bone destruction is a late manifestation of possible orbital or cranial infection. Organisms may traverse the lamina papyracea to involve the orbit or invade the emissary veins of the ethmoid sinus to reach the cavernous sinus without bony destruction.⁶²² However, absence of sinus involvement by CT scan has a strong negative predictive value for rhino-orbito-cerebral diseases. MRI is substantially more sensitive than CT scan at detecting orbital and brain involvement; the most common finding of orbital disease is oedema in the orbital muscles.⁶¹⁸⁻⁶²¹

For other body sites, no imaging studies have been shown to be sensitive or specific for mucormycosis. Thus, once mucormycosis is suspected, treatment should be initiated empirically pending final confirmation, which typically requires biopsy and culture. In pulmonary mucormycosis, CT guided needle biopsy was found to be superior in diagnosing pulmonary mucormycosis over BAL.^{623,624} However, since patients with haematological malignancies commonly have thrombocytopenia and coagulopathies, CT guided needle biopsy may be contraindicated and warrant the use of BAL as the initial diagnostic procedure.

Radiographic imaging has also been used to assess response to therapy. After adequate treatment, a decreasing extent of ground-glass opacities surrounding a reversed halo, central necrotic cavity or air-crescent sign may occur with recovery.^{340,625} However, a confounding effect is seen during recovery of neutrophil counts in neutropenic patients. Such patients can have apparent radiographic worsening as the neutrophils recover. This radiographic effect has not been linked to worse clinical outcome. Indeed, in the only randomised controlled trial for mucormycosis ever conducted, the lack of radiographic changes during the first 30 days of therapy did not indicate negative clinical outcome up to 90 days.⁶²⁶ Hence, clinicians should avoid making definitive therapeutic decisions based on short-term radiographic changes, particularly in the absence of changes in a patient's clinical condition.

Table S 1. Recommendations on imaging studies in mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Diabetic with facial pain, sinusitis, proptosis, ophthalmoplegia, amaurosis	To diagnose mucormycosis	Cranial CT	A	Iu	Centeno Radiology 1981 ⁶²⁷ Gamba Radiology 1986 ⁶²⁸ Reed CID 2008 ⁶²⁰	N=12 N=10 N=41 Destruction of bone is rare and late—most common finding is sinusitis indistinguishable from bacterial sinusitis.

Diabetic with facial pain, sinusitis, proptosis, ophthalmoplegia, amaurosis with bone destruction on CT	To determine extent of disease	Cranial MRI for orbit, CNS, cavernous sinus thrombosis	A	Iiu	Mohindra Mycoses 2007 ⁶¹⁹ Koc IntJNeurosci 2007 ⁶¹⁸ Herrera Skull Base 2009 ⁶²¹ Reed CID 2008 ⁶²⁰	N=27 N=3 N=5 N=41 Higher sensitivity of MRI for orbit and CNS
Diabetic with facial pain, sinusitis, proptosis, ophthalmoplegia, amaurosis	To diagnose mucormycosis	Sinus endoscopy	A	III	Plowes Hernandez ActaOtoEsp 2015 ³⁷⁵ Garcia-Romero CaseRepID 2011 ⁶²⁹	N=5 N=2 Consider repeating endoscopy at individual intervals
Asia, specifically China and India: No underlying diseases, flank pain, fever, haematuria, with sterile urine & blood cultures	To diagnose and to determine extent of renal mucormycosis	CT or MRI	A	III	Chugh AmJKidDis 1993 ⁶³⁰	N=4
					Sharma BrJRadiol 2006 ⁶³¹	N=1
					Marak MedMycol 2010 ⁶⁰⁵	N=2
					Dhaliwal Lancet 2015 ⁶³²	N=1, thin cortical enhancement ("cortical rim sign")
Asia, specifically China and India: No underlying diseases, flank pain, fever, haematuria, with sterile urine & blood cultures	To diagnose and determine	abdominal ultrasound	B	III	Sharma BrJRadiol 2006 ⁶³⁴	N=1
					Dhaliwal Lancet 2015 ⁶³²	N=1
Asia, specifically India: Diabetic adult on dialysis OR malnourished/premature child with broad-spectrum antibiotic therapy and with abdominal mass, distension or bilious vomiting, with or without gastrointestinal bleeding	To diagnose mucormycosis	Endoscopic or CT-guided biopsy	A	Iir	Kaur Mycoses 2018 ⁵⁹⁸	N=176
Any	To prove mucormycosis	CT-guided biopsy	A	Iiu	Lass-Flörl CID 2007 ⁶²³ Rickerts CID 2007 ⁶²⁴	N=61 N=27 Higher sensitivity than BAL
Any	To determine disease response or progression	Weekly CT	A	Iiu	Nam EurRadiol 2018 ³⁴⁰ Choo DiagnIntervRadiol 2014 ⁶²⁵	N=20 N=5 In particular in unstable patients
Any	To detect dissemination	PET-CT	B	Iir	Douglas CurrOpID 2017 ⁶³⁵	
Haematologic malignancy	To detect dissemination	Staging images of head/sinuses, chest, abdomen	B	III	Pagano Haematol 2004 ⁶³⁶ Chamilos CID 2005 ⁶⁰⁹	Mucormycosis may extend more rapidly than aspergillosis
Haematologic malignancy with pneumonia	To differentiate mucormycosis from invasive aspergillosis	CT / reversed halo	B	Iiu	Wahba CID 2008 ⁶¹⁶ Marchiori Chest 2012 ⁶¹⁰ Legouge CID 2014 ⁶¹⁵ Jung CMI 2015 ²²⁹ Nam EurRadiol 2018 ³⁴⁰	N=8 N=79 N=16 N=24 N=20 See Figure 3
Haematologic malignancy with pneumonia	To differentiate mucormycosis from invasive aspergillosis	CT / pleural effusion	C	IIh	Chamilos CID 2005 ⁶⁰⁹	N=16
					Marchiori Chest 2012 ⁶¹⁰	N=18
Haematologic malignancy with pneumonia	To differentiate mucormycosis from invasive aspergillosis	CT / >10 nodular infiltrates	C	IIh	Chamilos CID 2005 ⁶⁰⁹ Marchiori Chest 2012 ⁶¹⁰	N=16 N=18
Haematologic malignancy with pneumonia	To differentiate mucormycosis from invasive aspergillosis	CT pulmonary angiography/ vessel occlusion	C	III	Henzler SciRep 2017 ⁶³⁷ Stanzani CID 2015 ⁶¹⁷ Sonnet AJR 2005 ⁶¹¹	N=12 N=2 N=1 Negative serum and BAL galactomannan suggestive of mucormycosis

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; CT, computed tomography; MRI, magnetic resonance tomography; CNS, central nervous system; BAL, bronchoalveolar lavage; PET, positron emission tomography

Histopathology in mucormycosis

Table S 2. Recommendations on interpretation of tissue-based diagnosis of mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To diagnose	Histopathology	A	Ilu	Chakrabarti PGJ 2009 ⁶³⁸ Ben-Ami J Infect 2009 ⁵⁸⁷ Rüping JAC 2010 ⁶³⁹ Skiada CMI 2011 ⁶⁴⁰ Frater APLM2001 ⁶⁴¹	Hyphal diameter of invasive aspergillosis is typically 3-5 µm, whereas those of mucormycosis tend to be 6-16 µm or even up to 25 µm (Figure 4A-C).
Any	To diagnose	Immuno-histochemistry	B	Ilu	Jensen J Pathol 1997 ⁶⁴² Jung CID 2015 ⁶⁴³ Sunagawa JpnJID 2013 ⁴⁵⁴	Monoclonal antibodies against <i>R. arrhizus</i> are commercially available (BioRad, code MCA2577, clone WSSA-RA-1) and have been proven useful for differentiating aspergillosis from mucormycosis. Sensitivity 100%, specificity 100% for mucormycosis. In 23 probable mucormycosis cases, 20 (87%) were positive.
Any	To diagnose	Molecular based tests on <u>fresh</u> tissue	B	Ilu	Schwarz JCM 2006 ⁶⁴⁴ Lass-Flörl CID 2007 ⁶²³ Lau JCM 2007 ⁶⁴⁵ Rickerts CID 2007 ⁶²⁴ Kasai JCM 2008 ⁶⁴⁶ Hrncirova JCM 2010 ⁶⁴⁷ Bernal-Martinez CMI 2013 ⁶⁴⁸ Buitrago JCM 2014 ⁶⁴⁹ Alanio CMI 2015 ⁶⁵⁰ Guinea J PlosOne 2017 ¹⁷⁹ Springer JMM 2016 ⁶⁵¹ Zaman JMM 2017 ⁶⁵²	Not commercially available, limited standardisation, various DNA targets (ITS, 18S, 28S, CytB), various techniques (PCR +/- sequencing, semi-nested PCR, qPCR +/- HRM), Mucorales-specific or panfungal assays, fresh material preferred over paraffin embedded Can be used on several clinical specimens incl. fresh and formalin-fixed paraffin-embedded. Identified Mucorales in 26 cases negative by culture. Fresh tissue is preferred over FFPE tissue.
Any	To diagnose	Molecular based tests on <u>FFPE</u> tissue	B	Ilu	Hayden Diag Mol Path 2002 ⁶⁵³ Nagao J Derm Sci 2005 ⁶⁵⁴ Bialek J Clin Pathol 2005 ⁶⁵⁵ Rickerts EJCMI 2006 ⁶⁵⁶ Lau JCM 2007 ⁶⁴⁵ Hata JCM 2008 ⁶⁵⁷ Dannaoui JCM 2010 ⁶⁵⁸ Hammond JCM 2011 ⁶⁵⁹ Buitrago CMI 2013 ⁶⁶⁰ Gade Med Mycol 2017 ⁶⁶¹ Guinea J PlosOne 2017 ¹⁷⁹ Ghadi Mycoses 2018 ⁶⁶² Bernal-Martinez CMI 2013 ⁶⁴⁸ Salehi JCM 2016 ⁶⁶³ Springer JMM 2016 ^{651,664} Drogari-Apiranthitou PRP 2016 ⁶⁶⁵	Not commercially available, limited standardisation, wide heterogeneity of DNA targets and methods, variable sensitivity Sensitivity 100%, specificity 100% Sensitivity 62%, specificity 100%, identification to genus and species level Can be used on several clinical specimens incl. fresh and formalin-fixed paraffin-embedded. Sensitivity 79%, specificity 100% Fresh tissue is preferred over FFPE tissue.
Autopsy						
All	To diagnose	Histopathology and molecular testing on positive histopathology	A	Ilu	Ruangritchankul IJCE 2015 ⁶⁶⁶ Ghadi Mycoses 2018 ⁶⁶²	Prevalence 0.5%, fungal DNA detected in all histopathologically positive samples.
Haematology	To diagnose	Histopathology	A	Ilu	Lewis Mycoses 2013 ⁶⁶⁷	Increasing incidence, 8-13% of all invasive fungal infections

All	To diagnose	Histopathology	A	llu	Shimodaira Mycoses 2012 ⁶⁶⁸	General hospital in Japan, over 50 yrs, prevalence ~0.1%, higher in haematology
All	To diagnose	Gross pathology	C	llu	Chermetz Mycopathol 2016 ⁶⁹⁵ Davodi ECT 2015 ⁶⁶⁹ Dhaliwal Lancet 2015 ⁶³²	Necrotic and haemorrhagic lesions in all organs incl. skin, haemorrhagic ulceration of skin and gastrointestinal surfaces with black necrotising margins, granulomatous reactions in chronic lesions.
SoR, strength of recommendation; QoE, quality of evidence; PCR, polymerase chain reaction; qPCR, quantitative PCR; RFLP, restriction fragment length polymorphism; FFPE, formalin-fixed-paraffin-embedded						

Antigen biomarkers

Evidence – Antigens to specifically detect Mucorales from clinical samples are not commercially available. In haematology patients or patients with compatible chest CT imaging results, galactomannan testing in blood and BAL has been used to decrease the likelihood of mucormycosis.⁶⁷⁰⁻⁶⁷² A high level of clinical suspicion is warranted since false positives and mixed infections can also occur.⁶⁷³ Most Mucorales have low amounts of (1→3) β-D-glucan (BDG), usually below the limit of detection of the assay, but certain *Rhizopus* spp. could yield positive results.^{441,674-680} A recent publication has developed an ELISA and lateral-flow immunoassay (LFIA) that is able to detect several fungal pathogens including *Mucor* spp. and *Rhizopus arrhizus*.⁶⁸¹ This test could potentially be used as a new rapid diagnostic marker, although as currently developed, it is not able to distinguish Mucorales from Ascomycota.

Mucorales-specific T cells have been evaluated in haematological patients to diagnose and monitor treatment.⁶⁸²⁻⁶⁸⁴ Although these tests are not commercially available, if further developed they might be useful as an alternative, non-invasive diagnostic marker for mucormycosis.

Detection of a serum disaccharide by mass spectrometry (MS) has been useful for the diagnosis of nine out of 10 patients with mucormycosis.⁶⁸⁵ Although this method is unable to distinguish Mucorales from other fungal pathogens, it might be useful in the future if combined with other markers as well as clinical suspicion.

Recommendations — Specific serological markers to detect Mucorales are currently not available. Use of galactomannan to exclude mucormycosis is moderately recommended, although mixed infections do occur. Other assays such as ELISA, LFIA and MS still require validation and can be only marginally recommended currently. The group does not recommend the use of BDG for diagnosis of mucormycosis (**Table S 3**).

Culture and microscopy

Evidence – Culture of specimens is essential for diagnosis of mucormycosis, since it allows species identification and antifungal susceptibility testing. A positive culture from a sterile site confirms the diagnosis, while a positive culture from a non-sterile site must be combined with clinical and radiological evidence of disease to achieve a probable diagnosis.

Unfortunately, culture is falsely negative in up to half of cases of mucormycosis.^{8,686} The organisms grow well *in vitro*, but homogenisation of the tissue may cause viability loss of the nonseptate, fragile hyphal forms of these fungi.⁶⁸⁷ Thus, grinding of specimens should be avoided since this has been associated with lower recovery rates and slicing of tissue is recommended.^{534,584,688-690}

As well, some strains grow better at 30°C than 37°C, and growth at two temperatures may also increase the yield of culture. Cultures of Mucorales are generally characterised by rapidly growing cotton candy like colonies. Identification to genus level can be reached if the isolate sporulate, but microscopic identification to species level requires a high level of mycological expertise. Of note, some species – such as *Apophysomyces elegans* or *Saksenaia vasiformis* – require specific media, for example, water agar with 0.1% yeast extract, potato dextrose agar or Czapek agar, to permit sufficient sporulation for microscopic identification. Subculture of the primary isolate and its incubation at different temperatures can help to differentiate genera. Specific morphological features such as presence of rhizoids, collumellae, shape and size of sporangia and sporangiospores can help in presumptive genus identification (**Table S 3**).⁶⁹¹⁻⁶⁹⁵

Direct microscopy specially using fluorescent brighteners together with dilacerating agents such as KOH can be used for a rapid presumptive diagnosis of mucormycosis, but identification to genus or species level is not possible at this stage. As in histopathological specimens, Mucorales are characterised by non-septate or pauci-septate, irregular, ribbon-like hyphae. As with histopathological investigations, artificial septa may occur due to hyphal folding or growth of one hyphae traversing another. An important diagnostic feature is the wide angle of non-dichotomous branching (≥45-90 degree) and greater hyphal diameter as compared to other filamentous fungi, ranging from 6 to 25 μm (and even larger) (**Figure 4D-F**).^{534,584,623,641,696}

Table S 3. Recommendations on microscopy, culture and antigen biomarkers in mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To diagnose	Direct microscopy preferably using fluorescent brighteners (Calcofluor White, Blankophor)	A	Iu	Lass-Flörl CID 2007 ⁶²³ McDermott OralSurgOralMedOralPathol OralRadiolEndod 2010 ⁶⁹⁶ Roden CID 2005 ⁵³⁴ Glazer Chest 2000 ⁶⁹⁷ Lanternier CID 2012 ⁵⁸⁴ Frater ArchPathLabMed 2001 ⁶⁴¹	Allows rapid presumptive diagnosis, non-septate or pauci-septate, irregular, ribbon-like hyphae, branching angle 45-90°, hyphal diameter 6-25µm. No identification to genus and species level.
Any	To diagnose	Culture	A	Iir	Ribes CMR 2000 ⁶⁹⁰ Roden CID 2005 ⁵³⁴ Kontoyiannis AmJClinPathol 2007 ⁶⁸⁹ Lanternier CID 2012 ⁵⁸⁴ Kennedy CMI 2016 ⁶⁸⁸	Culture is essential since it allows species identification and susceptibility testing. Avoid grinding of clinical sample. Rapidly growing cotton-candy like colonies indicate Mucorales.
Any	To identify to genus level	Culture conditions including incubation at 30°C and 37°C	A	Iir	Padhye JCM 1988 ⁶⁹⁴ Alvarez JCM 2010 ⁶⁹¹ Garcia-Hermoso MBio 2018 ⁶⁹⁸ De Hoog CBS 2001 ⁶⁹² Walsh ASM Press 2018 ⁶⁹⁵	Microscopic identification can be performed if isolates sporulate in culture, but requires high level of expertise. Incubation at different temperatures helps to differentiate genera.
Haematology patients	To exclude mucormycosis	Galactomannan ODI in blood	B	Iu	Maertens CID 2005 ⁶⁷¹	N=1/117 missed mucormycosis; if galactomannan ODI negative, consider false negative, mucormycosis, or alternative diagnosis; if galactomannan ODI positive, consider invasive aspergillosis, mixed infection or false positive result
Any with positive chest CT imaging	To exclude mucormycosis	Galactomannan ODI in BAL	B	III	Sinko TID 2008 ⁶⁷² Borras JCM 2010 ⁶⁷⁰	N=2 missed mucormycoses
Haematology patients	To diagnose	(1→3)-β-D-glucan in blood	D	Iu	Odabasi MedMycol 2006 ⁶⁷⁹ Ostrosky-Zeichner CID 2005 ⁶⁸⁰ Chamilos PLOS One 2010 ⁶⁷⁵ Ibrahim AAC 2005 ⁶⁷⁷ Angebauld OFID 2016 ⁶⁷⁴ Son PLOS One 2017 ⁴⁴¹ Liss Mycoses 2016 ⁶⁷⁸ Egger JInfect 2018 ⁶⁷⁶	Some <i>Rhizopus</i> spp. contain 1,3-β-D-glucan at a concentration above the threshold of detection
Haematology patients	To diagnose and monitor treatment	ELISpot or mucormycosis directed CD4+CD154+cells	C	Iu	Potenza PLOS One 2016 ⁶⁸⁴ Potenza Blood 2011 ⁶⁸³ Bacher AJRCCM 2015 ⁶⁸² Page IJMM 2018 ⁶⁹⁹	Not commercially available
Any	To diagnose	ELISA and LFIA	C	III	Burnham-Marusich mSphere 2018 ⁶⁸¹	Potential new rapid diagnostic marker. Not discriminatory of Mucorales vs. Ascomycota

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; ODI, optical density index; BAL, bronchoalveolar lavage; ELISpot, enzyme-linked immuno spot; ELISA, enzyme-linked immunosorbent assay; LFIA, lateral-flow immunoassay

Susceptibility testing

Evidence – The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) have developed standardised methodologies for antifungal susceptibility testing of Mucorales.^{700,701} These methods recommend 24 hours incubation time for this group. Agreement between these two methods has been found to be high (**Table S 4**), especially for triazoles, although EUCAST minimum inhibitory concentrations (MICs) tend to be higher than those of CLSI.⁷⁰²⁻⁷⁰⁴ Commercial methods such as E-test® have been evaluated for Mucorales yielding, in some cases, conflicting results with standard methods, especially for amphotericin B and posaconazole.⁷⁰⁵⁻⁷⁰⁷

Epidemiological cut-off values have been determined for some species but clinical breakpoints have not been defined, by either the EUCAST or the CLSI, and as a result, classification of isolates as susceptible or resistant is not possible.⁷⁰⁸ *In vitro* MICs show that amphotericin B is the most active compound against most species within the order, although some such as *Cunninghamella* spp. have higher MICs.⁷⁰⁹⁻⁷¹² Posaconazole has two-fold (EUCAST) to three-fold (CLSI) fold lower geometric MICs than isavuconazole, while isavuconazole reaches 3-4 times higher blood concentrations.^{702,713} *Rhizopus* spp. usually have high MICs of posaconazole⁷¹⁴ whereas isavuconazole demonstrated reduced *in vitro* activity against *Mucor circinelloides*.⁷⁰² Other triazoles have MICs

that are above the clinically achievable drug concentrations.⁷⁰² Itraconazole showed variable MICs that have been reported to be strain-dependent. Voriconazole and echinocandins show high MICs against these fungi.^{703,704,707-712,715-721}

High doses of amphotericin B were effective against experimental infections by Mucorales in mice.^{722,723} Murine models of infections with *Rhizopus microsporus* and *R. arrhizus* have shown good correlation between posaconazole MICs and *in vivo* response.⁷²⁴⁻⁷²⁶ Correlation between lower amphotericin B MICs and better outcomes has also been reported in patients with mucormycosis.^{715,727} However, it should be emphasised that no clinical data are available to validate breakpoints for any antifungal drug against the Mucorales.

Antifungal combinations against these fungi have been studied *in vitro* in a few studies, and findings have shown synergistic combinations against some strains and species.^{707,728,729} However, their correlation with the clinical outcome needs to be further analysed (Table S 4).

Table S 4. Recommendations on antifungal susceptibility testing in mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To establish epidemiologic knowledge	Susceptibility testing	A	Ilu	Vitale JCM 2012 ⁷¹²	N=66
					Almyroudis AAC 2007 ⁷¹¹	N=217
					Dannaoui JAC 2003 ⁷¹⁶	N=36
					Sun AAC 2002 ⁷²⁰	N=37
					Torres-Narbona AAC 2007 ⁷²¹	N=45
					Alastruey-Izquierdo AAC 2009 ⁷⁰⁹	N=77
					Chakrabarti JCM 2010 ⁷¹⁵	N=18
					Chowdhary AAC 2015 ⁷⁰⁴	N=124
					Chowdhary Mycoses 2014 ⁷⁰³	N=80
					Espinel-Ingroff AAC 2015 ⁷⁰⁸	N=894
					Alastruey-Izquierdo CMI 2009 ⁷¹⁴	Review
					Halliday IJAA 2016 ⁷¹⁷	N=14
					Jain Mycopathologia 2015 ⁷¹⁸	N=9
					Arikan Med Mycol 2008 ⁷⁰⁷	N=11
Singh Mycoses 2005 ⁷¹⁹	N=15					
Guinea PlosOne 2017 ⁷¹⁹	N=19					
Any	To guide treatment	Correlation of MIC/MFC with outcome	B	III	Rodriguez AAC 2009 ⁷²⁴ Rodriguez AAC 2010 ⁷²⁵	Animal, posaconazole more effective in <i>R. microsporus</i> & <i>R. arrhizus</i> strains with MIC 0.25 µg/ml as compared to those with MIC 2 µg/ml.
					Spreghini JAC 2010 ⁷²⁶	N=1 strain <i>R. arrhizus</i> , high posaconazole MFC associated with failure
Any	To support combination treatment	Synergy testing	C	Ilu	Biswas JAC 2013 ⁷²⁸	N=10, 3/10 synergy miltefosine/voriconazole, 5/10 synergy miltefosine/posaconazole
					Dannaoui AAC 2002 ⁷²⁹	N=35, 25% synergy amphotericin B/terbinafine, 44% synergy voriconazole/terbinafine
Any	To guide treatment	EUCAST / CLSI reference microdilution methods	C	Ilu	CLSI M38-A2 ⁷³⁰ EUCAST ⁷⁰⁰ Espinel-Ingroff AAC 2015 ⁷⁰⁸ Chowdhary Mycoses 2014 ⁷⁰³	Recommended incubation 24h, no data for clear correlation between MIC and clinical outcome 87% agreement between Etest and CLSI amphotericin B MIC, EUCAST MIC higher than CLSI MIC
					Chowdhary AAC 2015 ⁷⁰⁴	essential agreement between isavuconazole 98%, posaconazole 87%, amphotericin B 66%
					Arendrup AAC 2015 ⁷⁰²	N=72, essential agreement 75-83% for isavuconazole
					Chakrabarti JCM 2010 ⁷¹⁵	N=18, <i>A. elegans</i> , limited data, suggests <i>in vitro</i> and <i>in vivo</i> correlation
Any	To guide treatment	Correlation of CLSI MIC with outcome	C	Ilu	Lamoth JCM 2016 ⁷²⁷	Some correlation of amphotericin B MIC
					Caramalho AAC 2015 ⁷⁰⁵ Lamoth JCM 2015 ⁷⁰⁶	Conflicting results about correlation between E-test® and reference methods

SoR, strength of recommendation; QoE, quality of evidence; N, number of strains investigated; MIC, minimum inhibitory concentration; MFC, minimal fungicidal concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; CLSI, Clinical and Laboratory Standards Institute

Molecular-based methods for direct detection

Evidence—Several studies have shown that molecular detection of Mucorales DNA in tissue samples has clinical utility in both fresh^{179,623,624,644-652} and formalin-fixed paraffin-embedded tissue specimens.^{179,645,648,653-661,663-665} In all studies, in-house techniques were used, as commercial test were not available until recently. Most of the described in-house techniques lack external validation. As various DNA targets (ITS, 18S, 28S, cytochrome B), and various techniques [PCR +/- sequencing, semi-nested PCR, qPCR +/- high resolution melting (HRM)] implemented in either Mucorales-specific or pan-fungal assays have been evaluated, there is a lack of standardisation. The International Society for Human and Animal Mycology (ISHAM) working group, Fungal PCR Initiative is currently working to address this issue. Overall, the test performance is improved with fresh specimens rather than formalin-fixed paraffin-embedded tissue samples.

Detection of Mucorales DNA in blood and other fluids has further been investigated as a non-invasive method of early diagnosis or pre-emptive therapy.^{428,646,664,731-741} One of the first attempts to detect Mucorales DNA in serum was performed in a patient with pulmonary *C. bertholletiae* infection. The retrospective analysis of serum samples with pan-fungal PCR showed that DNA detection was positive two days before the appearance of pulmonary infiltrates.⁷³⁴ Subsequently, two qPCR tests have been tested in a rabbit model of pulmonary mucormycosis, which demonstrated that DNA could be detected in serum of infected animals.⁶⁴⁶ More recently, in a retrospective study, a combination of three separate qPCRs targeting the repeat target 18S rDNA allowing the detection of *Mucor/Rhizopus*, *Lichtheimia*, and *Rhizomucor*, was tested in 10 patients with mucormycosis. DNA detection was possible in nine out of 10 patients, 3 to 68 days before standard diagnosis.⁷³⁸ In a nationwide retrospective study, the same set of qPCRs was tested in 44 patients with proven or probable mucormycosis. qPCR was positive in 81% of patients and preceded classical diagnosis by several days.⁷³⁷ A new specific qPCR for *Cunninghamella* has also been developed.⁷³² One study also suggested that circulating Mucorales DNA could be detected several days before standard diagnosis in burns patients with wound mucormycosis and that early treatment of burns patients based on a positive qPCR positive in blood could be beneficial in terms of mortality.⁷³⁵ It has been shown that DNA detection could be also of interest in other clinical samples such as cerebrospinal fluid (CSF),⁴²⁸ and BAL.^{736,739,741}

Recently, PCR amplification of the single target gene *CotH*, a Mucorales-specific gene, showed positive results when tested in serum, BAL, and urine; both in an experimental animal model and in patients with mucormycosis.⁷³¹ Overall, there is still a lack of standardisation of DNA detection and currently there are a limited number of commercial assays and these lack extensive clinical validation (**Table S 5**).

Table S 5. Recommendations on molecular-based methods for direct detection of Mucorales

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To diagnose	Molecular based tests on <u>fresh</u> tissue	B	Iiu	Schwarz JCM 2006 ⁶⁴⁴ Lass-Flörl CID 2007 ⁶²³ Lau JCM 2007 ⁶⁴⁵ Rickerts CID 2007 ⁶²⁴ Kasai JCM 2008 ⁶⁴⁶ Hrncirova JCM 2010 ⁶⁴⁷ Bernal-Martinez CMI 2013 ⁶⁴⁸ Buitrago JCM 2014 ⁶⁴⁹ Alanio CMI 2015 ⁶⁵⁰ Guinea J PlosOne 2017 ¹⁷⁹ Springer JMM 2016 ⁶⁵¹	Not commercially available, limited standardisation, various DNA targets (ITS, 18S, 28S, CytB), various techniques (PCR +/- sequencing, semi-nested PCR, qPCR +/- HRM), Mucorales-specific or panfungal assays, fresh material preferred over paraffin embedded
					Zaman JMM 2017 ⁶⁵²	Identified Mucorales in 26 cases negative by culture.
						Fresh tissue is preferred over FFPE tissue.
Any	To diagnose	Molecular based tests on <u>FFPE</u> tissue	B	Iiu	Hayden Diag Mol Path 2002 ⁶⁵³ Nagao J Derm Sci 2005 ⁶⁵⁴ Bialek J Clin Pathol 2005 ⁶⁵⁵ Rickerts EJCMID 2006 ⁶⁵⁶ Lau JCM 2007 ⁶⁴⁵ Hata JCM 2008 ⁶⁵⁷ Dannaoui JCM 2010 ⁶⁵⁸ Hammond JCM 2011 ⁶⁵⁹ Buitrago CMI 2013 ⁶⁶⁰ Gade Med Mycol 2017 ⁶⁶¹ Guinea J PlosOne 2017 ¹⁷⁹ Ghadi Mycoses 2018 ⁶⁶² Bernal-Martinez CMI 2013 ⁶⁴⁸	Not commercially available, limited standardisation, wide heterogeneity of DNA targets and methods, variable sensitivity
						Sensitivity 100%, specificity 100%

					Salehi JCM 2016 ⁶⁶³	Sensitivity 62%, specificity 100%, identification to genus and species level
					Springer JMM 2016 ^{651,664}	Can be used on several clinical specimens incl. fresh and formalin-fixed paraffin-embedded.
					Drogari-Apiranthitou PRP 2016 ⁶⁶⁵	Sensitivity 79%, specificity 100%
						Fresh tissue is preferred over FFPE tissue.
Any	To diagnose	Molecular based tests on serum, plasma, or whole blood	B	Ilu	Millon CID 2013 ³²⁰	N=10, 90% qPCR+ and earlier than culture/histology, good correlation with classical diagnosis
					Millon CMI 2016 ⁷⁴²	N=44, national study, 81% qPCR+
					Kasai JCM 2008 ⁶⁴⁶	Animal
					Kobayashi Respirology 2004 ⁷³⁴	N=1, PCR+ before pulmonary infiltrate
					Springer JMM 2016 ⁶⁶⁴	N=5, probable/proven mucormycosis, 5/5 PCR+
					Shigemura IJID 2014 ⁴²⁸	N=1, cerebral mucormycosis qPCR+ in serum and CSF
					Shigemura IJ Haem 2014 ⁴²⁹	N=1, disseminated mucormycosis
					Ino Int Med 2017 ⁷³³	N=4, whole blood testing
					Bellanger BMT 2018 ⁷³²	N=1, serum and BAL
Burn	To diagnose	Molecular based tests on serum, plasma, or whole blood	B	Ilu	Legrand CID 2016 ⁷³⁵	N=77, circulating DNA may allow early detection of skin mucormycosis
Any	To diagnose	Molecular based tests on body fluids	B	Ilu	Shigemura IJID 2014 ⁴²⁸	N=1, cerebral mucormycosis: CSF burden > serum burden
					Springer JCM 2018 ⁷⁴¹	N=96, BALF, recommended extraction method provided
					Lengerova JCM 2014 ⁷³⁶	N=91, BALF, PCR/HRM +/- RQ-PCR: PCR/HRM has high NPV (haematology)
					Scherer JCM 2018 ⁷³⁹	N=24, BALF
Any	To diagnose	Molecular based	B	III	Baldin JCM 2018 ⁷³¹	CotH amplification in urine samples from mice infected with different Mucorales (90% sensitivity and 100% specificity) CotH amplification in urine samples from 4 patients with mucormycosis Assay is discriminatory against aspergillus infected mice

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; ITS, internal transcribed spacer; CytB, cytochrome b; PCR, polymerase chain reaction; qPCR, quantitative PCR; HRM, high resolution melting; FFPE, formalin-fixed paraffin-embedded; CNS, central nervous system; BAL, bronchoalveolar lavage; BALF, BAL fluid; RQ-PCR, real-time quantitative PCR; NPV, negative predictive value

Genus and species identification

Evidence — (continued)

Identification of the species of Mucorales in culture by standard mycological methods such as morphology is notoriously difficult because the different species share similar morphological characteristics. This has been highlighted by molecular description of cryptic species that can hardly be distinguished morphologically.^{691,710,743-745} Moreover, some species fail to sporulate on standard media, precluding a timely and easy morphological identification.⁶⁹⁴ Comparison of morphological versus molecular identification showed better performance of molecular approaches.^{522,746-748} A high level of concordance (>90%) between morphology and molecular identification may only be seen in reference laboratories.⁷⁴⁶ The recent release of commercially developed Mucorales PCR assays are likely to be of limited use for species identification, as these are usually designed to detect the order Mucorales as a whole, or individual genera, but not down to a species level. Several DNA targets have been evaluated for a reliable identification to the species level. The best informative target should have a large interspecies (between species) and a low intraspecies (within a given species) sequence variability. Moreover, a comprehensive and accurate database must be available. Several studies have shown that internal transcribed spacer (ITS) sequencing was a reliable and accurate method for identification to the species level.^{644,654,703,749} Based on published results and expert opinions, both the ISHAM Working Group on Fungal Molecular Identification and the CLSI have recommended using ITS sequencing as a first-line method for species identification of Mucorales.^{730,750} A reliable database, such as those developed by CBS

(<http://www.westerdijknstitute.nl/Collections/BioLoMICSSequences.aspx>) or ISHAM (<http://its.mycologylab.org>) should be used for sequence pairwise alignment. In one study, ITS2 PCR confirmed mucormycosis in 27 cases (54 %; CI 59.4–68.2). By comparison, Mucorales-specific PCR amplifying 18S was able to amplify DNA and the sequence enabled the identification of Mucorales species in all patients.⁶⁵² Other DNA targets have also been evaluated including 18S, 28S, cytochrome b, and FTR1,^{657,751-754} and could be used as alternatives. However, for some of these targets there is less evidence of their usefulness. Whole genome sequencing has been used successfully to establish epidemiology in outbreak investigations, but overall there is limited evidence on genotyping methods.^{698,755}

Alternative methods for rapid identification of filamentous fungi in clinical microbiology laboratories have been evaluated such as carbon assimilation profiles using the commercialised kits ID32C and API 50 CH (bioMérieux, Marcy l’Etoile, France),⁷⁵⁶ and MALDI-TOF mass spectrometry.⁷⁵⁷⁻⁷⁶⁸ Several studies showed a good identification by MALDI-TOF when an in-house database was used.^{760,766} Commercial databases performed less well. In one study that tested 111 strains, only 49.5% of correct identification to the species level was achieved.⁷⁶⁸ A multicentre study using another commercial database achieved 86% of correct identification to the species level.⁷⁶⁵ Although MALDI-TOF identification of Mucorales seems promising, more data are needed to validate this technique and commercially available databases should be improved (**Table S 6**), molecular approaches remaining the gold standard.

For recommendations refer to **Table S 6**.

Table S 6. Recommendations on genus and species identification of Mucorales

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To establish epidemiologic knowledge	Molecular identification to species level by ITS sequencing	A	Ilu	Schwarz JCM 2006 ⁶⁴⁴	ITS, good target
					CLSI MM-18A 2008 ⁷³⁰	Good discrimination of genera
					Balajee JCM 2009 ⁷⁵⁰	ITS sequencing as first-line identification technique
					Chakrabarti JCM 2003 ⁷⁶⁹	Good identification of <i>A. elegans</i> with ITS
					Chowdhary Mycoses 2014 ⁷⁰³	ITS, good target, N=80
					Nagao JDermSci 2005 ⁶⁵⁴	ITS, identification of 5 <i>Rhizopus</i> spp.
Any	To identify species	Molecular identification to species level vs morphology	A	Ilu	Kontoyiannis JID 2005 ⁵²²	N=27
					Alvarez JCM 2009 ⁷⁴⁶	N=190
					Bonifaz Mycoses 2014 ⁷⁴⁷	N=22
					Yang AnnLabMed 2016 ⁷⁴⁸	N=12
						Molecular identification superior over morphological identification
Any	To establish epidemiology in outbreak investigation	Whole genome sequencing	A	Ilu	Etienne PlosOne 2012 ⁷⁵⁵	N=22, wound infections
					Garcia-Hermoso mBio 2018 ⁶⁹⁸	N=21, burns unit
Any	To establish epidemiologic knowledge	Molecular identification to species level with other DNA targets	C	Ilu	Voigt JCM 1999 ⁷⁵⁴	28S PCR + sequencing
					Machouart JCM 2006 ⁷⁵²	18S PCR + RFLP
					Hall JCM 2004 ⁷⁵¹	28S MicroSeq kit
					Hata JCM 2008 ⁶⁵⁷	Cytochrome b real-time PCR
					Nyilasi CMI 2008 ⁷⁵³	FTR1 sequencing
MALDI-TOF						
Any	To establish routine organism identification and epidemiologic knowledge	MALDI-TOF identification	B	Ilu	De Carolis CMI 2012 ⁷⁵⁹	N=10 species
					Schrödl JCM 2012 ⁷⁶⁶	Range of MALDI-TOF available
					Dolatabadi JMM 2015 ⁷⁶⁰	<i>Rhizopus</i> and <i>Lichtheimia</i> studies
					Riat IJID 2015 ⁷⁶⁴	Limited evaluations for other Mucorales
					Ranque Mycoses 2014 ⁷⁶³	Limited data. In-house databases remain essential.
					Becker MedMycol 2014 ⁷⁵⁷	In-house library versus commercial library
					Schulthess JCM 2014 ⁷⁶⁷	Extraction preferred to direct plating
					McMullen JCM 2016 ⁷⁶²	
					Sanguinetti JCM 2017 ⁷⁷⁰	
					Chen FrontMicrob 2015 ⁷⁵⁸	3 strains, poor identification score
					Lau JCM 2013 ⁷⁶¹	N=8 species
Shao JCM 2018 ⁷⁶⁸	111 strains. 49.5% of identification with commercial database					
Any	To diagnose	MALDI-TOF detection of pan-fungal disaccharide	C	Ilu	Mery JCM 2016 ⁶⁸⁵	N=10 mucormycoses, Sensitivity 90%, may be useful if galactomannan negative with imaging positive
Any	To identify to species level	MALDI-TOF identification	B	Ilu	Rychert JCM 2018 ⁷⁶⁵	N=118 strains, multicentre study Vitek MS v3.0 MALDI-TOF, confirmation by DNA sequencing, 86% correctly identified to species level

Any	To identify to species level	Carbon assimilation for species identification	C	Ilu	Schwarz JCM 2006 ⁶⁴⁴	N=54, ID32C and API 50 CH kits allowed precise and accurate identification
SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; ITS, internal transcribed spacer; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; MALDI-TOF, matrix assisted laser desorption ionisation time of flight; MS, mass spectrometry						

Treatment approaches to mucormycosis

Surgical treatment for mucormycosis

Evidence – Various authors have reported higher cure and survival rates through surgical interventions.^{94,534,584,586,638,640,771-781} It should be noted that many patients may be too sick to undergo surgery.

Surgical treatment is important for local control of mucormycosis, but multiple sites of infection can be present in disseminated infection. Surgery can be separated into major groups: debridement of the skin and soft tissue, debridement of rhino-orbito-cerebral mucormycosis, orbital exenteration, lung resection, debridement of bone, and visceral resections in for example liver, spleen, peritoneal structures, or transplanted organs.

Skin and soft tissue mucormycosis should be treated by radical surgical debridement with margins clear of infection, although it is currently unclear how to define such margins. Identifying margins of infected borders during the surgical procedure may be achieved in real time using fluorescent brightener on the resected tissue.⁶⁹⁶

This approach limits unnecessary resection of non-infected tissue particularly in craniofacial areas. Currently, debridement extends until clean tissue is seen, but no intraoperative microscopic evaluation is done. Patients need to be closely followed after surgery to identify new necrosis, which must be managed by repeated debridement. Complete resection could cure mucormycosis and lead to long term survival.^{747,773,775,776} In rhino-orbital infection, complete debridement, including endoscopic debridement or excision of infected tissues, increased survival rates in a cohort of solid organ transplant recipients.⁷⁸² Adapting the extent of surgery to the distribution of mucormycosis improves outcome and reduces unnecessary loss of healthy tissue.⁷⁸¹

If lung resection is performed, patients may benefit from emergency surgery to prevent bleeding as well as from elective surgery, which has been shown to increase survival.^{100,783} Liver resection with complete removal of mucormycosis (“R0 resection”) is feasible and leads to prolonged survival. In addition, drainage of an abscess caused by mucormycosis followed by resection of an infected part of the liver is feasible. Resection of the peritoneal surface should be part of visceral surgical treatment. The rate of surgical complications after visceral resection appears to be acceptable.^{474,772,775-777} For patients after solid organ transplantation recipients and graft mucormycosis, surgical debridement, removal of the transplanted organ and/or re-transplantation are options that increase survival probability. More than 80% of patients with osteoarticular mucormycosis undergo surgical intervention, including debridement, fixation, and grafting with an overall response rate of 76%.⁵⁸⁶ Early surgical treatment is preferred over late surgical intervention, such that surgeons should be involved in the management team and in the decision plans at the time of diagnosis (**Table S 7**).^{534,640,771,783}

In trauma patients, mucormycosis mostly manifests as a soft tissue infection, although subfascial muscular layers may also be involved. A wide variety of trauma mechanisms has been reported, ranging from traffic accidents, war theatre injuries and natural disaster, to injections and insect bites. Early, radical, repeated surgical debridement is indicated and can lead to a definitive cure (**Table S 7**).⁵⁶²

Table S 7. Recommendations on surgical treatment for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To cure and to increase survival rates	Repeated surgery in addition to antifungal treatment	A	Ilu	Tedder Ann Thor Surg 1994 ⁷⁷⁸	N=90
					Nithyanandam IJO 2003 ⁷⁸¹	N=34
					Roden CID 2005 ⁵³⁴	N=470
					Greenberg AAC 2006 ⁷⁷⁴	N=19
					Zaoutis PIDJ 2007 ⁷⁸⁰	N=92, paediatric
					Chakrabarti PostgrMedJ 2009 ⁶³⁸	N=45
					Singh JID 2009 ⁵⁵⁴	N=50, SOT
					Sun AmJTranspl 2009 ⁷⁸³	N=11, SOT
					Sun Transplant 2010 ⁷⁸²	N=10, SOT
					Skiada CMI 2011 ⁶⁴⁰	N=99
					Lantermier CID 2012 ⁵⁸⁴	N=59
					Vironneau CMI 2014 ⁷⁷⁹	N=22, rhino-orbito-cerebral
Taj-Aldeen MM 2017 ⁵⁸⁶						
Any	To cure	Intraoperative assessment of clean margins	C	III	McDermott OralSurgOralMed OralPathoOralRadiolEndod 2010 ⁶⁹⁶	N=1

HIV infected	To cure	Surgical debridement + amphotericin B formulation	A	Iir	Moreira JInfect 2016 ⁵⁶⁰	N=67
Skin	To cure	Surgical debridement + liposomal amphotericin B 5-7 mg/kg/d and/or posaconazole and/or caspofungin	B	Iir	Bonifaz CurrFunInfectRep 2015 ⁷⁸⁴	
Skin	To cure	Mohs microscopically controlled micrographic surgery as an alternative treatment method	C	III	Clark DermSurg 2003 ⁷⁷³	N=1, similar to the management of cutaneous carcinomas, Mohs surgery removes all the infected tissue in layers, giving adequate margins
Rhino-orbito-cerebral	To increase survival rates	Extensive surgical debridement and antifungal therapy	A	Ilu	Bhansali PostgrMedJ 2004 ⁷⁸⁵	N=26
					Chakrabarti PostgrMedJ 2009 ⁶³⁸	N=14
					Vironneau CMI 2014 ⁷⁷⁹	N=22, 14/22 diabetic
Rhino-orbito-cerebral, SOT adults	To increase survival rates	Surgical debridement + amphotericin B, lipid formulation, dose not given	A	IIh	Sun Transplant 2010 ⁷⁸²	N=90, 52% died, 57% CNS, (74% died)
Lung, haematology patients	To cure	Emergency and elective lung resection	A	Ilu	Chretien CMI 2016 ¹⁰⁰	N=12, mostly aspergillosis, emergency surgery to prevent bleeding, elective surgery to cure before new chemotherapy or HSCT, 30 day mortality 6%, median survival after surgery 21 months
Lung, SOT adults	To cure	Surgical debridement + amphotericin B, lipid formulation or posaconazole, dose not given	A	IIh	Sun AmJTranspl 2009 ⁷⁸³	N=31, 90d mortality 45%
Intraabdominal	To cure	Abdominal resection (liver, spleen, omentectomy)	A	Ila	Li WorldJGastroenterol 2010 ⁷⁷⁵ Su DMID 2012 ⁷⁷⁷ Tuysuz Mycoses 2014 ⁴⁷⁴ Busca Mycoses 2010 ⁷⁷² Schlebusch JCM 2005 ⁷⁷⁶	
Intraabdominal, post SOT	To cure	Debridement + AmB formulations	A	Iir	Almyroudis AmJTanspl 2006 ⁷⁷¹	N=13
Intraabdominal & allograft, post liver SOT	To cure	Debridement + 2nd liver SOT	B	III	Gurevich TID 2012 ⁷⁸⁶	N=1
Liver, haematology patients	To cure	Drainage of liver abscess, then liver resection + liposomal amphotericin B	A	III	Su DMID 2012 ⁷⁷⁷ Tuysuz Mycoses 2014 ⁴⁷⁴ Busca Mycoses 2010 ⁷⁷²	Single cases, drainage of liver abscess followed resection, combined with Amphotericin B, liposomal
Healthcare-associated						
Any site, post-surgical	To cure	Debridement + antifungals	A	Ilu	Roden CID 2005 ⁵³⁴	N=32, mostly soft tissue, 38% died
					Almyroudis AmJTanspl 2006 ⁷⁷¹	N=70
					Tilak IndJDermVenereol 2009 ⁵⁶⁴	N=2, abdominal wall necrosis may be misdiagnosed as necrotising fasciitis
					Skiada CMI 2011 ⁶⁴⁰	N=18
					Nain IndJSurg 2015 ³³⁸	N=3, very aggressive disease
Wound infection, post kidney SOT	To cure	Debridement + vacuum sealing	B	III	Chen TransplantProc 2018 ⁷⁸⁷	N=4
Intramuscular injection	To cure	Surgical debridement and antifungal therapy	A	III	Chakrabarti JCM 2003 ⁷⁶⁹	N=2, recovery within 15-40 days
					Chander Infect Dis 2016 ⁷⁸⁸	N=4, severe skin and soft tissue necrosis
Intravenous access	To cure	Surgical debridement and antifungal therapy	A	III	Wollstein CanJPlastSurg 2010 ⁷⁸⁹	N=1, skin mucormycosis, iv access in the forearm
Injuries, accidents and disasters						
Insect/spider bite	To cure	Surgical debridement and antifungal treatment	A	III	Soman JIMSA 2010 ⁷⁹⁰	N=2, slower pace of illness, lack of suspicion of diagnosis
Motor vehicle accident	To cure	Repeat surgical debridement and antifungal therapy	A	Ilu	Moran JHandSurg 2006 ⁷⁹¹	N=3, soil contamination, average 10 debridements
					Ayala-Gaytan Mycoses 2009 ⁷⁹²	N=3, soil-contaminated skin lesions

					Ingram MedMycol 2014 ⁷⁹³ Nain IndJSurg 2015 ³³⁸	N=9, 78% of all trauma-related cases N=2, both died
Blunt trauma, at construction site	To cure	Repeat surgical debridement and antifungal therapy	A	III	Chakrabarti JCM 2003 ⁷⁶⁹	N=1, death within one day of therapy
Farm / gardening accidents	To cure	Surgical debridement and antifungal therapy	A	Ilu	Moran JHandSurg 2006 ⁷⁹¹ Lanternier CID 2012 ⁵⁸⁴	N=4, average 10 debridements N=11, trauma had lower mortality than haematology
Tornado	To cure	Surgical debridement and antifungal therapy	A	Ilu	Neblett Fanfair NEJM 2012 ⁵⁶¹	N=13
Volcanic cataclysm	To cure	Repeat surgical debridement and antifungal therapy	A	Ilu	Patino WorldJSurg 1991 ⁷⁹⁴	N=8 among 38 patients with necrotising fasciitis
Combat or blast injury with recurrent necrosis	To cure	Surgery + antifungal treatment	A	Iiur	Warkentien CID 2012 ⁵⁶² Rodriguez MilMed 2018 ⁷⁹⁵	N=16 28% mixed infection, risk factors for mucormycosis include dismantled blast injury, traumatic lower limb amputation, extensive perineal injury, mass transfusion
SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; SOT, solid-organ transplantation; CNS, central nervous system; HSCT, haematopoietic stem cell transplantation						

Drug treatment for mucormycosis

Prophylaxis

Evidence – There is no evidence for primary prophylaxis directed solely towards mucormycosis. Usually prophylaxis is directed against a broad range of fungal infections, including candidiasis and aspergillosis. Breakthrough mucormycosis has been a rare event during prophylaxis with posaconazole oral suspension,⁷⁹⁶⁻⁸⁰¹ and exposure due to posaconazole delayed release tablets,^{802,803} or intravenous infusions^{804,805} may result in even lower invasive fungal infection rates (**Table S 8**).^{806,807}

Secondary prophylaxis

Evidence – A frequent clinical question refers to the choice of secondary prophylaxis to prevent recurrence, specifically in immunosuppressed patients. In the absence of a consensus definition of secondary prophylaxis, we defined it as either continued treatment in a patient who had been diagnosed with mucormycosis and responded to treatment, or as restarted treatment in a patient with successful disease control now immunocompetent, but scheduled for a new period of immunosuppression, e.g. HSCT. The evidence base for treatment decisions, for example for transitioning to posaconazole,⁸⁰⁸ or isavuconazole to facilitate outpatient treatment, is sparse (**Table S 8**).^{809,810}

Table S 8. Recommendations on prophylaxis for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Neutropenic or GvHD	To prevent	Posaconazole DR tablet 2x300 mg d1, 1x300 mg from d2	B	Ilu	Duarte AAC 2014 ⁸⁰² Cornely JAC 2016 ⁸⁰³ Chin AAC 2017 ⁸⁰⁷	Higher trough levels than oral suspension
Neutropenic or GvHD	To prevent	Posaconazole iv 2x300 mg d1, 1x300 mg from d2	B	III	Maertens AAC 2014 ⁸⁰⁵ Cornely JAC 2017 ⁸⁰⁴	Intravenous administration recommended when oral dosing not feasible
Neutropenic or GvHD	To prevent	Posaconazole oral suspension 3x200 mg/d	C	Ilu	Cornely NEJM 2007 ⁷⁹⁶	N=0/304 breakthrough
					Ullmann NEJM 2007 ⁷⁹⁷	N=0/301 breakthrough
					Pagano CID 2012 ⁸⁰¹	N=0/260 breakthrough
					Cornely AAC 2012 ⁸⁰⁶	N=0/75 breakthrough
					Cho Mycoses 2015 ⁷⁹⁹	N=2/140 breakthrough
					Lamoth CID 2017 ⁷⁹⁸	N=2/279 breakthrough
Neutropenic	To prevent	Isavuconazole po/iv 3x200 mg d1-2, 1x200 mg/d from d3 or 1x200 mg/d from d1	C	Ilu	Rausch CID 2018 ⁸¹¹	N=4/100 breakthrough
					Gebremariam AAC 2017 ⁸¹²	Animal model, lower tissue burden of <i>R. delemar</i> with isavuconazole and with posaconazole, improved survival
ALL induction chemotherapy	To prevent	Amphotericin B, liposomal 5 mg/kg biw	D	I	Cornely JAC 2017 ⁸¹³	Not better than placebo, but no proven breakthrough mould infection in either study arm
Neutropenic or GvHD	To prevent	Fluconazole, itraconazole, voriconazole, any dose	D	Iir	Lass-Flörl Drugs 2011 ⁸¹⁴	Fluconazole and voriconazole not active, itraconazole may yield some activity, likely inferior to posaconazole

SOT adult, lung & heart	To prevent	Isavuconazole po/iv 3x200 mg d1-2, 1x200 mg/d from d3 or 1x200 mg/d from d1	C	Iiu	Wu AAC 2018 ⁸¹⁵	N=21, pharmacokinetic study
SOT, adult	To prevent	Isavuconazole po/iv 3x200 mg d1-2, 1x200 mg/d from d3 or 1x200 mg/d from d1	C	Iia	Rivosecchi ECCMID 2017 ⁸¹⁶	N=187, no breakthrough mucormycosis
SOT adult, lung & heart	To prevent	Posaconazole iv 2x300 mg d1, 1x300 mg from d2	C	III	No reference found.	
SOT adult, lung & heart	To prevent	Posaconazole oral suspension 3x200 mg/d	C	III	Shields AAC 2011 ⁸¹⁷	N=4
Immunosuppressed with prior diagnosis of mucormycosis	To prevent recurrence, <u>secondary prophylaxis</u>	Surgical resection and last drug effective in the same patient	A	III	Nosari BMT 2007 ⁸⁰⁹	N=3
					Hoover MedPedOnc 1997 ⁸¹⁰	N=1
					Marty LancetID 2016 ⁸⁰⁸	N=12, transition from amphotericin B to oral posaconazole after 3-6 weeks if feasible
SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; GvHD, graft-versus-host disease; DR, delayed release; ALL, acute lymphoblastic leukaemia; SOT, solid-organ transplantation						

Fever-driven treatment

Evidence – For the clinical situation of unexplained fever with negative imaging results, no reference supports initiation of mucormycosis-directed treatment. However, in high-risk patients with prolonged fever during neutropenia, empirical treatment with liposomal amphotericin B is an accepted strategy that is also active against mucormycosis.⁸¹⁸

Diagnosis-driven treatment

Evidence – Short delays in treatment initiation substantially increase mortality rates in haematological malignancy patients.⁸¹⁹ With any new nodular opacities in haematology patients, breakthrough mucormycosis must be considered.⁸¹¹

Table S 9. Recommendations on treatment decision points in mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Fever-driven treatment						
Any with fever of unknown origin, imaging negative	To cure mucormycosis	Fever-driven treatment	D	III	No reference found.	
Any neutropenic with fever of unknown origin, unresponsive to antibiotics, galactomannan negative, imaging positive, but not typical	To cure mucormycosis	Fever-driven treatment	C	III	No reference found.	May be regarded as diagnosis-driven
Diagnosis-driven treatment						
Any immunocompromised with suspected mucormycosis	To increase survival	Immediate treatment initiation	A	Iiu	Chamilos CID 2008 ⁸¹⁹	N=70, treatment initiation ≥6 days after symptom onset increased 12-week mortality from 48.6% to 82.9%
Critically ill burn patients	To increase survival	Treatment based on qPCR <u>serum</u> screening	C	Iih	Legrand CID 2016 ⁷³⁵	N=75, period A: treatment after positive culture/biopsy, survival 1/5; period B: treatment after positive in house qPCR screening 2x/week, survival 2/3
Haematologic malignancy, radiologic suspicion, galactomannan negative	To direct appropriate therapy	Treatment based on qPCR <u>blood</u> screening	C	III	Ino Intern Med 2017 ⁷³³	N=4, all survived, in house qPCR
SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; qPCR, quantitative polymerase chain reaction						

First-line antifungal combination therapy

For recommendations, refer to **Table S 10**.

Table S 10. Recommendations on first-line antifungal combination therapy for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Combat or blast injury with recurrent necrosis	To cure	Liposomal amphotericin B + posaconazole or voriconazole + topical 0.025% Dakin's solution	C	Iiur	Warkentien CID 2012 ⁵⁶² Rodriguez MilMed 2018 ⁷⁹⁵	N=16 28% mixed infection, risk factors for mucormycosis include dismounted blast injury, traumatic lower limb amputation, extensive perineal injury, mass transfusion
Any	To cure	Liposomal amphotericin B + caspofungin	C	Iiu	Abidi Mycoses 2014 ⁸²⁰ Kyvernitakis CMI 2016 ⁸²¹	N=101, no benefit for combination N=27, propensity score analysis, no benefit for combination
Any	To cure	Amphotericin B formulation + caspofungin	C	III	Reed CID 2008 ⁶²⁰	N=7 (6/7 diabetic), superior success and survival time compared to polyene monotherapy particularly for amphotericin B lipid complex and in patients with cerebral involvement
Haematologic malignancy	To cure	Liposomal amphotericin B + caspofungin	C	Iiu	Klimko Mycoses 2014 ²⁵⁰	N=36, combination treatment (52%) was associated with favourable prognosis
Any	To cure	Liposomal amphotericin B + (anidulafungin or micafungin)	C	III	Ibrahim AAC 2008 ⁸²²	Animal study, improved survival rate with combination
Haematologic malignancy	To cure	Liposomal amphotericin B + posaconazole oral suspension	C	Iiu	Kyvernitakis CMI 2016 ⁸²¹	N=16, propensity score analysis, no benefit for combination
Any	To cure	Liposomal amphotericin B + (posaconazole DR tablet or iv)	C	Iiu	Jenks IJAA 2018 ⁸²³	N=10, overall survival 4/6 in those with combination versus 0/4 in those with single agent therapy
Haematologic malignancy	To cure	Liposomal amphotericin B + caspofungin + posaconazole	C	Iiu	Kyvernitakis CMI 2016 ⁸²¹	N=106, propensity score analysis, no benefit for combination

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; DR, delayed release

Antifungal salvage treatment

For recommendations, refer to **Table S 11**.

Table S 11. Recommendations on antifungal salvage treatment for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Refractory disease						
Refractoriness	To cure	Isavuconazole iv or po 3x200 mg d1-2, 1x200 mg from d3	A	Iih	Marty Lancet ID 2016 ⁸⁰⁸	N=11
Refractoriness	To cure	Posaconazole DR tablet or iv 2x300 mg d1, 1x300 mg from d2	A	Iit	Duarte AAC 2014 ⁸⁰² Maertens AAC 2014 ⁸⁰⁵ Cornely JAC 2016 ⁸⁰³ Cornely JAC 2017 ⁸⁰⁴	Higher serum concentrations than oral suspension, iv bridging when oral dosing not feasible
Refractoriness	To cure	Amphotericin B, liposomal 10 mg/kg	A	Iiut	Cornely CID 2007 ⁸²⁴ Lanternier JAC 2015 ⁸²⁵	N=4 N=44
Refractoriness	To cure	Amphotericin B, liposomal 5 mg/kg	B	III	Pagano Haematol 2004 ⁶³⁶	N=8, prior amphotericin B deoxycholate
Refractoriness	To cure	Amphotericin B, lipid complex 5 mg/kg	B	Iiu	Walsh CID 1998 ⁸²⁶ Larkin Inf Med 2003 ⁸²⁷	N=16 N=23
Refractoriness	To cure	Posaconazole oral suspension 4x200 mg/d or 2x400 mg/d	C	Iiu	Greenberg AAC 2006 ⁷⁷⁴ van Burik CID 2006 ⁸²⁸ Skiada CMI 2011 ⁶⁴⁰ Vehreschild CRM 2012 ⁸²⁹	N=19, 4 diabetes N=81*, 30 diabetes N=61 N=15 [#]
Refractoriness	To cure	Combination of liposomal amphotericin OR lipid complex + posaconazole	C	Iiu	Ibrahim AAC 2009 ⁸³⁰ Pagano Haematol 2013 ⁸³¹	Animal, not superior N=29, posaconazole added, d84 response 16/29

Intolerance and toxicity

Toxicity	To cure	Isavuconazole iv or po 3x200 mg d1-2, 1x200 mg from d3	A	Ih	Marty Lancet ID 2016 ⁸⁰⁸	N=5
					Marty Mycoses 2018 ⁸⁷³	N=8
					DiPippo Mycoses 2018 ⁸³²	N=23
Toxicity	To cure	Posaconazole DR tablet or iv 2x300 mg d1, 1x300 mg from d2	A	Iit	Duarte AAC 2014 ⁸⁰² Maertens AAC 2014 ⁸⁰⁵ Cornely JAC 2016 ⁸⁰³ Cornely JAC 2017 ⁸⁰⁴	Higher serum concentrations than oral suspension, iv bridging when oral dosing not feasible
Toxicity, renal	To cure	Amphotericin B, liposomal 5 mg/kg	B	III	Pagano Haematol 2004 ⁶³⁶	N=8, prior amphotericin B deoxycholate
Toxicity, renal	To cure	Amphotericin B, lipid complex 5 mg/kg	B	Ilu	Larkin Inf Med 2003 ⁸²⁷	N=18, pre-existing nephropathy
Toxicity, renal	To cure	Amphotericin B colloidal dispersion 5 mg/kg	B	Ilu	Herbrecht EJCMI 2001 ⁸³³	N=21
Toxicity	To cure	Posaconazole oral suspension 4x200 mg/d or 2x400 mg/d	C	Ilu	Greenberg AAC 2006 ⁷⁷⁴	N=5
					van Burik CID 2006 ⁸²⁸	N=43*
					Vehreschild CRM 2012 ⁸²⁹	N=15 [#]

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; DR, delayed release
*33 patients had refractory disease and were intolerant; 11 individuals overlap between van Burik⁸²⁸ and Greenberg⁷⁷⁴ reports; [#]The reason for salvage treatment, *i.e.* refractoriness vs intolerance, was not reported in this study.

Treatment duration for mucormycosis

Table S 12. Recommendations on treatment duration for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To cure infection	Continue treatment until complete response on imaging and permanent reversal of immunosuppression	A	III	No reference found.	Treatment duration is being determined on a case-by-case basis and depends, <i>e.g.</i> on the extent of surgery, the organs involved, and ongoing immunosuppression
Any	To reach stable disease	1st line treatment by iv antifungal until stable disease	B	Ilu	Lanternier JAC 2015 ⁸²⁵	N=34, median duration 21 days, followed by unspecified further treatment
Any	To reach stable disease	1st line treatment by intravenous antifungal until stable disease and PCR negativity	C	Ilu	Millon CMI 2016 ⁷³⁷	N=44, no commercial test
Any	To facilitate oral treatment in stable disease	Isavuconazole po 3x200 mg d1-2, 1x200 mg from d3	A	Ih	Marty LancetID 2016 ⁸⁰⁸	N=37, median duration 84 days
Any	To facilitate oral treatment in stable disease	Posaconazole DR tablet 2x300 mg d1, 1x300 mg from d2	A	Iit	Duarte AAC 2014 ⁸⁰² Cornely JAC 2016 ⁸⁰³	Higher trough levels than oral suspension, prophylaxis study
Any	To facilitate oral treatment in stable disease	Posaconazole oral suspension 4x200 mg/d or 2x400 mg/d	C	Ilu	van Burik CID 2006 ⁸²⁸ Greenberg AAC 2006 ⁷⁷⁴ Davoudi Mycopath 2014 ¹¹²	N=91 N=24 N=1 Across different studies mean duration approx. 6 months (range 6-1005 days), remains case-by-case decision
					Ma JGID 2015 ²⁹⁸	N=1, Late relapse in long-term survivor
					Kim Mycoses 2016 ⁸³⁴	N=5
CNS involvement	To facilitate oral treatment in stable disease	Posaconazole DR tablet 2x300 mg d1, 1x300 mg from d2	C	III	Andrey IJID 2017 ⁸³⁵	N=1, surgical resection

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; PCR, polymerase chain reaction; DR, delayed release

Therapeutic drug monitoring (TDM)

Evidence – Antifungal agents, particularly triazole antifungals, may have unpredictable pharmacokinetics in patients with mucormycosis due to altered bioavailability, underlying organ dysfunction, or drug interactions that affect rates of drug metabolism and clearance. In some patients, this pharmacokinetic variability may contribute to treatment failure or drug toxicity.⁸³⁶ TDM is the most direct approach for detecting potentially subtherapeutic drug exposures in patients and guiding dosage adjustments. TDM has also been recommended in patients receiving triazole antifungal agents for the treatment of other life-threatening invasive fungal disease.⁶¹⁴ Therefore, it is reasonable to assume TDM could have similar clinical utility when managing patients with mucormycosis.

The therapeutic range of isavuconazole and posaconazole for mucormycosis is unknown. Preclinical data from animal infection models have shown that triazole pharmacodynamics for *A. fumigatus* and *R. arrhizus* are similar when triazole serum exposures (area under the curve, AUC) are indexed to the MIC.⁸³⁷ Simulations based on preclinical data predicted the highest probabilities of treatment response when posaconazole serum exposures exceeded 1-1.5 µg/ml for isolates with MICs up to 0.25 µg/ml, with proportionally higher serum exposures (>4 µg/ml) required for isolates with higher MICs (e.g. 2 µg/ml). However, these pharmacodynamic relationships have not been confirmed in patients with invasive mucormycosis. Serum levels of posaconazole >2 µg/ml may only be achievable in patients with non-licensed doses of posaconazole tablets or the IV formulation, and could predispose patients to increased risk of hepatotoxicity,⁸³⁸ or pseudohyperaldosteronism (Table S 13).⁸³⁹

No TDM was undertaken in isavuconazole-treated patients in the VITAL study.⁸⁰⁸ In the SECURE trial, TDM was performed in select clinical cases of patients with invasive aspergillosis (n=283 samples). Over 90% of patients achieved predicted target exposures and no relationship was observed between isavuconazole serum levels, treatment response, or liver toxicity.^{713,840} Moreover, the more recent study of 283 serum samples from real-world use and the SECURE clinical trial demonstrates nearly identical values (>1 µg/ml in 90% of patients) with concentrations as high as 9 µg/ml.⁸⁴¹ Therefore, there is no current evidence to suggest that routine TDM for isavuconazole is necessary. However, TDM could be useful as part of a comprehensive clinical assessment for any patients with progressing mucormycosis on isavuconazole therapy, or after patients are switched from IV to oral therapy to confirm adequate drug exposures (Table S 13).

Recommendations – Routine TDM is strongly recommended for patients with mucormycosis receiving treatment with posaconazole. Serum trough posaconazole concentrations of 1 µg/ml or higher in patients with infecting isolates with elevated MICs are recommended to reduce the risk of treatment failure. There is no clinical evidence supporting a need for routine TDM with isavuconazole. However, documentation of serum drug concentrations could be useful in some clinical situations such as suspected treatment failure, drug interactions, suspected toxicity or intolerance, obesity, or after switching from IV to oral therapy in a patient with documented mucormycosis (Table S 13).

Table S 13. Recommendations on therapeutic drug monitoring in mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Any	To reduce risk of treatment failure	Posaconazole oral suspension TDM for treatment target concentration >1 µg/ml	A	IIt	Dolton AAC 2012 ⁸³⁶	N=72, breakthrough during prophylaxis in those with significantly lower median concentrations, not specific for mucormycosis
SOT adults, lung/heart	To reduce risk of treatment failure	Posaconazole DR tablet or iv TDM for treatment target concentration >1 µg/ml	A	Iia	Haidar IDWeek 2017 ⁸⁴² Jeong JAC 2017 ⁸⁴³	N=17 N= 78, lung transplant
Any	To reduce risk of treatment failure in <i>Rhizopus arrhizus</i>	Posaconazole TDM for treatment target concentration >1.5 µg/ml	C	IIt	Lewis AAC 2014 ⁸³⁷	Maximum reduction in lung fungal burden observed with posaconazole doses achieving serum levels > 4 µg/ml for <i>R. arrhizus</i> isolate with MIC of 2.0 µg/ml
Any	To reduce risk of treatment failure in <i>Mucor</i> spp.	Posaconazole TDM for treatment target concentration >4 µg/ml	C	IIt	Lewis AAC 2014 ⁸³⁷	Maximum reduction in lung fungal burden observed with posaconazole doses achieving serum levels > 4 µg/ml for <i>R. arrhizus</i> isolate with MIC of 2 µg/ml
Any	To reduce risk of treatment failure	Isavuconazole TDM for treatment target concentration >1 µg/ml	C	III	Marty LancetID 2016 ⁸⁰⁸ Andes AAC 2018 ⁸⁴¹ Desai AAC 2017 ⁸⁴⁰ Kaindl JAC 2018 ⁷¹³	No TDM undertaken in VITAL study N=283 samples, 90% target reached TDM in select clinical cases from the SECURE study
Any	To reduce risk of treatment failure	Determine azole concentration in ascites, effusion, CSF	C	III	Felton CMR 2014 ⁸⁴⁴	Therapeutic range not established, single drug concentrations may not be interpretable

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; TDM, therapeutic drug monitoring; DR, delayed release; MIC, minimum inhibitory concentration; CSF, cerebrospinal fluid

Specific considerations on treatment of mucormycosis in children

Evidence – As in adults, diagnosis and treatment of mucormycosis in children remain challenging. Evidence derives from case series, case reports and is extrapolated from adults.^{525,534,640,845-849} Predisposing factors, sites of infection and identified species are similar to adults.^{534,640,780,846-850} Specifically for neonates the most commonly reported site of infection is the gastrointestinal tract (54%), which is associated with increased mortality rate (78%).^{780,847,851,852} Mucormycosis is life threatening for immunocompromised children and premature neonates.^{780,846,847,850,853,854} The overall mortality rate among all age groups ranges from 33% to 56%, and reaches 64% to 89% in neonates with disseminated disease.^{846-848,850} In ages less than 12 months, disseminated infection and HSCT have been found to be independent prognostic factors (**Table S 14 and Table S 15**)^{780,846}.

As in previously published guidelines, the group considered four sources to grade therapeutic interventions: (i) evidence for efficacy from studies in adults; (ii) availability and quality of paediatric pharmacokinetic data and dosing recommendations; (iii) paediatric safety and supportive efficacy data; and (iv) regulatory approval for use in paediatric age groups (**Table S 14 and Table S 15**).¹

Recommendations – Immediate initiation of effective antifungal therapy in combination with appropriate surgical debridement – and, if feasible, control of underlying predisposing conditions – is strongly recommended.^{780,846,847,854-856} Liposomal amphotericin B and amphotericin B lipid complex are strongly supported as first-line treatment options among all age groups, with a preference for liposomal amphotericin B in CNS involvement.^{298,639,640,826,827,848,854,857-864} Amphotericin B deoxycholate is an alternative choice in the neonatal population, if liposomal amphotericin B or amphotericin B lipid complex are not available based on the existing tolerability and safety data.^{298,847,864} For both, paediatric and neonatal patients, a liposomal amphotericin B dose of 5-<10 mg/kg/d is strongly recommended.^{639,640,858,859,865-867} Due to the lack of clinical efficacy data, a dose of 10 mg/kg in selected cases as in CNS involvement is recommended with marginal strength and based on extrapolated clinical evidence from studies in adults, paediatric studies of safety, tolerability, and pharmacokinetics, and data from animal models.^{824,825,866} Salvage or continuation treatment options comprise isavuconazole and posaconazole for children ≥13 years and are supported with moderate strength.^{774,808,828,868-874} Oral posaconazole is dose-adjusted based on age with a general preference given to the delayed release tablet formulation for children ≥13 years; therapeutic drug monitoring (TDM) is advised for the oral solution (**Table S 15**).

For salvage treatment, combination therapy of amphotericin B lipid formulation plus caspofungin, or amphotericin B lipid formulation plus posaconazole for children ≥2 years of age is recommended with marginal strength (**Table S 15**).^{620,829,831,875-879} Indications of salvage therapy, duration of treatment and diagnosis are similar to those outlined for adults.

Table S 14. Recommendations on first-line treatment of mucormycosis in children

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Neonates	To cure	Amphotericin B formulation plus surgery	A	Iiu	Roilides AmJPerinatol 2009 ⁸⁵¹	N=59, neonates
Neonates	To cure	Amphotericin B, liposomal 5-<10 mg/kg/d	A	Iit	Juster-Reicher EJCMI 2003 ⁸⁵⁸	No neonatal PK available
					Kolve JAC 2009 ⁸⁵⁹	N=87, paediatric safety
					Rüping JAC 2010 ⁶³⁹	N=5, paediatric efficacy
					Shoham MedMycol 2010 ⁸⁶⁰	Adult efficacy
					Skiada CMI 2011 ⁶⁴⁰	Adult efficacy
Neonates	To cure	Amphotericin B, lipid complex 5 mg/kg/d	A	Iit	Würthwein AAC 2005 ⁸⁶³	N=30, neonatal PK and safety
					Wiley PIDJ 2005 ⁸⁶²	N=44, neonatal safety, <3 months
					Walsh PIDJ 1999 ⁸⁶¹	N=111, paediatric safety
					Walsh CID 1998 ⁸²⁶	Adult efficacy
					Larkin InfMed 2003 ⁸²⁷	Adult efficacy
Neonates	To cure	Amphotericin B, deoxycholate 1-1.5 mg/kg/d	C	III	Ma JGlobID 2015 ²⁹⁸	n=12, <1 yr, intracranial mucormycosis
Paediatric	To cure	Amphotericin B formulation and surgery	A	Iiu	Zaoutis PIDJ 2007 ⁷⁸⁰	N=157, paediatric, median 5 yrs
					Dehority JPHO 2009 ⁸⁵⁴	N=6, paediatric
					Roilides CMI 2009 ⁸⁴⁷	N=157, paediatric, median 5 yrs
					Pana BMCID 2016 ⁸⁴⁶	N=63, paediatric, 0-20 yrs
					Ardehsirpour Laryngosc 2013 ⁸⁵⁶	N=11, paediatric, 2-14 yrs

					Xhaard CMI 2012 ⁸⁵⁵	N=29, mixed paediatric and adult, 3-63 yrs
Paediatric	To cure	Amphotericin B, liposomal 5 - <10 mg/kg/d	A	IIt	Lestner AAC 2017 ⁸⁶⁵	N=47, paediatric PK, 1-17 yrs
					Seibel AAC 2017 ⁸⁶⁶	
					Hong AAC 2006 ⁸⁶⁷	N=39, paediatric PK, 0.2-17 yrs
					Dehority JPHO 2009 ⁸⁵⁴	N=6, paediatric safety, median 11 yrs
					Kolve JAC 2009 ⁸⁵⁹	N=84, paediatric safety (median age 11 yrs)
					Rüping JAC 2010 ⁶³⁹	N=5, paediatric efficacy
					Shoham MedMycol 2010 ⁸⁶⁰	Adult efficacy
					Skiada CMI 2011 ⁶⁴⁰	Adult efficacy
					Wattier JPIDS 2015 ⁸⁴⁸	N=14, paediatric efficacy
Paediatric	To cure	Amphotericin B, liposomal 10 mg/kg/d	C	IIt	Seibel AAC 2017 ⁸⁶⁶	N=12, paediatric PK and safety
					Lanternier JAC 2015 ⁸²⁵	Adult efficacy
Paediatric	To cure	Amphotericin B, lipid complex 5 mg/kg/d	A	IIt	Walsh AAC 2005 ⁸⁷⁸	N=6, paediatric PK, 21 d-16 yrs
					Walsh PIDJ 1999 ⁸⁶¹	N=111, paediatric safety
					Wiley PIDJ 2005 ⁸⁶²	N=548, paediatric safety, 0-20 yrs
					Walsh CID 1998 ⁸²⁶	Adult efficacy
Paediatric	To cure	Amphotericin B, deoxycholate, any dose	C	III	Bonifaz Mycoses 2014 ⁷⁴⁷	N=22, paediatric, (6 m -18 y)
					Ma JGlobID 2015 ²⁹⁸	N =51, mixed paediatric and adult, 15 d-79 yrs, CNS involved
SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; PK, pharmacokinetics; CNS, central nervous system						


Table S 15. Recommendations on salvage treatment of mucormycosis in children

Population	Intention	Intervention	SoR	QoE	Reference	Comment	
Paediatric patients ≥13 yrs and weighing ≥40 kg	To cure	Isavuconazole iv or po 3x200 mg d1-2, 1x200 mg from d3	B	IIt	Marty LancetID 2016 ⁸⁰⁸	Adult; assumption of similar PK in post-pubertal adolescents and absence of dose-dependent safety concerns	
Paediatric patients ≥13 yrs	To cure	Posaconazole oral suspension 4x200 mg/d or 2x400 mg/d	B	IIu	Krishna AAC 2007 ⁸⁷⁰	N=12, paediatric PK and safety oral suspension, 12-18 yrs	
					Welzen PIDJ 2011 ⁸⁷³	N=16, paediatric PK and safety, oral suspension, chronic granulomatous disease, 2-16 yrs	
					Arrieta ICAAC 2013 ⁸⁷⁴	N=43, Paediatric PK and safety (oral suspension; 2-18 yrs)	
					Lehrmbecher EJCMID 2010 ⁸⁷¹	N=15, paediatric safety, oral suspension, 3-6-17-5 yrs	
					Döring Med Mycol 2017 ⁸⁸⁰	N=27, paediatric safety, oral suspension, <17 yrs	
					Greenberg AAC 2006 ⁷⁷⁴	Adult efficacy	
					van Burik CID 2006 ⁸²⁸	Adult efficacy	
					Walsh CID 2007 ⁸⁷²	TDM rationale in treatment	
						No established paediatric dose; TDM for oral solution advised; target ≥1 µg/ml	
Paediatric patients ≥13 yrs	To cure	Posaconazole DR tablet or iv 2x300 mg d1, 1x300 mg from d2	B	IIt	Groll, IDWEEK 2017 ⁸⁸¹	N=57, paediatric PK and safety, iv and novel investigational DR suspension, 2-18 yrs	
					Duarte AAC 2014 ⁸⁰²	Adult PK and safety	
					Maertens AAC 2014 ⁸⁰⁵	Adult PK and safety	
					Cornely JAC 2016 ⁸⁰³	Adult PK and safety	
					Cornely JAC 2017 ⁸⁰⁴	Adult PK and safety	
Paediatric patients beyond 4 weeks to 12 yrs	To cure	Posaconazole oral suspension No established dose; individualised dosing based on body weight: Starting dose of 3x6 mg/kg/d plus TDM to maintain trough concentrations of 1-2.5 µg/ml	C	IIu	Arrieta ICAAC 2013 ⁸⁷⁴	N=43, Paediatric PK and safety (oral suspension; 2-18 yrs)	
					Döring BMCID 2012 ⁸⁶⁸	Paediatric safety (suspension; n=60; 0.7-11.5 yrs)	
					Döring Med Mycol 2017 ⁸⁸⁰	N=27, paediatric safety, oral suspension, <17 yrs	
					Welzen PIDJ 2011 ⁸⁷³	N=16, paediatric PK and safety, oral suspension, chronic granulomatous disease, 2-16 yrs	
						Lehrmbecher EJCMID 2010 ⁸⁷¹	N=15, paediatric safety, oral suspension, 3-6-17-5 yrs


					Vanstraelen PIDJ 2016 ⁸⁸²	N=8, paediatric PK study, oral suspension, prophylaxis, 13 yrs or younger (mean 6.7 ± 2.8)
					Mesini EJM 2018 ⁸⁸³	N=1, paediatric PK, tablets
						No established paediatric dose; TDM for oral solution advised; target ≥1 µg/ml
Paediatric patients including neonates	To cure	Amphotericin B lipid formulations, plus posaconazole oral suspension	C	IIIc	Vehreschild CRM 2013 ⁸²⁹	Adult efficacy
					Pagano Haematologica 2013 ⁸³¹	Adult efficacy
Paediatric patients including neonates	To cure	Amphotericin B, lipid formulations, plus caspofungin iv loading (1 st day): 70 mg/m ² ; maintenance: 50 mg/m ² neonates: 25 mg/m ²	C	IIIc	Saez-Llorens AAC 2009 ⁸⁷⁷	Neonatal PK caspofungin (n=18)
					Walsh AAC 2005 ⁸⁷⁸	Paediatric PK caspofungin (n=39; 2- <18 yrs)
					Neely AAC 2009 ⁸⁷⁵	Paediatric PK caspofungin (n=9; 3-24 mo)
					Zaoutis PIDJ 2009 ⁸⁷⁹	Paediatric safety caspofungin (n=171; 0- <18 y)
					Phulpin-Weibel Mycoses 2013 ⁸⁷⁶	N=5 paediatric efficacy
					Reed CID 2008 ⁶²⁰	Adult efficacy

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; PK, pharmacokinetics; DR, delayed release; TDM, therapeutic drug monitoring


Figure S 4. Optimal treatment pathway for mucormycosis in children
A. When all treatment modalities and antifungal drugs are available



B. When amphotericin B lipid formulations are not available



C. When isavuconazole and posaconazole iv and delayed release tablets are not available



Adjunctive treatments for mucormycosis

Iron homeostasis

Evidence – Iron is essential for the fungal metabolism.⁸⁸⁴⁻⁸⁸⁶ In animal models administration of iron as well as of the drug deferoxamine, which is an iron chelator for humans but can be used as a siderophore delivering iron to fungi, actually worsened mortality rates.⁸⁸⁷ Deferasirox is another iron chelator that cannot be used as a siderophore by Mucorales. Pre-clinical studies in mice found that deferasirox monotherapy in diabetic mice was as effective as liposomal amphotericin, and the combination of both drugs synergistically improved survival in mice.⁸⁸⁴ Of note, in the mouse study, deferasirox was toxic in neutropenic mice, and in order to detect even minor efficacy, it had to be considerably dose reduced compared to the doses administered to diabetic mice. The drug was found safe in a single arm study on – mostly diabetic – patients.⁸⁸⁸ A second, uncontrolled study successfully used deferasirox in diabetic patients.⁸⁸⁹

Subsequently, a double-blinded, randomised controlled study yielded an increased mortality rate in deferasirox recipients as compared to those treated with placebo (all patients treated with amphotericin).⁸ However, the study was small and enrolled mainly a haematologic malignancy population, rather than diabetic patients, for which the mouse study demonstrated greater efficacy.^{8,888} Furthermore, due to its small size, there was an imbalance in randomisation, such that more patients in the iron chelation arm had leukaemia or stem cell transplant than in the control arm. Deferasirox is known to be potentially toxic to the bone marrow and kidneys, and hence there is biological plausibility around potential harm in neutropenic patients with mucormycosis, in contrast to diabetic patients for which there is biological rationale to reduce iron levels.^{890,891} Indeed, in the randomised study, higher baseline serum iron and serum ferritin concentrations were associated with higher mortality.^{8,626} Thus, future research in this space is warranted.

Deferiprone, mentioned for completeness, is the third iron chelator and is currently given in thalassaemia major.⁸⁹² Deferiprone was shown to protect diabetic mice from mucormycosis,⁸⁹³ but has not yet been used to treat patients with mucormycosis. Enhanced iron delivery through iron chelators may be an untoward drug class effect,⁸⁹⁴ although the conflicting results may be explained by differential risk profiles.⁸⁸⁹ For now, this remains an area of uncertainty (**Table S 16**).

Recommendations – Administration of iron or deferoxamine to patients with mucormycosis is discouraged, and a conservative approach to blood transfusions may be warranted given the risk of free iron release during transfusions. Adjunctive deferasirox use should be avoided in patients with haematological malignancy; its use in patients with diabetes as a predominant risk factor merits further exploration in clinical trials (**Table S 16**).

Augmentation of host response

Evidence – In haematology patients with mucormycosis and ongoing neutropenia, granulocyte colony stimulating factor (G-CSF) has been added to antifungal treatment in several small patient series (**Table S 16**).^{525,534,557,636,895,896} In Belgium, a case has been described of a patient with extensive abdominal mucormycosis after trauma. Mucormycosis was unresponsive to conventional therapy and was treated successfully with a combination of the immunomodulator nivolumab and interferon- γ .⁸⁹⁷

Recommendations – The guideline group moderately supports G-CSF to augment host response against mucormycosis in patients with ongoing neutropenia (**Table S 16**).

Reducing host vulnerability

Evidence – Hyperglycaemia and ketoacidosis facilitate host infection and mucormycosis.⁸⁹⁸ Animal models of ketoacidosis express increased glucose-regulated protein (GRP-78), a receptor for *R. arrhizus* invasion.⁸⁹⁹ Mucorales spore coat protein homologues (CotH) are fungal ligands to GRP-78,⁹⁰⁰ and antibodies directed towards GRP-78 or CotH protect against experimental mucormycosis.^{899,900} Correction of ketoacidosis alleviates mucormycosis *in vitro* and *in vivo* (**Table S 16**).⁹⁰¹

Recommendations – The guideline group strongly supports controlling hyperglycaemia and ketoacidosis in patients with mucormycosis, specifically those with uncontrolled diabetes (**Table S 16**).

Hyperbaric oxygen exposure

Evidence – *In vitro* hyperbaric oxygen inhibits fungal growth.⁹⁰² Clinical reports on hyperbaric oxygen exposure in the context of mucormycosis are limited to cases or small series.^{27,397,628,821,903-905} Hyperbaric oxygen exposure has mostly been reported from patients with correctable risk factors for mucormycosis.⁵³⁴ These data are uncontrolled and retrospective, and the biological rationale for such therapy is unclear (**Table S 16**).

Recommendations – The guideline group supports a recommendation for hyperbaric oxygen exposure with moderate strength for diabetic patients (**Table S 16**).

Table S 16. Recommendations on adjunctive treatment for mucormycosis

Population	Intention	Intervention	SoR	QoE	Reference	Comment
Iron homeostasis						
Other than haematology	To cure	Deferasirox 20 mg/kg/d, d1-14	C	IIu	Ibrahim JCI 2007 ⁸⁸⁴	Animal, deferasirox increased survival rates
					Spellberg AAC 2009 ⁸⁸⁸	N=8, 6 diabetes, 2 SOT
					Soman JAC 2012 ⁸⁸⁹	N=7, 5 diabetes, all 7 successful
Haematology	To cure	Deferasirox 20 mg/kg/d, d1-14	D	II	Spellberg JAC 2012 ⁸	N=20, open randomised controlled, excess mortality with deferasirox
Any	To increase survival rate	Deferoxamine	D	II	Van Cutsem KidInternat 1989 ⁸⁸⁷ Boelart JCI 1993 ⁸⁸⁵	Animal, deferoxamine increased mortality
Any	To increase survival rate	Administration of iron	D	IIu	Van Cutsem KidInternat 1989 ⁸⁸⁷	Animal, iron increased mortality
					Boelaert JCI 1993 ⁸⁸⁵	
					Ibrahim JCI 2007 ⁸⁸⁴	
					Spellberg MedMycol 2012 ⁶²⁶	Higher baseline serum iron and ferritin associated with mortality
Augmentation of host response						
Haematology, ongoing neutropenia	To augment host response	G-CSF, dose not reported	B	IIu	Pagano BJH 1997 ⁵⁵⁷	N=8
					Kontoyiannis CID 2000 ⁸⁹⁶	N=14
					Pagano Haematol 2004 ⁶³⁶	N=18
					Roden CID 2005 ⁵³⁴	N=18
					Kara IntJClinPract 2007 ⁸⁹⁵	N=5
					Pagano JChemoth 2009 ⁵²⁵	N=8
Haematologic malignancy ongoing neutropenia	To augment host response	Granulocyte transfusion, dose not reported	C	IIur	Kontoyiannis CID 2000 ⁸⁹⁶	N=8
					Roden CID 2005 ⁵³⁴	N=7
Haematologic malignancy ongoing neutropenia	To augment host response	Granulocyte transfusion + IFN γ 1b	C	III	Safdar Cancer 2006 ⁹⁰⁶	N=4
Diabetes	To augment host response	GM-CSF 250-425 μ g/d	C	III	Garcia-Diaz CID 2001 ⁹⁰⁷	N=3
Any	To cure	Adoptive immunotherapy, T cells generated in response to <i>R. arrhizus</i> antigens	C	III	Schmidt JID 2012 ⁹⁰⁸	<i>in vitro</i>
Any	To cure	Nivolumab + interferon- γ	C	III	Grimaldi Lancet ID 2017 ⁸⁹⁷	N=1
Reducing host vulnerability						
Diabetes	To improve response to treatment and to cure	Control of hyperglycaemia and ketoacidosis	A	III	Ibrahim MolMicro 2010 ⁸⁸⁶	Animal, anti-fungal iron permease
					Rammaert Diabetes Metab 2012 ⁸⁹⁸	Review
					Gebremariam JCI 2014 ⁹⁰⁰	Animal, anti-GRP-78
					Gebremariam JCI 2016 ⁹⁰¹	Animal, bicarbonate
Glucocorticosteroid recipients	To cure	Rapidly taper glucocorticosteroid dose to discontinue, if feasible, or reduce dose to minimum required	A	IIr	Lionakis Lancet 2003 ⁹⁰⁹	
Hyperbaric oxygen exposure						
Diabetes	To cure	Exposure to 100% hyperbaric oxygen	B	IIr	Gamba Radiology 1986 ⁶²⁸	N=5
					Ferguson RevInfectDis 1988 ⁹⁰⁴	N=5, 4/5 recovered
					Garcia-Covarrubias RevInvClin 2004 ⁹⁰⁵	N=5, 1 diabetes
					John CMI 2005 ⁹⁰³	N=28, 17 diabetes (6% died)
					John CMI 2005 ⁹⁰³	N=28, 5 haematologic
Haematology	To cure	Exposure to 100% hyperbaric oxygen	C	IIu	Roden CID 2005 ⁵³⁴	N=44 (50% died), mixed
					Ribeiro Mycopathol 2013 ³⁹⁷	N=1
					Almannai PHO 2013 ²⁷	N=1, paediatric
					Kyvernitakis CMI 2016 ⁸²¹	N=11

SoR, strength of recommendation; QoE, quality of evidence; N, number of subjects investigated; SOT, solid organ transplantation; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GRP, gastrin releasing peptide

Intensive care and critically ill patients with mucormycosis

Evidence – A paucity of data exists regarding mucormycosis in the intensive care unit (ICU). Patients may develop mucormycosis in the ICU, or be admitted to the ICU for further management.⁹¹⁰⁻⁹¹³ Mucormycosis as a complication of critical care was initially reported four decades ago, when three previously non-immunocompromised patients developed mucormycosis following corticosteroid therapy.⁹¹⁴ A few case reports and small series in the ICU setting have subsequently been reported.^{910,913,915} Unpublished data from a single centre found that 37% of mucormycosis cases were in patients being treated in the ICU.⁹¹⁶ Many patients at risk for mucormycosis are frequently managed in the ICU. These include patients with haematological malignancy, solid organ transplant recipients, patients with other immunodeficiencies, trauma patients, those with diabetes mellitus, and a multitude of patients with wound dressings. An outbreak of gastric mucormycosis in ICU patients was described in association with the use of contaminated wooden tongue depressors in critically ill patients.⁵⁷⁴ Management of mucormycosis in the ICU involves a four-pronged approach in combination – correction of underlying conditions where feasible, source control, appropriate antifungal therapy, and relevant supportive care. Correction of underlying conditions includes the management of ketoacidosis and correction of hyperglycaemic states in diabetic patients, modulation and weaning of corticosteroids and immunosuppressives, and reducing the duration of neutropenia in haematology patients. Source control involves the removal of infected tissue, drainage of septic collections, and removal of any infected devices. Source control and surgical intervention are key elements in the ICU management of mucormycosis, particularly for rhinocerebral, complicated gastrointestinal, skin and soft tissue forms.^{771,778,917-920} Other presentations should be evaluated on an individual basis. Repeated surgical intervention may be necessary to achieve suitable source control. Appropriate and specific antifungal therapy is discussed in detail in the context of the guideline.

Relevant supportive care of the critically ill patient with mucormycosis is an integral component of the quartet of management of such patients, and entails the same principles as those advocated for all patients with sepsis and septic shock. Important aspects include need for airway protection and mechanical ventilation, attention to haemodynamics, glycaemic control, venous thromboembolism prophylaxis, nutritional support, transfusion policy, and renal replacement therapy where necessary.^{917,921} Several of these aspects are reviewed in detail in recent evidence-based publications addressing sepsis.^{917,921} In general, haemodynamic support involves judicious fluid administration, and in the setting of septic shock, the introduction of vasopressor support to achieve an initial target mean arterial blood pressure of 65 mmHg.^{917,922} The use of corticosteroids, although controversial, may be considered in the setting of septic shock (hydrocortisone 50 mg 6-hourly intravenously for 5-7 days, or up to the weaning of vasopressor therapy, followed by tapering of the dose as guided by clinical response).^{921,923} Airway protection with mechanical ventilation should be instituted where necessary, in patients unable to protect their airway, or where airway clearance is problematic, with the aim of maintaining normoxia.^{924,925} Glucose levels should be maintained at <180 mg/dL (10 mmol/L), and nutritional support commenced once the patient is haemodynamically stable, preferably via the enteral route.^{921,923} A restrictive haemoglobin target of 7 g/dL is appropriate for non-bleeding patients without active myocardial ischaemia.^{926,927} Pharmacological venous thromboembolism prophylaxis should be provided to all patients where no contraindications exist. Low molecular weight heparins are preferred to unfractionated heparin. Mechanical modes of prophylaxis such as intermittent pneumatic compression devices should be used when pharmacological prophylaxis is contraindicated. Combination mechanical and pharmacological prophylaxis should be used whenever possible.^{921,923}

Recommendations – In critically ill patients in the ICU, a combined four-pronged management approach is strongly recommended. This includes correction of the underlying conditions where feasible, source control, appropriate antifungal therapy, and relevant supportive care.

Health economics

Evidence – Only very few studies have analysed the economic burden of mucormycosis. Based on hospital charges and on ICD-9 coding in the USA, mucormycosis was associated with an average hospital stay of 17 days, and with one out of three patients requiring re-admission. The costs per stay were estimated at USD 112,419.⁵³⁰ In paediatric patients with fungal sinusitis, the duration of hospitalisation and associated costs were estimated to be 3 to 5 times, and 7 to 13 times higher, respectively.⁹²⁸ In patients with haematological malignancies in the United Kingdom, first-line treatment with isavuconazole was shown to reduce costs compared to standard treatment with liposomal amphotericin B followed by posaconazole.⁹²⁹ This was primarily driven by lower costs for drug acquisition and hospitalisation.

Recommendations – Due to variation of drug acquisition costs and duration of hospitalisation, future studies are needed to validate findings in other geographical settings and patient groups.

Future directions

Unmet needs

Unmet needs in mucormycosis differ between regions and institutions. Rapid diagnostics to identify with good specificity patients with mucormycosis in the early stages of infection are critical. Newer molecular-based approaches, including the detection of Mucorales DNA in the blood of patients,^{320,742} and Mucorales-specific *CotH* gene in clinical samples,⁹³⁰ have yielded promising results but require large-scale clinical validation. Similarly, markers of host response that recognise fungus-specific T cells or their products (*e.g.* cytokines are worthy of further exploration).^{682,684}

As a medical emergency, a multidisciplinary approach with early consultation with specialists from the treating team, radiologists, infectious diseases specialists, microbiologists, pathologists, and surgical colleagues is of paramount importance in the proper management of mucormycosis. This is often challenging, as clinical manifestations vary, and present to physicians with disparate expertise. Access to multidisciplinary care may be limited by logistic difficulties, and in some countries, by geographical isolation.

The absence of ready access to current or new antifungal drugs also limits proper care and affects outcome. In resource-limited countries, liposomal amphotericin B and posaconazole availability can be restricted due to high costs, and pharmaceutical companies are constrained by their own terms of references. In high-income countries, the delay from discovery of a new agent with promising *in vitro* and *in vivo* animal results to the stage of clinical trials and then to registration and community availability spans years. Human ethics review boards, government and regulatory bodies need to work with clinicians to accelerate their access.

The importance of continuing to develop novel antifungal agents that are characterised by good efficacy, pharmacokinetic and pharmacodynamic characteristics, and safety cannot be overemphasised. Ideally, these new drugs should have a novel mode of action, be fungicidal and orally available, have a long half-life, and penetrate well into difficult body sites, such as the brain.

Constraints in optimising management

Successful treatment of mucormycosis remains challenging due to several reasons. Diagnosis of deep-seated mucormycosis is often delayed due to the unspecific clinical features of the infection and a lack of rapid, user-friendly, biomarker tests. In daily clinical practice, diagnosis of mucormycosis is often based on conventional techniques such as microscopy and culture with poor sensitivity. In addition, mucormycosis may be masked in patients with *Aspergillus* co-infections. Evaluation of a consecutive case series showed that delaying amphotericin B therapy is an independent predictor of mortality.⁸¹⁹ Lipid formulations of amphotericin B are the cornerstone for the treatment of mucormycosis. However, due to cost issues amphotericin B deoxycholate remains the only affordable treatment option in many low and medium income countries, despite its toxicity. Moreover, amphotericin B is unavailable in 27% of countries, resulting in an unserved population of nearly 500 million.⁹³¹ A study conducted in a West-Indian infectious diseases clinic revealed that as many as 35% of patients with mucormycosis left against medical advice because of various reasons including hospitalisation costs and drug toxicity.³⁶⁵ Liposomal amphotericin B has a much more favourable safety profile than amphotericin B deoxycholate, but toxicity rates increase with increasing dosages. Nephrotoxicity and hypokalaemia rates as high as 30% were reported in patients treated with 10 mg/kg liposomal amphotericin B.⁸²⁴

Surgical debridement is associated with better survival, and is often feasible in cases of skin and soft tissue involvement but much more difficult in severely immunocompromised and/or critically ill patients suffering from deep-organ mucormycosis such as pulmonary or cerebral mucormycosis.

Priority research questions

To address unmet needs in the management of mucormycosis, the immediate research priorities can be grouped into three broad categories: microbiology laboratory tools, antifungal therapeutics, and clinical management.

In the microbiology lab, the development and validation of sensitive and specific diagnostic tests for mucormycosis that can be applied to serum, BAL and tissue is the most pressing research priority. Studies in this area should not only include standardisation and validation of existing techniques, for example PCR, but also pursue novel diagnostic targets. The success of cell-wall glucan-based assays for other medically relevant fungi suggests that identification of cell-wall polysaccharides unique to mucormycetes should be pursued. Developing antibodies for tissue immunohistochemistry that can distinguish hyphae of mucormycetes from those of other filamentous hyphae will not only aid in the diagnosis of mucormycosis, but also help identify cases of mixed mould infection. In addition to these diagnostic studies, the development of clinically relevant antifungal susceptibility testing, including the identification and clinical validation of breakpoints is required.

Although the introduction of azoles with activity against mucormycetes has offered alternatives to amphotericin B products, direct comparisons of these agents with each other and with amphotericin B lipid formulations are lacking. Understanding the relative efficacy of these agents in specific populations will be critical in refining treatment algorithms for mucormycosis. The identification and development of therapies with novel mechanisms of action against these organisms are also clearly required. In addition to conventional small-molecule approaches,

innovative solutions such as passive immunotherapy and chimeric antigen receptor T-cell therapy may hold promise and should be explored.

Additionally, studies to define optimal care pathways that incorporate existing and emerging tools and therapies should not be neglected. Defining the duration of antifungal therapy and markers of treatment response are needed to guide appropriate antifungal stewardship and optimal clinical care. Further research is required to define the role of antifungal prophylaxis, diagnostic/imaging-driven and clinically driven approaches for specific patient populations. Finally, clinical studies evaluating the role of TDM in guiding azole antifungal therapy in specific clinical populations will be invaluable in managing these challenging infections.

References

1. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clin Microbiol Infect* 2014; **20** (Suppl 3): 5-26.
2. Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. *Clin Microbiol Infect* 2014; **20** (Suppl 3): 1-4.
3. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect* 2012; **18** (Suppl 7): 19-37.
4. Hoenigl M, Gangneux JP, Segal E, et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. *Mycoses* 2018; **61**(11): 885-94.
5. Ullmann AJ, Cornely OA, Donnelly JP, et al. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. *Clin Microbiol Infect* 2012; **18** (Suppl 7): 1-8.
6. Kavanagh BP. The GRADE system for rating clinical guidelines. *PLoS Med* 2009; **6**(9): e1000094.
7. Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ* 2016; **352**: i1152.
8. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. *J Antimicrob Chemother* 2012; **67**(3): 715-22.
9. El Zein S, El-Sheikh J, Zakhem A, Ibrahim D, Bazarbachi A, Kanj SS. Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series. *Infection* 2018; **46**(6): 811-21.
10. Abdollahi A, Shokohi T, Amirrajab N, et al. Clinical features, diagnosis, and outcomes of rhino-orbito-cerebral mucormycosis- A retrospective analysis. *Curr Med Mycol* 2016; **2**(4): 15-23.
11. Abela L, Toelle SP, Hackenberg A, Scheer I, Gungor T, Plecko B. Fatal outcome of rhino-orbital-cerebral mucormycosis due to bilateral internal carotid occlusion in a child after hematopoietic stem cell transplantation. *Pediatr Infect Dis J* 2013; **32**(10): 1149-50.
12. Abidi MZ, Coelho-Prabhu N, Hargreaves J, et al. Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature. *Case Rep Med* 2014; **2014**: 637492.
13. Abuzayed B, Al-Abadi H, Al-Otti S, Baniyaseen K, Al-Sharki Y. Neuronavigation-guided endoscopic endonasal resection of extensive skull base mucormycosis complicated with cerebral vasospasm. *J Craniofac Surg* 2014; **25**(4): 1319-23.
14. Acharya S, Shukla S, Noman O, Dawande P. Isolated pulmonary mucormycosis presenting as cavitary lesion in an immunocompetent adult: A rare case report. *Int J Appl Basic Med Res* 2016; **6**(1): 73-4.
15. Afolayan O, Copeland H, Hargrove R, Zaheer S, Wallen JM. Successful Treatment of Invasive Pulmonary Mucormycosis in an Immunocompromised Patient. *Ann Thorac Surg* 2016; **101**(4): e117-9.
16. Afolayan O, Copeland H, Zaheer S, Wallen JM. Pulmonary Mucormycosis Treated With Lobectomy. *Ann Thorac Surg* 2017; **103**(6): e531-e3.
17. Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. *Contemp Clin Dent* 2017; **8**(4): 662-6.
18. Aggarwal D, Chander J, Janmeja AK, Katyal R. Pulmonary tuberculosis and mucormycosis co-infection in a diabetic patient. *Lung India* 2015; **32**(1): 53-5.
19. Agrawal P, Saikia U, Ramanaathan S, Samujh R. Neonatal small intestinal zygomycosis misdiagnosed as intussusception in a two-day-old child with a review of the literature. *Fetal Pediatr Pathol* 2013; **32**(6): 418-21.
20. Ahamed SK, Al Thobaiti Y. Mucormycosis: a challenge for diagnosis and treatment--2 case reports and review of literature. *Oral Health Dent Manag* 2014; **13**(3): 703-6.

21. Ahmadinejad Z, Khazraiyani H, Ghanbari F, Ahmadi B, Gerami Shoar M. Cutaneous Mucormycosis in a Diabetic Patient following Traditional Dressing. *Case Rep Dermatol Med* 2013; **2013**: 894927.
22. Ahmed Y, Delaney S, Markarian A. Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. *Am J Otolaryngol* 2016; **37**(2): 152-5.
23. Al Barbarawi MM, Allouh MZ. Successful Management of a Unique Condition of Isolated Intracranial Mucormycosis in an Immunocompetent Child. *Pediatr Neurosurg* 2015; **50**(3): 165-7.
24. Alghamdi A, Lutynski A, Minden M, Rotstein C. Successful treatment of gastrointestinal mucormycosis in an adult with acute leukemia: case report and literature review. *Curr Oncol* 2017; **24**(1): e61-e4.
25. Alharbi M, Jhinger RK, Wuerz T, Walkty A. Marked peripheral eosinophilia due to prolonged administration of posaconazole. *JMM Case Rep* 2017; **4**(6): e005100.
26. Al-Jabri S, Al-Abri M, Al-Hinai A, Al-Azri F. Bilateral Ocular Ischaemic Syndrome-Rare Complication of Rhinocerebral Mucormycosis in an Omani Patient: Case report and literature review. *Sultan Qaboos Univ Med J* 2013; **13**(1): 137-42.
27. Almannai M, Imran H, Estrada B, Siddiqui AH. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. *Pediatr Hematol Oncol* 2013; **30**(3): 184-6.
28. Al-Otaibi AM, Al-Shahrani DA, Al-Idrissi EM, Al-Abdely HM. Invasive mucormycosis in chronic granulomatous disease. *Saudi Med J* 2016; **37**(5): 567-9.
29. Al-Tarrah K, Abdelaty M, Behbahani A, Mokaddas E, Soliman H, Albader A. Cutaneous mucormycosis postcosmetic surgery: A case report and review of the literature. *Medicine (Baltimore)* 2016; **95**(27): e4185.
30. Alvarado-Lezama J, Espinosa-Gonzalez O, Garcia-Cano E, Sanchez-Cordova G. [Emphysematous gastritis secondary to gastric mucormycosis]. *Cir Cir* 2015; **83**(1): 56-60.
31. Al-Zaydani IA, Al-Hakami AM, Joseph MR, et al. Aggressive cutaneous zygomycosis caused by *Apophysomyces variabilis* in an immunocompetent child. *Med Mycol Case Rep* 2015; **10**: 11-3.
32. Anaparthi UR, Deepika G. A case of subcutaneous zygomycosis. *Indian Dermatol Online J* 2014; **5**(1): 51-4.
33. Anders UM, Taylor EJ, Martel JR, Martel JB. Acute orbital apex syndrome and rhino-orbito-cerebral mucormycosis. *Int Med Case Rep J* 2015; **8**: 93-6.
34. Anderson A, McManus D, Perreault S, Lo YC, Seropian S, Topal JE. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. *Med Mycol Case Rep* 2017; **17**: 11-3.
35. Angali RK, Jeshtadi A, Namala VA, Gannepalli A. Fatal rhino-orbito-cerebral mucormycosis in a healthy individual. *J Oral Maxillofac Pathol* 2014; **18**(3): 460-3.
36. Annigeri RA, Parameswaran A. Zygomycosis Presenting as Acute Bilateral Renal Artery Thrombosis in a Healthy Young Male. *J Assoc Physicians India* 2015; **63**(4): 77-9.
37. Antony SJ, Parikh MS, Ramirez R, Applebaum B, Friedman G, Do J. Gastrointestinal Mucormycosis Resulting in a Catastrophic Outcome in an Immunocompetent Patient. *Infect Dis Rep* 2015; **7**(3): 6031.
38. Arroyo MA, Schmitt BH, Davis TE, Relich RF. Detection of the Dimorphic Phases of *Mucor circinelloides* in Blood Cultures from an Immunosuppressed Female. *Case Rep Infect Dis* 2016; **2016**: 3720549.
39. Asimakopoulos P, Supriya M, Kealey S, Vernham GA. A case-based discussion on a patient with non-otogenic fungal skull base osteomyelitis: pitfalls in diagnosis. *J Laryngol Otol* 2013; **127**(8): 817-21.
40. Athavale DD, Jones R, O'Donnell BA, Forer M, Biggs N. Non-Exenteration Management of Sino-Orbital Fungal Disease. *Ophthalmic Plast Reconstr Surg* 2017; **33**(6): 426-9.
41. Augustine HFM, White C, Bain J. Aggressive Combined Medical and Surgical Management of Mucormycosis Results in Disease Eradication in 2 Pediatric Patients. *Plast Surg (Oakv)* 2017; **25**(3): 211-7.
42. Austin CL, Finley PJ, Mikkelsen DR, Tibbs B. Mucormycosis: a rare fungal infection in tornado victims. *J Burn Care Res* 2014; **35**(3): e164-71.
43. Avcu G, Karapinar DY, Yazici P, et al. Difficult diagnosis of invasive fungal infection predominantly involving the lower gastrointestinal tract in acute lymphoblastic leukaemia. *Med Mycol Case Rep* 2016; **11**: 1-4.
44. Avelar Rodriguez D, Ochoa Virgen G, Miranda Ackerman RC. A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association. *BMJ Case Rep* 2017; **2017**.
45. Ayadi-Kaddour A, Ammar J, Ismail O, et al. [Pulmonary zygomycosis in a diabetic child complicated with thrombus of the left atrial auricle]. *Arch Pediatr* 2014; **21**(11): 1241-5.
46. Ayadi-Kaddour A, Braham E, Marghli A, et al. [Fatal pulmonary mycosis in a diabetic and cirrhotic patient]. *Tunis Med* 2015; **93**(4): 259-62.
47. Ayaz M, Moein R. Myocutaneous Mucormycosis in a Diabetic Burnt Patient Led to Upper Extremity Amputation; A Case Report. *Bull Emerg Trauma* 2017; **5**(1): 58-62.

48. Azar MM, Assi R, Patel N, Malinis MF. Fungal Mycotic Aneurysm of the Internal Carotid Artery Associated with Sphenoid Sinusitis in an Immunocompromised Patient: A Case Report and Review of the Literature. *Mycopathologia* 2016; **181**(5-6): 425-33.
49. Bachelet JT, Buiuret G, Chevallier M, Bergerot JF, Ory L, Gleizal A. [Conidiobolus coronatus infections revealed by a facial tumor]. *Rev Stomatol Chir Maxillofac Chir Orale* 2014; **115**(2): 114-7.
50. Backer H, Beeres FJ, Rossi M, Scheiwiller A. Gastric perforation after duodenopancreatectomy. *Med Mycol Case Rep* 2017; **18**: 21-3.
51. Badior M, Trigo F, Eloy C, Guimaraes JE. Mucor infection: difficult diagnosis. *Clin Drug Investig* 2013; **33 Suppl 1**: S19-21.
52. Bakshi SS. Rhino-orbital mucormycosis in a patient with diabetes. *Lancet Diabetes Endocrinol* 2017; **5**(3): 234.
53. Banerjee S, Peck KN, Feldman MD, Schuster MG, Alwine JC, Robertson ES. Identification of fungal pathogens in a patient with acute myelogenous leukemia using a pathogen detection array technology. *Cancer Biol Ther* 2016; **17**(4): 339-45.
54. Bellazreg F, Hattab Z, Meksi S, et al. Outcome of mucormycosis after treatment: report of five cases. *New Microbes New Infect* 2015; **6**: 49-52.
55. Benachinmardi KK, Rajalakshmi P, Veenakumari HB, et al. Successful treatment of primary cerebral mucormycosis: Role of microbiologist. *Indian J Med Microbiol* 2016; **34**(4): 550-3.
56. Benites BM, Fonseca FP, Parahyba CJ, Arap SS, Novis YA, Fregnani ER. Extensive Oral Mucormycosis in a Transplanted Patient. *J Craniofac Surg* 2017; **28**(1): e4-e5.
57. Bergantim R, Rios E, Trigo F, Guimaraes JE. Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia. *Clin Drug Investig* 2013; **33** (Suppl 1): S51-5.
58. Bernardo RM, Gurung A, Jain D, Malinis MF. Therapeutic Challenges of Hepatic Mucormycosis in Hematologic Malignancy: A Case Report and Review of the Literature. *Am J Case Rep* 2016; **17**: 484-9.
59. Bernhardt A, de Boni L, Kretzschmar HA, Tintelnot K. [Molecular biological identification of fungal pathogens in FFPE tissue from cases of cephalic mycosis]. *Pathologie* 2013; **34**(6): 540-7.
60. Bertumen JB, Schell WA, Joyce M, Alley C, Woods CW. Diagnostic difficulty identifying Apophysomyces trapeziformis septic arthritis in a patient with multiple myeloma. *JMM Case Rep* 2016; **3**(6): e005075.
61. Bezdicek M, Lengerova M, Ricna D, et al. Rapid detection of fungal pathogens in bronchoalveolar lavage samples using panfungal PCR combined with high resolution melting analysis. *Med Mycol* 2016; **54**(7): 714-24.
62. Bhagat M, Rapose A. Rapidly progressing dual infection with Aspergillus and Rhizopus: when soil inhabitants become deadly invaders. *BMJ Case Rep* 2016; **2016**.
63. Bharadwaj R, Madakshira MG, Bharadwaj P, Sidhu HS. Sclerosing Mediastinitis Presenting as Complete Heart Block. *J Clin Diagn Res* 2017; **11**(5): Ed12-ed4.
64. Bhaskar N, Chhabra V, Kaushal N, Aggarwal S. Rare Opportunistic Bread Mold Fungal Infection of Maxillary Sinus in a Diabetic Patient. *Int J Appl Basic Med Res* 2017; **7**(3): 202-4.
65. Bhat MT, Hegde HV, Santhosh MC, Rao RP. Orbital exenteration under trigeminal block: An innovative method of regional anesthesia. *Saudi J Anaesth* 2013; **7**(4): 470-3.
66. Bhatnagar A, Agarwal A. Naso-orbital fistula and socket reconstruction with radial artery forearm flap following orbital mucormycosis. *Natl J Maxillofac Surg* 2016; **7**(2): 197-200.
67. Bini R, Addeo A, Maganuco L, Fontana D, Viora T, Leli R. The role of surgery in a case of diffuse mucormycosis with haematemeses and gastric necrosis. *Ann R Coll Surg Engl* 2014; **96**(5): e31-3.
68. Biradar S, Patil SN, Kadeli D. Mucormycosis in a Diabetic Ketoacidosis Patient: A Case Report. *J Clin Diagn Res* 2016; **10**(5): Od09-10.
69. Bird J, Telang G, Robinson-Bostom L. Two pink nodules in a patient with acute myeloid leukemia. *J Cutan Pathol* 2014; **41**(6): 483-6.
70. Biswas D, Kotwal A, Kakati B, Ahmad S. Amphotericin B Resistant Apophysomyces elegans Causing Rhino-oculo-Cerebral Mucormycosis in an Immunocompetent Host. *J Clin Diagn Res* 2015; **9**(8): Dd01-2.
71. Bonifaz A, Stchigel AM, Guarro J, et al. Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus. *J Clin Microbiol* 2014; **52**(12): 4428-31.
72. Bourcier J, Heudes PM, Morio F, et al. Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016). *Mycoses* 2017; **60**(8): 526-33.
73. Bowles RJ, Mitchell JJ, Price C, Ipaktchi K. Severe mycosis as a rare infection after a corn auger injury of the hand: a case report. *Patient Saf Surg* 2015; **9**: 22.
74. Bozorgi V, Talebitaheer M, Shalbah N, Radmanesh N, Nasri F, Ansari-Ramandi MM. Epidemiological aspects and clinical outcome of patients with Rhinocerebral zygomycosis: a survey in a referral hospital in Iran. *Pan Afr Med J* 2016; **24**: 232.

75. Cadelis G. [Hemoptysis complicating bronchopulmonary mucormycosis in a diabetic patient]. *Rev Pneumol Clin* 2013; **69**(2): 83-8.
76. Caillot D, Legouge C, Lafon I, et al. [Retrospective study of 25 cases of pulmonary mucormycosis in acute leukaemia]. *Rev Mal Respir* 2018; **35**(4): 452-64.
77. Calvert W, Mullassery D, Shukla R, Lamont G. Novel therapeutic use of Versajet for intestinal mucormycosis. *BMJ Case Rep* 2014; **2014**.
78. Camargo JF, Yakoub D, Cho-Vega JH. Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole. *Mycopathologia* 2015; **180**(3-4): 187-92.
79. Campbell A, Cooper C, Davis S. Disseminated mucormycosis in a paediatric patient: Lichthemia corymbifera successfully treated with combination antifungal therapy. *Med Mycol Case Rep* 2014; **6**: 18-21.
80. Capria S, De Angelis F, Gentile G, et al. Complete remission obtained with azacitidine in a patient with concomitant therapy related myeloid neoplasm and pulmonary mucormycosis. *Mediterr J Hematol Infect Dis* 2013; **5**(1): e2013048.
81. Carceller F, Onoro G, Buitrago MJ, et al. Cunninghamella bertholletiae infection in children: review and report of 2 cases with disseminated infection. *J Pediatr Hematol Oncol* 2014; **36**(2): e109-14.
82. Carnovale S, Daneri GL. [Lichtheimia sp. in an immunodepressed patient]. *Rev Argent Microbiol* 2014; **46**(2): 161-2.
83. Castrejon-Perez AD, Welsh EC, Miranda I, Ocampo-Candiani J, Welsh O. Cutaneous mucormycosis. *An Bras Dermatol* 2017; **92**(3): 304-11.
84. Cateau E, Randriamalala E, Elsendoorn A, Giot JP, du Sorbier CM, Rodier MH. Fatal-mixed cutaneous zygomycosis-aspergillosis: a case report. *Mycopathologia* 2013; **176**(5-6): 423-7.
85. Chaaban MR, Bell W, Woodworth BA. Invasive mucormycosis in an immunocompetent patient with allergic fungal rhinosinusitis. *Otolaryngol Head Neck Surg* 2013; **148**(1): 174-5.
86. Chaari A, Ghadoun H, Ben Algia N, Bahloul M, Bouaziz M. [Mucormycosis: an unusual cause of unilateral exophthalmia]. *J Mycol Med* 2013; **23**(2): 140-3.
87. Chahal HS, Abgaryan N, Lakshminarayanan R, Glover AT. Orbital Mucormycosis Following Periorbital Cutaneous Infection. *Ophthalmic Plast Reconstr Surg* 2017; **33**(3S Suppl 1): S146-s8.
88. Chamdine O, Gaur AH, Broniscer A. Effective treatment of cerebral mucormycosis associated with brain surgery. *Pediatr Infect Dis J* 2015; **34**(5): 542-3.
89. Charles P, Kahn JE, Ackermann F, Honderlick P, Lortholary O. Renal mucormycosis complicating extracorporeal membrane oxygenation. *Med Mycol* 2013; **51**(2): 193-5.
90. Chen CY, Sheng WH, Tien FM, et al. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013. *J Microbiol Immunol Infect* 2018.
91. Chen YX, He YX, Zhou H, Wang M, Su SO. Rapidly progressive rhino-orbito-cerebral mucormycosis in a patient with type 2 diabetes: A case report. *Exp Ther Med* 2017; **13**(3): 1054-6.
92. Cheng W, Wang G, Yang M, et al. Cutaneous mucormycosis in a patient with lupus nephritis: A case report and review of literature. *Medicine (Baltimore)* 2017; **96**(42): e8211.
93. Cheng Y, Gao Y, Liu XY, Wang GY, Zhang GQ, Gao SQ. Rhinocerebral mucormycosis caused by *Rhizopus arrhizus* var. *tonkinensis*. *J Mycol Med* 2017; **27**(4): 586-8.
94. Cheong HS, Kim SY, Ki HK, Kim JY, Lee MH. Oral mucormycosis in patients with haematologic malignancies in a bone marrow transplant unit. *Mycoses* 2017; **60**(12): 836-41.
95. Chermetz M, Gobbo M, Rupel K, et al. Combined Orofacial Aspergillosis and Mucormycosis: Fatal Complication of a Recurrent Paediatric Glioma-Case Report and Review of Literature. *Mycopathologia* 2016; **181**(9-10): 723-33.
96. Chi M, Kim HJ, Basham R, Yoon MK, Vagefi R, Kersten RC. Temporal Artery Calciphylaxis Presenting as Temporal Arteritis in a Case of Rhinorbitocerebral Mucormycosis. *Ophthalmic Plast Reconstr Surg* 2015; **31**(5): e132-5.
97. Choi WT, Chang TT, Gill RM. Gastrointestinal Zygomycosis Masquerading as Acute Appendicitis. *Case Rep Gastroenterol* 2016; **10**(1): 81-7.
98. Chow KL, McElmeel DP, Brown HG, Tabriz MS, Omi EC. Invasive gastric mucormycosis: A case report of a deadly complication in an immunocompromised patient after penetrating trauma. *Int J Surg Case Rep* 2017; **40**: 90-3.
99. Chow V, Khan S, Balogun A, Mitchell D, Muhlschlegel FA. Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient - the need for prompt treatment. *Med Mycol Case Rep* 2015; **8**: 5-9.
100. Chretien ML, Legouge C, Pages PB, et al. Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre. *Clin Microbiol Infect* 2016; **22**(9): 782-7.

101. Christopheit M, Lindner A, Surov A, et al. Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. *Mycoses* 2013; **56**(1): 90-2.
102. Cofre F, Villarroel M, Castellon L, Santolaya ME. [Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia]. *Rev Chilena Infectol* 2015; **32**(4): 458-63.
103. Colovic N, Arsic-Arsenijevic V, Barac A, Suvajdzic N, Lekovic D, Tomin D. Mucormycosis of the paranasal sinuses in a patient with acute myeloid leukemia. *Srp Arh Celok Lek* 2016; **144**(11-12): 657-60.
104. Compain F, Ait-Ammar N, Botterel F, Gibault L, Le Pimpec Barthes F, Dannaoui E. Fatal Pulmonary Mucormycosis due to *Rhizopus homothallicus*. *Mycopathologia* 2017; **182**(9-10): 907-13.
105. Corey KE, Gupta NK, Agarwal S, Xiao HD. Case records of the Massachusetts General Hospital. Case 32-2013. A 55-year-old woman with autoimmune hepatitis, cirrhosis, anorexia, and abdominal pain. *N Engl J Med* 2013; **369**(16): 1545-53.
106. Coronel-Perez IM, Rodriguez-Rey EM, Castilla-Guerra L, Dominguez MC. Primary Cutaneous Mucormycosis Due to *Saksenea vasiformis* in an Immunocompetent Patient. *Actas Dermosifiliogr* 2015; **106**(6): 516-8.
107. Cortez J, Gomes BC, Speidel A, et al. Mind the gap: Management of an emergent and threatening invasive fungal infection-a case report of rhino-orbital-cerebral and pulmonary mucormycosis. *Med Mycol Case Rep* 2013; **2**: 79-84.
108. Couldwell WT, MacDonald JD, Taussky P. Complete resection of the cavernous sinus-indications and technique. *World Neurosurg* 2014; **82**(6): 1264-70.
109. Crisan AM, Ghiaur A, Stancioaca MC, et al. Mucormycosis during Imatinib treatment: case report. *J Med Life* 2015; **8**(3): 365-70.
110. Dave VP, Sharma S, Yogi R, Reddy S. *Apophysomyces elegans*: a novel cause of endogenous endophthalmitis in an immunocompetent individual. *Int Ophthalmol* 2014; **34**(6): 1285-9.
111. Davies BW, Smith JM, Hink EM, Durairaj VD. Increased Incidence of Rhino-Orbital-Cerebral Mucormycosis After Colorado Flooding. *Ophthalmic Plast Reconstr Surg* 2017; **33**(3S Suppl 1): S148-s51.
112. Davoudi S, Anderlini P, Fuller GN, Kontoyiannis DP. A long-term survivor of disseminated *Aspergillus* and mucorales infection: an instructive case. *Mycopathologia* 2014; **178**(5-6): 465-70.
113. Davoudi S, Manshadi SA, Salehi MR, Yazdi F, Khazravi M, Fazli JT. Fatal cutaneous mucormycosis after kidney transplant. *Exp Clin Transplant* 2015; **13**(1): 82-5.
114. Dayan D, Abu-Abeid S, Klausner JM, Sagie B. Disseminated mucormycosis-induced perforated intestine in a late presenting AIDS patient with steroid-dependent secondary hemophagocytic lymphohistiocytosis. *Aids* 2015; **29**(16): 2216-7.
115. de Almeida Junior JN, Ibrahim KY, Del Negro GM, et al. *Rhizopus arrhizus* and *Fusarium solani* Concomitant Infection in an Immunocompromised Host. *Mycopathologia* 2016; **181**(1-2): 125-9.
116. de Chaumont A, Pierret C, Janvier F, Goudard Y, de Kerangal X, Chapuis O. Mucormycosis: a rare complication of an amputation. *Ann Vasc Surg* 2014; **28**(4): 1035.e15-9.
117. de Clerck F, Van Ryckeghem F, Depuydt P, et al. Dual disseminated infection with *Nocardia farcinica* and *Mucor* in a patient with systemic lupus erythematosus: a case report. *J Med Case Rep* 2014; **8**: 376.
118. De Leonardis F, Perillo T, Giudice G, Favia G, Santoro N. Recurrent Rhino-Ocular-Cerebral Mucormycosis in a Leukemic Child: A Case Report and Review of Pediatric Literature. *Pediatr Rep* 2015; **7**(3): 5938.
119. Delie A, Vlummens P, Creytens D, Steel E. Cutaneous mucormycosis as result of insulin administration in an AML patient: Case report and review of the literature. *Acta Clin Belg* 2017; **72**(5): 352-6.
120. Denu RA, Rush PS, Ahrens SE, Westergaard RP. Idiopathic CD4 lymphocytopenia with giant cell arteritis and pulmonary mucormycosis. *Med Mycol Case Rep* 2014; **6**: 73-5.
121. Desai RP, Joseph NM, Ananthkrishnan N, Ambujam S. Subcutaneous zygomycosis caused by *Mucor hiemalis* in an immunocompetent patient. *Australas Med J* 2013; **6**(7): 374-7.
122. Desoubeaux G, Leperlier M, Chaussade H, et al. [Cutaneous mucormycosis caused by *Rhizopus microsporus*]. *Ann Dermatol Venereol* 2014; **141**(3): 201-5.
123. Devana SK, Bora GS, Mavuduru RS, Panwar P, Kakkar N, Mandal AK. Successful management of renal mucormycosis with antifungal therapy and drainage. *Indian J Urol* 2016; **32**(2): 154-5.
124. Devars du Mayne M, Gratacap M, Malinvaud D, Grenouillet F, Bonfils P. An uncommon cause of allergic fungal sinusitis: *Rhizopus oryzae*. *Ear Nose Throat J* 2015; **94**(1): E17-20.
125. Deyo JC, Nicolsen N, Lachiewicz A, Kozlowski T. Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression. *J Pharm Pract* 2017; **30**(2): 261-5.
126. Dhakar MB, Rayes M, Kupsky W, Tselis A, Norris G. A Cryptic Case: Isolated Cerebral Mucormycosis. *Am J Med* 2015; **128**(12): 1296-9.

127. Di Carlo P, Pirrello R, Guadagnino G, et al. Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: a case report and literature review. *Case Rep Med* 2014; **2014**: 527062.
128. di Coste A, Costantino F, Tarani L, et al. Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: a case report and review of the literature. *Ital J Pediatr* 2013; **39**: 77.
129. Di Palma A, Sebjang H, Schwenter F. Gastrointestinal mucormycosis after abdominal aortic aneurysm repair and prolonged hospitalization: A case report and review of the literature. *Int J Surg Case Rep* 2016; **27**: 195-7.
130. Di Pentima MC, Chan S, Powell J, Napoli JA, Walter AW, Walsh TJ. Topical amphotericin B in combination with standard therapy for severe necrotizing skin and soft-tissue mucormycosis in an infant with bilineal leukemia: case report and review. *J Pediatr Hematol Oncol* 2014; **36**(7): e468-70.
131. Dien Bard J, Mangahis A, Hofstra TC, Bender JM. First case report of bloodstream infection by *Rhizomucor pusillus* in a child with hemophagocytic lymphohistiocytosis. *Med Mycol Case Rep* 2014; **5**: 20-3.
132. Dimaka K, Mallis A, Naxakis SS, et al. Chronic rhinocerebral mucormycosis: a rare case report and review of the literature. *Mycoses* 2014; **57**(11): 699-702.
133. Do GW, Jung SW, Jun JB, Seo JH, Nah YW. Colonic mucormycosis presented with ischemic colitis in a liver transplant recipient. *World J Gastroenterol* 2013; **19**(22): 3508-11.
134. Dodemont M, Hites M, Bailly B, et al. When you can't see the wood for the trees. *Mucor circinelloides*: A rare case of primary cutaneous zygomycosis. *J Mycol Med* 2015; **25**(2): 151-4.
135. Dogra V, Talwar D, Saxena R, Dabral C, Joshi S, Bansal S. Trilogy of sequential infections in a diabetic male. *Respirol Case Rep* 2015; **3**(4): 155-8.
136. Dube P, Saroa R, Palta S. Coinfections in Intensive Care Unit with pulmonary tuberculosis and mucormycosis: A clinical dilemma. *Indian J Crit Care Med* 2016; **20**(3): 191-3.
137. Durila M, Pavlicek P, Hadacova I, Nahlovsky J, Janeckova D. Endogenous Heparinoids May Cause Bleeding in *Mucor* Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report. *Medicine (Baltimore)* 2016; **95**(8): e2933.
138. Dusart A, Duprez T, Van Snick S, Godfraind C, Sindic C. Fatal rhinocerebral mucormycosis with intracavernous carotid aneurysm and thrombosis: a late complication of transsphenoidal surgery? *Acta Neurol Belg* 2013; **113**(2): 179-84.
139. Dutta S, Sarkar S, Linka U, Dora S. Conidiobolomycosis: A case report of rare fungal infection from the eastern India. *Indian Dermatol Online J* 2015; **6**(6): 393-5.
140. Dwarakanath S, Kumar V, Blackburn J, Castresana MR. A rare case of multi-chambered fungal endocarditis from a virulent *Cunninghamella* infection. *Eur Heart J* 2014; **35**(6): 343.
141. Dworsky ZD, Bennett R, Kim JM, Kuo DJ. Severe medication-induced peripheral neuropathy treated with topical doxepin cream in a paediatric patient with leukaemia. *BMJ Case Rep* 2017; **2017**.
142. Ebadi M, Alavi S, Ghojevand N, Aghdam MK, Yazdi MK, Zahiri A. Infantile splenorenopancreatic mucormycosis complicating neuroblastoma. *Pediatr Int* 2013; **55**(6): e152-5.
143. Echaiz JF, Burnham CA, Bailey TC. A case of *Apophysomyces trapeziformis* necrotizing soft tissue infection. *Int J Infect Dis* 2013; **17**(12): e1240-2.
144. Egelund EF, Egelund TA, Ng JS, Wassil SK, Peloquin CA. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. *Pharmacotherapy* 2013; **33**(1): e1-8.
145. Eickhardt S, Braendstrup P, Clasen-Linde E, et al. A non-fatal case of invasive zygomycete (*Lichtheimia corymbifera*) infection in an allogeneic haematopoietic cell transplant recipient. *Apms* 2013; **121**(5): 456-9.
146. Elguazzar S, Benouachane T, Nasri A, Malihy A, Tligui H, Bentahila A. [Iliofemoral cutaneous mucormycosis with endopelvic extension in an immunocompetent child]. *Arch Pediatr* 2013; **20**(7): 754-7.
147. El-Mahallawy HA, Khedr R, Taha H, Shalaby L, Mostafa A. Investigation and Management of a *Rhizomucor* Outbreak in a Pediatric Cancer Hospital in Egypt. *Pediatr Blood Cancer* 2016; **63**(1): 171-3.
148. Elsiessy H, Saad M, Shorman M, et al. Invasive mucormycosis in a patient with liver cirrhosis: case report and review of the literature. *Hepat Mon* 2013; **13**(8): e10858.
149. Enani MA, Alharthi BN, Dewanjee N, Bhat NA, Fagih M. Spontaneous gastric ulcer perforation and acute spleen infarction caused by invasive gastric and splenic mucormycosis. *J Glob Infect Dis* 2014; **6**(3): 122-4.
150. Epstein JB, Kupferman SB, Zabner R, et al. Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review. *Support Care Cancer* 2016; **24**(8): 3343-6.
151. Erami M, Shams-Ghahfarokhi M, Jahanshahi Z, Sharif A, Razzaghi-Abyaneh M. Rhinocerebral mucormycosis due to *Rhizopus oryzae* in a diabetic patient: a case report. *J Mycol Med* 2013; **23**(2): 123-9.

152. Ermak D, Kanekar S, Specht CS, Wojnar M, Lowden M. Looks like a stroke, acts like a stroke, but it's more than a stroke: a case of cerebral mucormycosis. *J Stroke Cerebrovasc Dis* 2014; **23**(8): e403-e4.
153. Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. *Infection* 2014; **42**(2): 429-32.
154. Espildora-Hernandez J, Perez-Lopez C, Abarca-Costalago M, Nuno-Alvarez E. Pulmonary Mucormycosis at Onset of Diabetes in a Young Patient. *Arch Bronconeumol* 2017; **53**(9): 531-3.
155. Farid S, AbuSaleh O, Liesman R, Sohail MR. Isolated cerebral mucormycosis caused by *Rhizomucor pusillus*. *BMJ Case Rep* 2017; **2017**.
156. Farojov R, Aydin O, Yilmaz C, et al. Rhino-Orbita-Maxillary Mucormycosis After Liver Transplantation: A Case Report. *Transplant Proc* 2016; **48**(9): 3210-3.
157. Farooq AV, Patel RM, Lin AY, Setabutr P, Sartori J, Aakalu VK. Fungal Orbital Cellulitis: Presenting Features, Management and Outcomes at a Referral Center. *Orbit* 2015; **34**(3): 152-9.
158. Forrester JD, Chandra V, Shelton AA, Weiser TG. Gastrointestinal mucormycosis requiring surgery in adults with hematologic malignant tumors: literature review. *Surg Infect (Larchmt)* 2015; **16**(2): 194-202.
159. Foshee J, Luminais C, Casey J, et al. An evaluation of invasive fungal sinusitis outcomes with subsite analysis and use of frozen section analysis. *Int Forum Allergy Rhinol* 2016; **6**(8): 807-11.
160. Frank GS, Smith JM, Davies BW, Mirsky DM, Hink EM, Durairaj VD. Ophthalmic manifestations and outcomes after cavernous sinus thrombosis in children. *J aapos* 2015; **19**(4): 358-62.
161. Frey Gutierrez ME, Martinez GW, Alvarez Milan L, Acuna Vassallo JP, Trinajstic EM. [Mucormycosis cutanea- clinical case presentation souvenir etiopatogenia diagnosis and treatment]. *Rev Fac Cien Med Univ Nac Cordoba* 2016; **73**(4): 302-5.
162. Fu KA, Nguyen PL, Sanossian N. Basilar artery territory stroke secondary to invasive fungal sphenoid sinusitis: a case report and review of the literature. *Case Rep Neurol* 2015; **7**(1): 51-8.
163. Galvan Fernandez J, Jimenez Cuenca MI, Molpeceres Martinez I, Alvarez-Quinones ML. A rare cause of emphysematous infectious gastritis. *Rev Esp Enferm Dig* 2017; **109**(5): 368.
164. Garcia-Sepulveda R, Navarrete-Solis J, Villanueva-Lozano H, et al. Photoletter to the editor: Atypical primary cutaneous mucormycosis of the scalp. *J Dermatol Case Rep* 2017; **11**(2): 32-4.
165. Garcia-Vidal C, Salavert Lleti M. [Immunopathogenesis of invasive mould infections]. *Rev Iberoam Micol* 2014; **31**(4): 219-28.
166. Gardiner BJ, Simpson I, Khuu MH, Kidd SE, Lo CH, Jenkin GA. An unusual ulcer: A case of cutaneous mucormycosis caused by *Rhizopus oryzae*. *Med Mycol Case Rep* 2015; **7**: 8-11.
167. Garlapati K, Chavva S, Vaddeswarupu RM, Surampudi J. Fulminant mucormycosis involving paranasal sinuses: a rare case report. *Case Rep Dent* 2014; **2014**: 465919.
168. Gaut D, Cone BD, Gregson AL, Agopian VG. Gastrointestinal Mucormycosis After Orthotopic Liver Transplantation Presenting as Femoral Nerve Palsy: A Case Report and Review of the Literature. *Transplant Proc* 2017; **49**(7): 1608-14.
169. Gayathri Devi HJ, Mohan Rao KN, Prathima KM, Moideen R. Pulmonary mucormycosis presenting with vocal cord paralysis. *Respir Med Case Rep* 2013; **9**: 15-7.
170. Gelman A, Valdes-Rodriguez R, Bhattacharyya S, Yosipovitch G. A case of primary cutaneous mucormycosis caused by minor trauma. *Dermatol Online J* 2015; **21**(1).
171. Gen R, Horasan ES, Vaysoglu Y, Arpaci RB, Ersoz G, Ozcan C. Rhino-orbito-cerebral mucormycosis in patients with diabetic ketoacidosis. *J Craniofac Surg* 2013; **24**(2): e144-7.
172. Ghuman MS, Kaur S, Bhandal SK, Ahluwalia A, Saggarr K. Bilateral optic nerve infarction in rhino-cerebral mucormycosis: A rare magnetic resonance imaging finding. *J Neurosci Rural Pract* 2015; **6**(3): 403-4.
173. Giudice G, Cutrignelli DA, Sportelli P, et al. Rhinocerebral Mucormycosis with Orosinusal Involvement: Diagnostic and Surgical Treatment Guidelines. *Endocr Metab Immune Disord Drug Targets* 2016; **16**(4): 264-9.
174. Gode S, Turhal G, Ozturk K, Aysel A, Midilli R, Karci B. Acute invasive fungal rhinosinusitis: Survival analysis and the prognostic indicators. *Am J Rhinol Allergy* 2015; **29**(6): e164-9.
175. Goel P, Jain V, Sengar M, Mohta A, Das P, Bansal P. Gastrointestinal mucormycosis: a success story and appraisal of concepts. *J Infect Public Health* 2013; **6**(1): 58-61.
176. Gomez-Camarasa C, Rojo-Martin MD, Miranda-Casas C, et al. Disseminated infection due to *Saksenaea vasiformis* secondary to cutaneous mucormycosis. *Mycopathologia* 2014; **177**(1-2): 97-101.
177. Gowda ME, Mohan MS, Verma K, Roy ID. Implant rehabilitation of partial maxillectomy edentulous patient. *Contemp Clin Dent* 2013; **4**(3): 393-6.
178. Grannan BL, Yanamadala V, Venteicher AS, Walcott BP, Barr JC. Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. *J Clin Neurosci* 2014; **21**(10): 1819-21.

179. Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. *PLoS One* 2017; **12**(6): e0179136.
180. Gupta A, Jain S, Agrawal C, Kapoor G. Successful outcome of mucormycosis in two children on induction therapy for acute lymphoblastic leukemia. *Indian J Med Paediatr Oncol* 2013; **34**(4): 313-6.
181. Gupta KL, Joshi K, Bhat A, Kohli HS, Jha V, Sakhuja V. Mucormycosis of the transplanted kidney with renal papillary necrosis. *Exp Clin Transplant* 2013; **11**(6): 554-7.
182. Gupta N, Kumar A, Singh G, Ratnakar G, Vinod KS, Wig N. Breakthrough mucormycosis after voriconazole use in a case of invasive fungal rhinosinusitis due to *Curvularia lunata*. *Drug Discov Ther* 2017; **11**(6): 349-52.
183. Gupta N, Singh G, Aggarwal K, Thakar A, Xess I. Invasive Mucormycosis in a Case of Aluminium Phosphide Poisoning. *J Clin Diagn Res* 2017; **11**(4): Dd01-dd2.
184. Gupta V, Rajagopalan N, Patil M, Shivaprasad C. Aspergillus and mucormycosis presenting with normal chest X-ray in an immunocompromised host. *BMJ Case Rep* 2014; **2014**.
185. Gutierrez-Delgado EM, Trevino-Gonzalez JL, Montemayor-Alatorre A, et al. Chronic rhino-orbito-cerebral mucormycosis: A case report and review of the literature. *Ann Med Surg (Lond)* 2016; **6**: 87-91.
186. Guymer C, Khurana S, Suppiah R, Hennessey I, Cooper C. Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukaemia. *BMJ Case Rep* 2013; **2013**.
187. Haas BM, Clayton JD, Elicker BM, Ordovas KG, Naeger DM. CT-Guided Percutaneous Lung Biopsies in Patients With Suspicion for Infection May Yield Clinically Useful Information. *AJR Am J Roentgenol* 2017; **208**(2): 459-63.
188. Habroosh FA, Eatamadi H, Mohamed RM. Concomitant orbital aspergillosis and mucormycosis in a 17 months old immunocompetent child. *Saudi J Ophthalmol* 2017; **31**(3): 193-5.
189. Hadgaonkar S, Shah K, Bhojraj S, Nene A, Shyam A. Isolated Mucormycotic Spondylodiscitis of Lumbar Spine-A Rare Case Report. *J Orthop Case Rep* 2015; **5**(2): 55-7.
190. Hagel S, Ewald C, Doenst T, Sachse S, Roedel J, Pletz MW. Ventriculitis due to infection with *Rhizopus arrhizus*. *Med Mycol Case Rep* 2015; **10**: 18-20.
191. Hallur V, Singh G, Rudramurthy SM, Kapoor R, Chakrabarti A. Demodex mite infestation of unknown significance in a patient with rhinocerebral mucormycosis due to *Apophysomyces elegans* species complex. *J Med Microbiol* 2013; **62**(Pt 6): 926-8.
192. Hamdi T, Karthikeyan V, Alangaden GJ. Mucormycosis in a renal transplant recipient: case report and comprehensive review of literature. *Int J Nephrol* 2014; **2014**: 950643.
193. Hammer MM, Madan R, Hatabu H. Pulmonary Mucormycosis: Radiologic Features at Presentation and Over Time. *AJR Am J Roentgenol* 2018; **210**(4): 742-7.
194. Hanifah M, Balachandran G, Rajesh NG. Subcutaneous mucor zygomycosis with potential life-threatening visceral complication. *Indian J Med Microbiol* 2013; **31**(2): 182-4.
195. Harman M, Ucmak D, Dal T. A rare case of mucormycosis in the scalp. *Acta Med Port* 2013; **26**(6): 754-7.
196. Harrasser N, Banke IJ, Hauschild M, et al. Clinical challenge: fatal mucormycotic osteomyelitis caused by *Rhizopus microsporus* despite aggressive multimodal treatment. *BMC Infect Dis* 2014; **14**: 488.
197. Hatahet MH, Narayanan M, Cleaves C, Zreik R. Disseminated mucormycosis in a patient with recent kidney transplantation: a case report and review of the literature. *Case Rep Nephrol Urol* 2013; **3**(1): 58-63.
198. Hazama A, Galgano M, Fullmer J, Hall W, Chin L. Affinity of Mucormycosis for Basal Ganglia in Intravenous Drug Users: Case Illustration and Review of Literature. *World Neurosurg* 2017; **98**: 872.e1-e3.
199. He R, Hu C, Tang Y, Yang H, Cao L, Niu R. Report of 12 cases with tracheobronchial mucormycosis and a review. *Clin Respir J* 2018; **12**(4): 1651-60.
200. He YY, Wang Y, Li M, Xue L, Li CH. [Concurrent mucormycosis in children with acute lymphoblastic leukemia at induced remission stage: two case report]. *Zhongguo Dang Dai Er Ke Za Zhi* 2014; **16**(2): 152-4.
201. Henn A, Mellon G, Benoit H, et al. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia. *Scand J Infect Dis* 2014; **46**(3): 231-4.
202. Heydari AA, Fata A, Mojtavavi M. Chronic cutaneous mucormycosis in an immunocompetent female. *Iran Red Crescent Med J* 2013; **15**(3): 254-5.
203. Higo T, Kobayashi T, Yamazaki S, et al. Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia. *Int J Clin Exp Pathol* 2015; **8**(10): 13639-42.
204. Hirabayashi KE, Kalin-Hajdu E, Brodie FL, Kersten RC, Russell MS, Vagefi MR. Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis. *Ophthalmic Plast Reconstr Surg* 2017; **33**(4): e94-e7.

205. Hirano T, Yamada M, Sato K, et al. Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. *BMC Pulm Med* 2017; **17**(1): 76.
206. Ho HC, Liew OH, Teh SS, Hanizaturana H, Ibrahim M, Shatriah I. Unilateral rhino-orbital-cerebral mucormycosis with contralateral endogenous fungal endophthalmitis. *Clin Ophthalmol* 2015; **9**: 553-6.
207. Hsieh TT, Tseng HK, Sun PL, Wu YH, Chen GS. Disseminated zygomycosis caused by *Cunninghamella bertholletiae* in patient with hematological malignancy and review of published case reports. *Mycopathologia* 2013; **175**(1-2): 99-106.
208. Hung HC, Shen GY, Chen SC, et al. Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge. *Case Rep Infect Dis* 2015; **2015**: 478789.
209. Hunt WR. Pulmonary Mucormycosis in a Patient With Poorly Controlled Diabetes After a Liver Transplant. *Am J Med Sci* 2017; **354**(2): e1.
210. Hussain FS, Hussain NS. A Unique Case of Intracranial Mucormycosis Following an Assault. *Cureus* 2016; **8**(7): e696.
211. Idiga J, Rootman DB, Nagiel A, Goldberg RA. Isolated Zygomycetes Endophthalmitis: A Case Report. *Ophthalmic Plast Reconstr Surg* 2015; **31**(6): e145-7.
212. Imai Y, Adachi Y, Kimura T, et al. An autopsy case of pulmonary fissure induced by zygomycosis. *Int J Gen Med* 2013; **6**: 575-9.
213. Imbernon A, Agud JL, Cuetara MS, et al. Successful therapy of progressive rhino-orbital mucormycosis caused by *Rhizopus arrhizus* with combined and sequential antifungal therapy, surgery and hyperbaric therapy. *Med Mycol Case Rep* 2014; **6**: 51-4.
214. Iqbal N, Irfan M, Jabeen K, Kazmi MM, Tariq MU. Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus. *J Thorac Dis* 2017; **9**(2): E121-e5.
215. Irga N, Kosiak W, Jaworski R, Komarnicka J, Birkholz D. Hyperthyroidism secondary to disseminated mucormycosis in a child with acute lymphoblastic leukemia: case report and a review of published reports. *Mycopathologia* 2013; **175**(1-2): 123-7.
216. Irtan S, Lamerain M, Lesage F, et al. Mucormycosis as a rare cause of severe gastrointestinal bleeding after multivisceral transplantation. *Transpl Infect Dis* 2013; **15**(6): E235-8.
217. Isgro G, Carlucci C, Giamberti A, Frigiola A, Ranucci M. Rhinocerebral zygomycosis: an unusual dramatic presentation in a paediatric cardiac patient without risk factors. *Eur Heart J Suppl* 2016; **18**(Suppl E): E19-e21.
218. Ishiwada N, Kitajima H, Morioka I, et al. Nationwide survey of neonatal invasive fungal infection in Japan. *Med Mycol* 2017.
219. Isidoro-Ayza M, Perez L, Cabanes FJ, et al. Central nervous system mucormycosis caused by *Cunninghamella bertholletiae* in a bottlenose dolphin (*Tursiops truncatus*). *J Wildl Dis* 2014; **50**(3): 634-8.
220. Itoh M, Oki M, Yanagi H, et al. Disseminated mucormycosis infection after the first course of dose-modified R-EPOCH for advanced-stage lymphoma. *Kansenshogaku Zasshi* 2014; **88**(6 Suppl 11): 7-10.
221. Iyengar S, Chambers CJ, Millsop JW, Fung MA, Sharon VR. Purple patches in an immunocompromised patient: a report of secondary disseminated cutaneous mucormycosis in a man with chronic lymphocytic leukemia. *Dermatol Online J* 2017; **23**(3).
222. Jaffer F, Beatty N, Ahmad K. Mucormycosis pulmonary abscess, containment in a patient with uncontrolled diabetes mellitus. *BMJ Case Rep* 2017; **2017**.
223. Jayakrishnan B, Al Aghbari J, Rizavi D, Srinivasan S, Lakhtakia R, Al Riyami D. Chronic renal failure presenting for the first time as pulmonary mucormycosis with a fatal outcome. *Case Rep Nephrol* 2015; **2015**: 589537.
224. Jensen TSR, Arendrup MC, von Buchvald C, Frandsen TL, Juhler M, Nygaard U. Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia. *J Pediatr Hematol Oncol* 2017; **39**(4): e211-e5.
225. Jeong SJ, Lee JU, Song YG, Lee KH, Lee MJ. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. *Mycoses* 2015; **58**(12): 746-52.
226. Jha R, Gude D, Chennamsetty S, Kotari H. Intracranial hypertension: An unusual presentation of mucormycosis in a kidney transplant recipient. *Indian J Nephrol* 2013; **23**(2): 130-2.
227. Jiang N, Zhao G, Yang S, et al. A retrospective analysis of eleven cases of invasive rhino-orbital-cerebral mucormycosis presented with orbital apex syndrome initially. *BMC Ophthalmol* 2016; **16**: 10.
228. Joichi Y, Chijimatsu I, Yarita K, et al. Detection of *Mucor velutinosus* in a blood culture after autologous peripheral blood stem cell transplantation : a pediatric case report. *Med Mycol J* 2014; **55**(2): E43-8.
229. Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. *Clin Microbiol Infect* 2015; **21**(7): 684.e11-8.
230. Kalaskar RR, Kalaskar AR, Ganvir S. Oral mucormycosis in an 18-month-old child: a rare case report with a literature review. *J Korean Assoc Oral Maxillofac Surg* 2016; **42**(2): 105-10.

231. Kalva N, Somaraju V, Puli S. A fatal case of gastrointestinal mucormycosis in immunosuppressed host. *Med J Armed Forces India* 2013; **69**(3): 285-7.
232. Kang SH, Kim HS, Bae MN, et al. Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis. *Infect Chemother* 2015; **47**(1): 49-54.
233. Kara M, Erdogan H, Toroslu T, et al. [Rhino-orbito-cerebral mucormycosis: two case reports in the light of the literature]. *Kulak Burun Bogaz Ihtis Derg* 2015; **25**(5): 295-301.
234. Karadeniz Ugurlu S, Selim S, Kopar A, Songu M. Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases. *Turk J Ophthalmol* 2015; **45**(4): 169-74.
235. Kataria SP, Sharma J, Singh G, Kumar S, Malik S, Kumar V. Primary breast mucormycosis: FNAC diagnosis of a rare entity. *Diagn Cytopathol* 2016; **44**(9): 761-3.
236. Katsantonis NG, Hunter JB, O'Connell BP, He J, Lewis JS, Jr., Wanna GB. Temporal Bone Mucormycosis. *Ann Otol Rhinol Laryngol* 2016; **125**(10): 850-3.
237. Kaur R, Bala K, Ahuja RB, Srivastav P, Bansal U. Primary cutaneous mucormycosis in a patient with burn wounds due to Lichtheimia ramosa. *Mycopathologia* 2014; **178**(3-4): 291-5.
238. Kawahara Y, Wada S, Nijima H, et al. Rhinocerebral Mucormycosis With Temporal Artery Thrombosis in an Adolescent Following HLA-haploidentical Stem Cell Transplantation. *J Pediatr Hematol Oncol* 2018; **40**(7): e461-e3.
239. Kazak E, Aslan E, Akalin H, et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. *J Mycol Med* 2013; **23**(3): 179-84.
240. Keklik M, Yildirim A, Ozturk F, et al. Rhinocerebral mucormycosis in a patient with acute promyelocytic leukemia. *Turk J Haematol* 2015; **32**(1): 96-7.
241. Khan AA, Kumaran V, Jain D, Siraj F, Aggarwal S. Hepatic mucormycosis in a patient of acute lymphoblastic leukemia: a case report with literature review. *Indian J Hematol Blood Transfus* 2013; **29**(2): 96-8.
242. Khan S, Waqar Elahi M, Ullah W, et al. Invasive Mucormycosis Induced Pneumopericardium: A Rare Cause of Pneumopericardium in an Immunocompromised Patient. *Case Rep Infect Dis* 2017; **2017**: 1424618.
243. Khandelwal A, Gupta P, Gupta A, Virmani V. Renal mucormycosis in aplastic anemia: a novel presentation. *Int Urol Nephrol* 2013; **45**(1): 285-8.
244. Khostelidi SN, Volkova AG, Popova MO, et al. [Invasive mucormycosis in patients with hemoblastosis in St.-Petersburg]. *Antibiot Khimioter* 2013; **58**(7-8): 23-9.
245. Kim JG, Park HJ, Park JH, et al. Importance of immediate surgical intervention and antifungal treatment for rhinocerebral mucormycosis: a case report. *J Korean Assoc Oral Maxillofac Surg* 2013; **39**(5): 246-50.
246. Kim MJ, Park PW, Ahn JY, et al. Fatal pulmonary mucormycosis caused by Rhizopus microsporus in a patient with diabetes. *Ann Lab Med* 2014; **34**(1): 76-9.
247. Kim ST, Kim WS, Lee HH, Kim JY. Successful treatment of invasive rhinopulmonary mucormycosis with an indolent presentation by combined medical and surgical therapy. *J Craniofac Surg* 2013; **24**(2): e182-4.
248. Kim YI, Kang HC, Lee HS, et al. Invasive pulmonary mucormycosis with concomitant lung cancer presented with massive hemoptysis by huge pseudoaneurysm of pulmonary artery. *Ann Thorac Surg* 2014; **98**(5): 1832-5.
249. Kleiniotiene G, Posiunas G, Raistenskis J, et al. Liposomal amphotericin B and surgery as successful therapy for pulmonary Lichtheimia corymbifera zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazole. *Med Oncol* 2013; **30**(1): 433.
250. Klimko NN, Khostelidi SN, Volkova AG, et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. *Mycoses* 2014; **57** (Suppl 3): 91-6.
251. Knoll BM. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery. *J Antimicrob Chemother* 2014; **69**(12): 3441-3.
252. Kogure Y, Nakamura F, Shinozaki-Ushiku A, et al. Pulmonary mucormycosis with embolism: two autopsied cases of acute myeloid leukemia. *Int J Clin Exp Pathol* 2014; **7**(6): 3449-53.
253. Kokkayil P, Pandey M, Agarwal R, Kale P, Singh G, Xess I. Rhizopus homothallicus Causing Invasive Infections: Series of Three Cases from a Single Centre in North India. *Mycopathologia* 2017; **182**(9-10): 921-6.
254. Kolekar JS. Rhinocerebral mucormycosis: a retrospective study. *Indian J Otolaryngol Head Neck Surg* 2015; **67**(1): 93-6.
255. Komur S, Inal AS, Kurtaran B, et al. Mucormycosis: a 10-year experience at a tertiary care center in Turkey. *Turk J Med Sci* 2016; **46**(1): 58-62.
256. Koteda S, Nomura K, Hashiguchi M, et al. [Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation]. *Rinsho Ketsueki* 2013; **54**(3): 311-5.
257. Kothari A, Shalin SC, Crescencio JC, Burgess MJ. Skin lesion in a patient with acute myeloid leukemia. *Transpl Infect Dis* 2017; **19**(1).

258. Kothari AC, Shroff S. Visual outcome with a multimodality approach in a case of rhino-orbito-cerebral mucormycosis. *J West Afr Coll Surg* 2016; **6**(1): 100-7.
259. Kucinskiene V, Sutkute A, Valiukeviciene S. Cutaneous fungal infection in a neonatal intensive care unit patient: a case report and literature review. *Pediatr Dermatol* 2014; **31**(3): 267-70.
260. Kulkarni RV, Thakur SS. Invasive Gastric Mucormycosis-a Case Report. *Indian J Surg* 2015; **77**(Suppl 1): 87-9.
261. Kumar C, Jain P, Wadhwa N, Diwaker P, Nirupma Panikar K. Nosocomial Jejunal Mucormycosis - an Unusual Cause of Perforation Peritonitis. *Iran J Pathol* 2017; **12**(3): 295-300.
262. Kumar Debata P, Keshari Panda S, Dash A, et al. "An unusual presentation of colonic mucormycosis mimicking carcinoma colon- a surgeon's perspective". *Int J Surg Case Rep* 2015; **10**: 248-51.
263. Kumar NS, Padala RK, Tirupati S, Tatikonda AK. Rhinocerebral Mucormycosis with Top of Basilar Artery Syndrome. *J Stroke Cerebrovasc Dis* 2016; **25**(2): 378-82.
264. Kumar P, Begum CZ, Thirumaran P, Manoharan K. Rhino cerebral mucormycosis in systemic lupus erythematosus. *Indian J Dermatol* 2013; **58**(2): 158.
265. Kursun E, Turunc T, Demiroglu YZ, Aliskan HE, Arslan AH. Evaluation of 28 cases of mucormycosis. *Mycoses* 2015; **58**(2): 82-7.
266. Kutlu M, Ergin C, Bir F, et al. Pulmonary mucormycosis due to *Lichtheimia ramosa* in a patient with HIV infection. *Mycopathologia* 2014; **178**(1-2): 111-5.
267. Kuy S, He C, Cronin DC, 2nd. Renal mucormycosis: a rare and potentially lethal complication of kidney transplantation. *Case Rep Transplant* 2013; **2013**: 915423.
268. Kyriopoulos EJ, Kyriakopoulos A, Karonidis A, et al. Burn injuries and soft tissue traumas complicated by mucormycosis infection: a report of six cases and review of the literature. *Ann Burns Fire Disasters* 2015; **28**(4): 280-7.
269. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. *Clin Microbiol Infect* 2016; **22**(9): 811.e1-e8.
270. Lagenaitte-Desmaizieres CF, Douma I, Agard E, El Chehab H, Ract-Madoux G, Dot C. [A rare cause of ophthalmoplegia, report of a case of mucormycosis]. *J Fr Ophthalmol* 2016; **39**(2): e21-3.
271. Lai MC, Zhang W, Yang Z, et al. First case report of isolated penile mucormycosis in a liver transplantation recipient. *Int J Infect Dis* 2014; **29**: 208-10.
272. Lakhdar K, Houari N, Elbouazzaoui A, et al. [Facial mucormycosis complicating severe angiocholitis: about a case]. *Pan Afr Med J* 2016; **25**: 246.
273. Langford S, Trubiano JA, Saxon S, Spelman D, Morrissey CO. Mucormycete infection or colonisation: experience of an Australian tertiary referral centre. *Mycoses* 2016; **59**(5): 291-5.
274. Lazar SP, Lukaszewicz JM, Persad KA, Reinhardt JF. Rhinocerebral *Mucor circinelloides* infection in immunocompromised patient following yogurt ingestion. *Del Med J* 2014; **86**(8): 245-8.
275. Le Gac G, Allyn J, Coolen-Allou N, et al. [Hepatic mucormycosis due to *Rhizopus microsporus*: A case report]. *Med Mal Infect* 2017; **47**(7): 504-7.
276. LeBlanc RE, Meriden Z, Sutton DA, Thompson EH, Neofytos D, Zhang SX. *Cunninghamella echinulata* causing fatally invasive fungal sinusitis. *Diagn Microbiol Infect Dis* 2013; **76**(4): 506-9.
277. Leclercq A, Cinotti E, Labeille B, Perrot JL, Cambazard F. Ex vivo confocal microscopy: a new diagnostic technique for mucormycosis. *Skin Res Technol* 2016; **22**(2): 203-7.
278. Lee JH, Hyun JS, Kang DY, Lee HJ, Park SG. Rare complication of bronchoesophageal fistula due to pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia: a case report. *J Med Case Rep* 2016; **10**: 195.
279. Lee JS, Kim HC, Park SW, et al. A case of isolated pulmonary mucormycosis in an immunocompetent host. *Tuberc Respir Dis (Seoul)* 2013; **74**(6): 269-73.
280. Lee SH, Son YG, Sohn SS, Ryu SW. Successful treatment of invasive gastric mucormycosis in a patient with alcoholic liver cirrhosis: A case report. *Exp Ther Med* 2014; **8**(2): 401-4.
281. Lee SW, Lee HS. [Gastric Mucormycosis Followed by Traumatic Cardiac Rupture in an Immunocompetent Patient]. *Korean J Gastroenterol* 2016; **68**(2): 99-103.
282. Lee ZJ, Chia C, Busmani I, Wong WK. A rare cause of ischemic gut: A case report. *Int J Surg Case Rep* 2016; **20**: 114-7.
283. Lewandowski L, Purcell R, Fleming M, Gordon WT. The use of dilute Dakin's solution for the treatment of angioinvasive fungal infection in the combat wounded: a case series. *Mil Med* 2013; **178**(4): e503-7.
284. Li H, Hwang SK, Zhou C, Du J, Zhang J. Gangrenous cutaneous mucormycosis caused by *Rhizopus oryzae*: a case report and review of primary cutaneous mucormycosis in China over Past 20 years. *Mycopathologia* 2013; **176**(1-2): 123-8.
285. Li Z, Liu C, Huang X, Gao Z. Nasal NK/T cell lymphoma with severe facial disfigurement in a 37-year-old male. *Int J Oral Maxillofac Surg* 2013; **42**(1): 102-5.

286. Lien MY, Chou CH, Lin CC, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. *PLoS One* 2018; **13**(6): e0197851.
287. Liu Y, Wu H, Huang F, Fan Z, Xu B. Utility of 18F-FDG PET/CT in diagnosis and management of mucormycosis. *Clin Nucl Med* 2013; **38**(9): e370-1.
288. Loganathan S, Ajay GAE, Thyagarajan U, Gokul RD. Invasive fungal infection in immunocompetent trauma patients - A case series. *J Clin Orthop Trauma* 2018; **9**(Suppl 1): S10-s4.
289. Lopez-Pastorini A, Koryllos A, Brockmann M, Windisch W, Stoelben E. Pseudoaneurysm of the pulmonary artery with massive haemoptysis due to an invasive pulmonary mucormycosis. *Thorax* 2016; **71**(2): 199-200.
290. Lorenzo de la Pena L, Martin Gonzalez C, Marca Almeida L. Gastrointestinal mucormycosis. Case report. *Med Clin (Barc)* 2016; **147**(12): e69-e70.
291. Lowe CD, Sainato RJ, Stagliano DR, Morgan MM, Green BP. Primary Cutaneous Mucormycosis in an Extremely Preterm Infant Successfully Treated with Liposomal Amphotericin B. *Pediatr Dermatol* 2017; **34**(3): e116-e9.
292. Lundy JB, Driscoll IR. Experience with proctectomy to manage combat casualties sustaining catastrophic perineal blast injury complicated by invasive mucor soft-tissue infections. *Mil Med* 2014; **179**(3): e347-50.
293. Lunge SB, Sajjan V, Pandit AM, Patil VB. Rhinocerebrocutaneous mucormycosis caused by Mucor species: A rare causation. *Indian Dermatol Online J* 2015; **6**(3): 189-92.
294. Luo C, Wang J, Hu Y, et al. Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature. *Mycopathologia* 2016; **181**(9-10): 753-8.
295. Luo Y, Zeng F, Huang X, et al. Successful treatment of a necrotizing fasciitis patient caused by Mucor indicus with amphotericin B and skin grafting. *Mycopathologia* 2014; **177**(3-4): 187-92.
296. Luo Z, Zhang L. Diagnosis and treatment of pulmonary mucormycosis: A case report. *Exp Ther Med* 2017; **14**(4): 3788-91.
297. Lyskova P, Zackova P, Petecukova V, et al. [Pulmonary mucormycosis caused by Rhizopus microsporus]. *Klin Mikrobiol Infekc Lek* 2013; **19**(4): 132-7.
298. Ma J, Jia R, Li J, et al. Retrospective Clinical Study of Eighty-One Cases of Intracranial Mucormycosis. *J Glob Infect Dis* 2015; **7**(4): 143-50.
299. Maffini F, Cocorocchio E, Pruneri G, et al. Locked-in syndrome after basilar artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. *Ecancermedicalscience* 2013; **7**: 382.
300. Mahadevaiah AH, Rajagopalan N, Patil M, C S. Coinfection of pulmonary mucormycosis and aspergillosis presenting as bilateral vocal cord palsy. *BMJ Case Rep* 2013; **2013**.
301. Mahmood A, Chaump M, Knoll B, Aswad B. Pulmonary zygomycosis in a diabetic patient: treated with pneumonectomy and antifungal agents. *RI Med J (2013)* 2014; **97**(9): 44-5.
302. Mahomed S, Basanth S, Mlisana K. The successful use of amphotericin B followed by oral posaconazole in a rare case of invasive fungal sinusitis caused by co-infection with mucormycosis and aspergillus. *IDCases* 2015; **2**(4): 116-7.
303. Malkan AD, Wahid FN, Rao BN, Sandoval JA. Aggressive Cunninghamella pneumonia in an adolescent. *J Pediatr Hematol Oncol* 2014; **36**(7): 581-2.
304. Mandegari E, Fu L, Arambu C, et al. Mucormycosis Rhinosinusitis at Diagnosis of Acute Lymphoblastic Leukemia: Diagnostics and Management Challenges in a Low-Middle-income Country. *J Pediatr Hematol Oncol* 2015; **37**(3): e173-7.
305. Mangaraj S, Sethy G, Patro MK, Padhi S. A rare case of subcutaneous mucormycosis due to Syncephalastrum racemosum: case report and review of literature. *Indian J Med Microbiol* 2014; **32**(4): 448-51.
306. Martin LB, Rodriguez MAM, Mercier N, et al. Rhizopus arrhizus Invasive Infection due to Self-Inflicted Scratch Injuries in a Diabetic Patient with Non-ketotic Acidosis. *Mycopathologia* 2017; **182**(9-10): 927-31.
307. Martin MS, Smith AA, Lobo M, Paramesh AS. Successful Treatment of Recurrent Pulmonary Mucormycosis in a Renal Transplant Patient: A Case Report and Literature Review. *Case Rep Transplant* 2017; **2017**: 1925070.
308. Marutsuka T, Masuda Y, Saishoji T. [Resected case of pulmonary mucormycosis]. *Kyobu Geka* 2013; **66**(3): 223-6.
309. Mathur NB, Gupta A. Neonatal zygomycosis with gastric perforation. *Indian Pediatr* 2013; **50**(7): 699-701.
310. Mathuram AJ, Mohanraj P, Mathews MS. Rhino-orbital-cerebral infection by Syncephalastrum racemosum. *J Assoc Physicians India* 2013; **61**(5): 339-40.

311. Matsumoto K, Yamamoto W, Ohgusa E, et al. Disseminated Cunninghamella bertholletiae infection with septic pulmonary embolism after allogeneic bone marrow transplantation. *Transpl Infect Dis* 2014; **16**(2): 304-6.
312. Mattioni J, Portnoy JE, Moore JE, Carlson D, Sataloff RT. Laryngotracheal mucormycosis: Report of a case. *Ear Nose Throat J* 2016; **95**(1): 29-39.
313. Mayayo E, Stchigel AM, Cano JF, Bernal-Escote X, Guarro J. [Necrotising fasciitis caused by Saksenaea vasiformis in an immunocompetent patient after a car accident]. *Rev Iberoam Micol* 2013; **30**(1): 57-60.
314. McCrory MC, Moore BA, Nakagawa TA, et al. Disseminated mucormycosis in an adolescent with newly diagnosed diabetes mellitus. *Pediatr Infect Dis J* 2014; **33**(10): 1094-6.
315. McSpadden RP, Martin JR, Mehrotra S, Thorpe E. Mucormycosis Causing Ludwig Angina: A Unique Presentation. *J Oral Maxillofac Surg* 2017; **75**(4): 759-62.
316. Mendez-Tovar LJ, Mejia-Mercado JA, Manzano-Gayosso P, Hernandez-Hernandez F, Lopez-Martinez R, Silva-Gonzalez I. [Frequency of invasive fungal infections in a Mexican High-Specialty Hospital. Experience of 21 years]. *Rev Med Inst Mex Seguro Soc* 2016; **54**(5): 581-7.
317. Mengji AK, Yaga US, Gollamudi N, Prakash B, Rajashekar E. Mucormycosis in a surgical defect masquerading as osteomyelitis: a case report and review of literature. *Pan Afr Med J* 2016; **23**: 16.
318. Mesa Varona D, Celis Sanchez J, Alfaya Munoz L, Avendano Cantos EM, Romero Moraleda L. Keratitis caused by Absidia corymbifera in an immunocompetent male with no corneal injuries. *Arch Soc Esp Oftalmol* 2015; **90**(3): 139-41.
319. Miguita e Souza J, Sproesser Junior AJ, Felippu Neto A, Fuks FB, Oliveira CA. Rhino facial zygomycosis: case report. *Einstein (Sao Paulo)* 2014; **12**(3): 347-50.
320. Millon L, Larosa F, Lepiller Q, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. *Clin Infect Dis* 2013; **56**(10): e95-101.
321. Mititelu R, Bourassa-Blanchette S, Sharma K, Roth V. Angioinvasive mucormycosis and paradoxical stroke: a case report. *JMM Case Rep* 2016; **3**(4): e005048.
322. Modaresi Esfeh J, Jackson W, Ansari-Gilani K, Putka B. An unusual cause of acute anemia in an immunosuppressed patient. *Gastroenterol Rep (Oxf)* 2016; **4**(3): 254-6.
323. Mohammadi R, Nazeri M, Sayedayn SM, Ehteram H. A successful treatment of rhinocerebral mucormycosis due to Rhizopus oryzae. *J Res Med Sci* 2014; **19**(1): 72-4.
324. Mohindra S, Gupta B, Gupta K, Bal A. Tracheal mucormycosis pneumonia: a rare clinical presentation. *Respir Care* 2014; **59**(11): e178-81.
325. Mondal AK, Saha A, Seth J, Mukherjee S. Subcutaneous Zygomycosis: A Report of One Case Responding Excellently to Potassium Iodide. *Indian J Dermatol* 2015; **60**(5): 500-2.
326. Monteagudo M, Palazon-Garcia E, Lozano-Setien E, Garcia-Garcia J. [The 'black turbinate sign' in a case of rhinocerebral mucormycosis]. *Rev Neurol* 2014; **58**(5): 234-5.
327. Moosavi Movahed M, Hosamirudsari H, Mansouri F, Mohammadzizia F. Spontaneous pneumothorax followed by reversed halo sign in immunocompromised patient with pulmonary mucormycosis. *Med Mycol Case Rep* 2015; **9**: 22-5.
328. Moreira J, Ridolfi F, Almeida-Paes R, Varon A, Lamas CC. Cutaneous mucormycosis in advanced HIV disease. *Braz J Infect Dis* 2016; **20**(6): 637-40.
329. Motaleb HY, Mohamed MS, Mobarak FA. A Fatal Outcome of Rhino-orbito-cerebral Mucormycosis Following Tooth Extraction: A Case Report. *J Int Oral Health* 2015; **7**(Suppl 1): 68-71.
330. Mouronte-Roibas C, Leiro-Fernandez V, Botana-Rial M, et al. Lichtheimia ramosa: A Fatal Case of Mucormycosis. *Can Respir J* 2016; **2016**: 2178218.
331. Mulki R, Masab M, Eiger G, Perloff S. Lethargy and vision loss: successful management of rhinocerebral mucormycosis. *BMJ Case Rep* 2016; **2016**.
332. Munoz J, Hughes A, Guo Y. Mucormycosis-associated intracranial hemorrhage. *Blood Coagul Fibrinolysis* 2013; **24**(1): 100-1.
333. Munshi S, Moazin M, Abu-Daff S, Urrahman MA, Alamoudi OJ, Almhrej AH. Renal mucormycosis in immunocompromised patient, treated with Robotic Nephrectomy: Case report and review of articles. *Urol Case Rep* 2017; **15**: 53-5.
334. Murphy AD, Williamson PA, Vesely M. Reconstruction of an extensive peri-orbital defect secondary to mucormycosis in a patient with myelodysplasia. *J Plast Reconstr Aesthet Surg* 2013; **66**(3): e69-71.
335. Mutchnick S, Soares D, Shkoukani M. To exenterate or not? An unusual case of pediatric rhinocerebral mucormycosis. *Int J Pediatr Otorhinolaryngol* 2015; **79**(2): 267-70.
336. Nagakawa H, Igari H, Konishi K, et al. [An autopsy case of tension pneumothorax due to the rupture of intrapulmonary cavity by mucormycosis during treatment with a ventilator]. *Med Mycol J* 2013; **54**(3): 285-9.

337. Nagendran ST, Lee NG, Fay A, Lefebvre DR, Sutula FC, Freitag SK. Orbital exenteration: The 10-year Massachusetts Eye and Ear Infirmary experience. *Orbit* 2016; **35**(4): 199-206.
338. Nain PS, Matta H, Singh K, Chhina D, Trehan M, Batta N. Post-operative Abdominal Wall Mucormycosis- a Case Series. *Indian J Surg* 2015; **77**(Suppl 2): 253-6.
339. Nair V, Sharma RK, Khanna A, Talwar D. Pulmonary mucormycosis diagnosed by convex probe endobronchial ultrasound-guided fine needle aspiration of cavity wall. *Lung India* 2017; **34**(2): 179-81.
340. Nam BD, Kim TJ, Lee KS, Kim TS, Han J, Chung MJ. Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings. *Eur Radiol* 2018; **28**(2): 788-95.
341. Nam Y, Jung J, Park SS, et al. Disseminated mucormycosis with myocardial involvement in a renal transplant recipient. *Transpl Infect Dis* 2015; **17**(6): 890-6.
342. Nandwani A, Jha PK, Duggal R, Kher V. Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient. *Indian J Nephrol* 2015; **25**(6): 373-6.
343. Narayanan MI S, Narayanan CD, Kindo AJ, Arora A, Haridas PA. Fatal fungal infection: the living dead. *J Surg Case Rep* 2014; **2014**(10).
344. Narayanan S, Panarkandy G, Subramaniam G, et al. The "black evil" affecting patients with diabetes: a case of rhino orbito cerebral mucormycosis causing Garcin syndrome. *Infect Drug Resist* 2017; **10**: 103-8.
345. Nasa M, Sharma Z, Lipi L, Sud R. Gastric Angioinvasive Mucormycosis in Immunocompetent Adult, A Rare Occurrence. *J Assoc Physicians India* 2017; **65**(12): 103-4.
346. Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. *Infect Drug Resist* 2016; **9**: 291-300.
347. Navanukroh O, Jitmuang A, Chayakulkeeree M, Ngamskulrungrroj P. Disseminated Cunninghamella bertholletiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review. *Transpl Infect Dis* 2014; **16**(4): 658-65.
348. Navarro Vergara DI, Barragan Pola G, Bonifaz A, Nunez Perez-Redondo C, Choreno Garcia O, Cicero Sabido R. [Pulmonary mucormycosis in a patient with kidney transplant and uncontrolled haemoptysis]. *Rev Iberoam Micol* 2017; **34**(4): 233-6.
349. Nayagam LS, Vijayanand B, Balasubramanian S. Isolated renal mucormycosis in an immunocompetent child. *Indian J Nephrol* 2014; **24**(5): 321-3.
350. Nezafati S, Kazemi A, Asgari K, Bahrami A, Naghili B, Yazdani J. Rhinocerebral mucormycosis, risk factors and the type of oral manifestations in patients referred to a University Hospital in Tabriz, Iran 2007-2017. *Mycoses* 2018; **61**(10): 764-9.
351. Nieto-Rios JF, Moreno-Coral LF, Zapata-Cardenas A, et al. [Successful treatment of rhino-orbital-cerebral mucormycosis in a kidney transplant patient]. *Nefrologia* 2014; **34**(1): 120-4.
352. Non L, Sta Cruz JP, Tuazon S. Sudden death in a patient with bone marrow transplant by a fungus among us. *BMJ Case Rep* 2014; **2014**.
353. Okubo Y, Ishiwatari T, Izumi H, et al. Pathophysiological implication of reversed CT halo sign in invasive pulmonary mucormycosis: a rare case report. *Diagn Pathol* 2013; **8**: 82.
354. Oladeji S, Amusa Y, Olabanji J, Adisa A. Rhinocerebral mucormycosis in a diabetic case report. *J West Afr Coll Surg* 2013; **3**(1): 93-102.
355. Oliveira FR, Couto NG, Bastos JO, Colleti JJ, Carvalho WB. Abdominal mucormycosis in a child: a case report. *Rev Soc Bras Med Trop* 2016; **49**(6): 796-8.
356. Ota H, Yamamoto H, Kimura M, et al. Successful Treatment of Pulmonary Mucormycosis Caused by Cunninghamella bertholletiae with High-Dose Liposomal Amphotericin B (10 mg/kg/day) Followed by a Lobectomy in Cord Blood Transplant Recipients. *Mycopathologia* 2017; **182**(9-10): 847-53.
357. Pacheco P, Ventura AS, Branco T, Goncalves L, Carvalho C. Clinical experience in invasive fungal infections. *Clin Drug Investig* 2013; **33** (Suppl 1): S23-6.
358. Paduraru M, Moreno-Sanz C, Olalla Gallardo JM. Primary cutaneous mucormycosis in an immunocompetent patient. *BMJ Case Rep* 2016; **2016**.
359. Pahwa M, Pahwa AR, Girotra M, Chawla A. Isolated renal mucormycosis in a healthy immunocompetent patient: atypical presentation and course. *Korean J Urol* 2013; **54**(9): 641-3.
360. Pajpani M, Webb R. Lingual necrosis caused by mucormycosis in a patient with aplastic anaemia: case report. *Br J Oral Maxillofac Surg* 2014; **52**(10): e144-6.
361. Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. *Surg Neurol Int* 2016; **7**: 61.
362. Pan AS, Srinath L. Mucormycosis in a patient with AIDS receiving systemic steroids. *J Am Osteopath Assoc* 2013; **113**(9): 708-11.
363. Panigrahi MK, Manju R, Kumar SV, Toi PC. Pulmonary mucormycosis presenting as nonresolving pneumonia in a patient with diabetes mellitus. *Respir Care* 2014; **59**(12): e201-5.

364. Park W, Jang M, Hwang E, et al. Allograft mucormycosis due to *Rhizopus microsporus* in a kidney transplant recipient. *Transplant Proc* 2014; **46**(2): 623-5.
365. Patel AK, Patel KK, Patel K, Gohel S, Chakrabarti A. Mucormycosis at a tertiary care centre in Gujarat, India. *Mycoses* 2017; **60**(6): 407-11.
366. Patel RD, Vanikar AV, Trivedi HL. Pheohyphomycosis in Renal Transplant Recipient Presenting as a Rare Case of Submandibular Salivary Gland Swelling. *J Clin Diagn Res* 2016; **10**(8): Ed05-6.
367. Pathak VK, Saxena R, Awasthi S, Gaur S, Singh SK. Rhinoorbitocerebral Mucormycosis with Maggots in a Neglected Diabetic Patient. *Indian J Otolaryngol Head Neck Surg* 2018; **70**(1): 156-8.
368. Pedemonte-Sarrias G, Gras-Cabrerizo JR, Rodriguez-Alvarez F, Montserrat-Gili JR. Rhinocerebral mucormycosis in a 5-month heart transplant recipient. *J Oral Maxillofac Pathol* 2015; **19**(3): 375-8.
369. Peixoto D, Gagne LS, Hammond SP, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. *J Clin Microbiol* 2014; **52**(3): 1016-9.
370. Peixoto D, Hammond SP, Issa NC, et al. Green herring syndrome: bacterial infection in patients with mucormycosis cavitory lung disease. *Open Forum Infect Dis* 2014; **1**(1): ofu014.
371. Penicaud M, Michel J, Belenotti P, et al. [Fungal sinusitis: report of two cases of indolent form of fungus usually invasive, up treatment and care]. *Rev Laryngol Otol Rhinol (Bord)* 2013; **134**(3): 149-52.
372. Pepeler MS, Acar K, Guzel Tunccan O, et al. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. *Case Rep Hematol* 2015; **2015**: 285360.
373. Pilch WT, Kinnear N, Hennessey DB. Saksenaia vasiformis infection in an immunocompetent patient in rural Australia. *BMJ Case Rep* 2017; **2017**.
374. Plewes K, Maude RJ, Ghose A, Dondorp AM. Severe falciparum malaria complicated by prolonged haemolysis and rhinomaxillary mucormycosis after parasite clearance: a case report. *BMC Infect Dis* 2015; **15**: 555.
375. Plowes Hernandez O, Prado Calleros HM, Soberon Marmissolle Daguerre GS, Sadek Gonzalez A. Rhino-orbito-cerebral mucormycosis. Management strategies to avoid or limit intracranial affection and improve survival. *Acta Otorrinolaringol Esp* 2015; **66**(6): 348-52.
376. Point S, Gabriel F, Begueret H, et al. Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient. *Med Mycol Case Rep* 2018; **19**: 13-7.
377. Pozo Laderas JC, Pontes Moreno A, Pozo Salido C, Robles Arista JC, Linares Sicilia MJ. [Disseminated mucormycosis in immunocompetent patients: A disease that also exists]. *Rev Iberoam Micol* 2015; **32**(2): 63-70.
378. Pozo-Laderas JC, Pontes-Moreno A, Robles-Arista JC, et al. [Mixed invasive fungal infection due to *Rhizomucor pusillus* and *Aspergillus niger* in an immunocompetent patient]. *Rev Iberoam Micol* 2015; **32**(1): 46-50.
379. Prabhu S, Alqahtani M, Al Shehabi M. A fatal case of rhinocerebral mucormycosis of the jaw after dental extractions and review of literature. *J Infect Public Health* 2018; **11**(3): 301-3.
380. Prasanna Kumar S, Ravikumar A, Somu L. Fungal necrotizing fasciitis of the head and neck in 3 patients with uncontrolled diabetes. *Ear Nose Throat J* 2014; **93**(3): E18-21.
381. Priyanka Akhilesh S, Kamal Sunder Y, Prasad P, Asha GM, Mohan A, Hitesh M. Diagnostic Dilemma in Appendiceal Mucormycosis: A Rare Case Report. *Case Rep Surg* 2016; **2016**: 9531840.
382. Raab P, Sedlacek L, Buchholz S, Stolle S, Lanfermann H. Imaging Patterns of Rhino-Orbital-Cerebral Mucormycosis in Immunocompromised Patients : When to Suspect Complicated Mucormycosis. *Clin Neuroradiol* 2017; **27**(4): 469-75.
383. Radhakrishnan N, Yadav SP, Oberoi J, Kulshreshta R, Bhalla S, Sachdeva A. Intestinal mucormycosis: a rare entity in pediatric oncology. *Pediatr Hematol Oncol* 2013; **30**(3): 178-83.
384. Rahman A, Akter K, Hossain S, Rashid HU. Rhino-orbital mucormycosis in a non-immunocompromised patient. *BMJ Case Rep* 2013; **2013**.
385. Rajagopal K, Watkins AC, Gibber M, et al. Reoperative lung transplantation for donor-derived pulmonary mucormycosis. *Ann Thorac Surg* 2014; **98**(1): 327-9.
386. Ramachandran L, Dewan S, Kumar V, Wankhade B. Mucormycosis causing pulmonary artery aneurysm. *Respir Med Case Rep* 2015; **16**: 71-3.
387. Ramaswami A, Pisharam JK, Aung H, et al. Co-incidental Plasmodium Knowlesi and Mucormycosis infections presenting with acute kidney injury and lower gastrointestinal bleeding. *Am J Case Rep* 2013; **14**: 103-5.
388. Ramirez J, Maguina P. Invasive Conidiobolomycosis Can Be Successfully Treated on Burn Survivors. *J Burn Care Res* 2017; **38**(1): e460-e3.
389. Rammaert B, Angebault C, Scemla A, et al. *Mucor irregularis*-associated cutaneous mucormycosis: Case report and review. *Med Mycol Case Rep* 2014; **6**: 62-5.

390. Ranjan P, Chipde SS, Vashistha S, Kumari N, Kapoor R. Reno-invasive fungal infection presenting as acute renal failure: importance of renal biopsy for early diagnosis. *Saudi J Kidney Dis Transpl* 2014; **25**(6): 1282-4.
391. Rasiyah S, Fernandes KD, Sajiv CT, Pawar B. A case of fatal disseminated *Apophysomyces elegans* infection in a renal allograft recipient. *Indian J Nephrol* 2014; **24**(1): 54-6.
392. Rathi M, Sengupta U, Yadav TD, Kumar S. *Zygomycetes* peritonitis in ambulatory peritoneal dialysis: Case report and review of literature. *Indian J Nephrol* 2014; **24**(4): 252-4.
393. Raviraj KS, Miglani P, Garg A, Agarwal PK. Gastric Mucormycosis with Hemolytic Uremic Syndrome. *J Assoc Physicians India* 2015; **63**(10): 75-6.
394. Rehman MU, Azam K, Hussain Z, Afreen A, Ahmed M. Disseminated Infection with Multiple Cold Abscesses Caused by *Rhizopus Arrhizus* in an Immunocompetent Girl. *J Coll Physicians Surg Pak* 2017; **27**(10): 648-50.
395. Reinbold C, Derder M, Hivelin M, Ozil C, Al Hindi A, Lantieri L. Using free flaps for reconstruction during infections by mucormycosis: A case report and a structured review of the literature. *Ann Chir Plast Esthet* 2016; **61**(2): 153-61.
396. Relloso S, Romano V, Landaburu MF, et al. *Saksenaia erythrospora* infection following a serious sailing accident. *J Med Microbiol* 2014; **63**(Pt 2): 317-21.
397. Ribeiro EF, dos Santos VM, Paixao GT, Cruz LR, Danilow MZ, Campos VF. Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen. *Mycopathologia* 2013; **175**(3-4): 295-300.
398. Riera F, Marangoni LD, Allende BL, et al. [Mucormycosis. Clinical cases and update]. *Rev Fac Cien Med Univ Nac Cordoba* 2014; **71**(4): 192-8.
399. Rodriguez JY, Rodriguez GJ, Morales-Lopez SE, Cantillo CE, Le Pape P, Alvarez-Moreno CA. *Saksenaia erythrospora* infection after medical tourism for esthetic breast augmentation surgery. *Int J Infect Dis* 2016; **49**: 107-10.
400. Rodriguez-Gutierrez G, Carrillo-Casas EM, Arenas R, et al. Mucormycosis in a Non-Hodgkin Lymphoma Patient Caused by *Syncephalastrum racemosum*: Case Report and Review of Literature. *Mycopathologia* 2015; **180**(1-2): 89-93.
401. Rodriguez-Lobato E, Ramirez-Hobak L, Aquino-Matus JE, et al. Primary Cutaneous Mucormycosis Caused by *Rhizopus oryzae*: A Case Report and Review of Literature. *Mycopathologia* 2017; **182**(3-4): 387-92.
402. Rose SR, Vallabhajosyula S, Velez MG, et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. *J Infect* 2014; **69**(3): 278-83.
403. Rudra GN. A case of rhinocerebral mucormycosis in diabetic patient. *J Assoc Physicians India* 2016; **64**(1): 100.
404. Sachdeva K. Rhino-oculo Cerebral Mucormycosis with Multiple Cranial Nerve Palsy in Diabetic Patient: Review of Six Cases. *Indian J Otolaryngol Head Neck Surg* 2013; **65**(4): 375-9.
405. Sahoo NK, Kulkarni V, Bhandari AK, Kumar A. Mucormycosis of the Frontal Sinus: A Rare Case Report and Review. *Ann Maxillofac Surg* 2017; **7**(1): 120-3.
406. Sahota R, Gambhir R, Anand S, Dixit A. Rhinocerebral Mucormycosis: Report of a Rare Case. *Ethiop J Health Sci* 2017; **27**(1): 85-90.
407. Salami A, Assouan C, Kouyate M, Kadre A, Yavo-Dosso N, N'Guessan ND. [Sinonasal mucormycosis revealed by a necrotic velar ulceration]. *J Mycol Med* 2015; **25**(3): 204-7.
408. Samarei R, Gharebaghi N, Zayer S. Evaluation of 30 cases of mucormycosis at a university hospital in Iran. *Mycoses* 2017; **60**(7): 426-32.
409. Sanavi S, Afshar R, Afshin-Majid S. Rhino-orbitocerebral mucormycosis in a patient with idiopathic crescentic glomerulonephritis. *Saudi J Kidney Dis Transpl* 2013; **24**(4): 768-72.
410. Sanchez Velazquez P, Pera M, Gimeno J, Zapatero A, Nolla J, Pera M. Mucormycosis: an unusual cause of gastric perforation and severe bleeding in immunocompetent patients. *Rev Esp Enferm Dig* 2017; **109**(3): 223-5.
411. Sanchez-Gil J, Guirao-Arrabal E, Parra-Garcia GD, et al. Nosocomial Rhinocerebral Mucormycosis: Two Cases with a Temporal Relationship. *Mycopathologia* 2017; **182**(9-10): 933-5.
412. Sanz-Bueno J, Castellanos-Gonzalez M, Rodriguez-Peralto JL, Rivera R. [Disseminated zygomycosis in a patient with chronic lymphocytic leukemia]. *Med Clin (Barc)* 2013; **140**(11): e21.
413. Saran S, Naranje K, Gurjar M, Bhadauria D, Kaul A, Poddar B. Isolated Renal Mucormycosis in Immunocompetent Children: A Report of Two Cases. *Indian J Crit Care Med* 2017; **21**(7): 457-9.
414. Sarrami AH, Setareh M, Izadinejad M, Afshar-Moghaddam N, Baradaran-Mahdavi MM, Meidani M. Fatal disseminated mucormycosis in an immunocompetent patient: a case report and literature review. *Int J Prev Med* 2013; **4**(12): 1468-71.

415. Sathe PA, Ghodke RK, Kandalkar BM. A Survivor of Neonatal Intestinal Mucormycosis. *J Clin Diagn Res* 2015; **9**(8): Ed24-5.
416. Sawardekar KP. Gangrenous Necrotizing Cutaneous Mucormycosis in an Immunocompetent Neonate: A Case Report from Oman. *J Trop Pediatr* 2018; **64**(6): 548-52.
417. Scharf EL, Cloft HJ, Wijdicks E. Mucor Thrombus. *Neurocrit Care* 2016; **24**(2): 268-72.
418. Schofield C, Stern A, Jevtic A. Disseminated zygomycosis due to *Mycoclados corymbifera* with cutaneous and cerebral involvement. *Australas J Dermatol* 2013; **54**(1): e8-11.
419. Selvamani M, Donoghue M, Bharani S, Madhushankari GS. Mucormycosis causing maxillary osteomyelitis. *J Nat Sci Biol Med* 2015; **6**(2): 456-9.
420. Seo YM, Hwang-Bo S, Kim SK, Han SB, Chung NG, Kang JH. Fatal systemic adenoviral infection superimposed on pulmonary mucormycosis in a child with acute leukemia: A case report. *Medicine (Baltimore)* 2016; **95**(40): e5054.
421. Sethi P, Balakrishnan D, Surendran S, Mohamed ZU. Fulminant zygomycosis of graft liver following liver transplantation. *BMJ Case Rep* 2016; **2016**.
422. Shah RJ, Katyayan MK, Katyayan PA, Chauhan V. Prosthetic rehabilitation of acquired maxillary defects secondary to mucormycosis: clinical cases. *J Contemp Dent Pract* 2014; **15**(2): 242-9.
423. Sharma D, Dahal K, Pathak B, Dahal U. Case of early-disseminated *Rhizopus microsporus* var. *microsporus* mucormycosis in a renal transplant patient. *Int Med Case Rep J* 2016; **9**: 139-43.
424. Shekar V, Sikander J, Rangdhol V, Naidu M. Facial nerve paralysis: A case report of rare complication in uncontrolled diabetic patient with mucormycosis. *J Nat Sci Biol Med* 2015; **6**(1): 226-8.
425. Shelburne SA, Ajami NJ, Chibucos MC, et al. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. *PLoS One* 2015; **10**(11): e0139851.
426. Sheybani F, Naderi HR, Sarvghad M, Ghabouli M, Arian M. How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review. *Med Mycol Case Rep* 2015; **8**: 29-31.
427. Shi GG, Shi L, Zhang ZY, et al. [Clinical analyses of the diagnosis and treatment of invasive fungal rhinosinusitis: report of 14 cases]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2016; **51**(8): 561-7.
428. Shigemura T, Nakazawa Y, Matsuda K, Motobayashi M, Saito S, Koike K. Evaluation of Mucorales DNA load in cerebrospinal fluid in a patient with possible cerebral mucormycosis treated with intravenous liposomal amphotericin B. *Int J Infect Dis* 2014; **29**: 200-2.
429. Shigemura T, Nakazawa Y, Matsuda K, et al. Serial monitoring of Mucorales DNA load in serum samples of a patient with disseminated mucormycosis after allogeneic bone marrow transplantation. *Int J Hematol* 2014; **100**(2): 206-9.
430. Shigemura T, Nishina S, Nakazawa H, Matsuda K, Yaguchi T, Nakazawa Y. Early detection of *Rhizopus* DNA in the serum of a patient with rhino-orbital-cerebral mucormycosis following allogeneic hematopoietic stem cell transplantation. *Int J Hematol* 2016; **103**(3): 354-5.
431. Shinde RV, Karande GS, Mohite ST, Patil SR. Rhino-orbital mucormycosis in diabetes mellitus. *J Clin Diagn Res* 2013; **7**(6): 1145-7.
432. Shiraishi K, Sasaki S, Sadamoto Y. Cutaneous mucormycosis in a patient with acute lymphocytic leukemia. *Eur J Dermatol* 2014; **24**(1): 116-7.
433. Shukla A, Bansal M, Husain M, Chhabra DK. Central nervous system mycosis: analysis of 10 cases. *Indian J Pathol Microbiol* 2014; **57**(4): 591-4.
434. Shukla A, Shrivastava N, Singh CA, Nayak B. Percutaneous Management of Systemic Fungal Infection Presenting As Bilateral Renal Fungal Ball. *J Endourol Case Rep* 2016; **2**(1): 152-4.
435. Silberstein E, Krieger Y, Rosenberg N, et al. Facial Reconstruction of a Mucormycosis Survivor by Free Rectus Abdominis Muscle Flap, Tissue Expansion, and Ocular Prosthesis. *Ophthalmic Plast Reconstr Surg* 2016; **32**(6): e131-e2.
436. Singh AK, Goel MM, Gupta C, Kumar S. Isolated renal zygomycosis in an immunocompetent patient. *BMJ Case Rep* 2014; **2014**.
437. Singh V, Singh M, Joshi C, Sangwan J. Rhinocerebral mucormycosis in a patient with type 1 diabetes presenting as toothache: a case report from Himalayan region of India. *BMJ Case Rep* 2013; **2013**.
438. Sirignano S, Blake P, Turrentine JE, Dominguez AR. Primary cutaneous zygomycosis secondary to minor trauma in an immunocompromised pediatric patient: a case report. *Dermatol Online J* 2014; **20**(6).
439. Sivagnanam S, Sengupta DJ, Hoogestraat D, et al. Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center. *Antimicrob Resist Infect Control* 2017; **6**: 123.
440. Snaith J, Burns K, Kok J, Chen S, Cheung NW. A case of rhino-orbital mucormycosis in diabetes with haematogenous cerebral spread. *Med Mycol Case Rep* 2016; **13**: 22-4.

441. Son HJ, Sung H, Park SY, et al. Diagnostic performance of the (1-3)-beta-D-glucan assay in patients with *Pneumocystis jirovecii* compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers. *PLoS One* 2017; **12**(11): e0188860.
442. Son JH, Lim HB, Lee SH, Yang JW, Lee SB. Early Differential Diagnosis of Rhino-Orbito-Cerebral Mucormycosis and Bacterial Orbital Cellulitis: Based on Computed Tomography Findings. *PLoS One* 2016; **11**(8): e0160897.
443. Sravani T, Uppin SG, Uppin MS, Sundaram C. Rhinocerebral mucormycosis: Pathology revisited with emphasis on perineural spread. *Neurol India* 2014; **62**(4): 383-6.
444. Sreenath G, Prakash AR, Kanth MR, Reddy PS, Vidhyadhari P. Rhinomaxillary mucormycosis with palatal perforation: a case report. *J Clin Diagn Res* 2014; **8**(9): Zd01-3.
445. Sriperumbuduri S, Kalidindi K, Megha H, Guditi S, Taduri G. An unusual case of gastrointestinal mucormycosis in a patient with nephrotic syndrome. *Indian J Nephrol* 2017; **27**(2): 145-7.
446. Sriranga R, Pawar S, Khot W, et al. Isolated Renal Mucormycosis. *J Assoc Physicians India* 2017; **65**(4): 77-81.
447. Srivastava N, Bansal V, Kantoor P. Palatal Mucormycosis in An Infant. *J Dent Child (Chic)* 2015; **82**(3): 153-6.
448. Stanistreet B, Bell D. Burn Wound Mucormycosis: A Case Study on Poor Wound Healing. *J Burn Care Res* 2017; **38**(2): e582-e4.
449. Stephen S, Subashini B, Thomas R, Philip A, Sundaresan R. Skull Base Osteomyelitis Caused by an Elegant Fungus. *J Assoc Physicians India* 2016; **64**(2): 70-1.
450. Stewart JI, D'Alonzo GE, Ciccolella DE, Patel NB, Durra H, Clauss HE. Reverse halo sign on chest imaging in a renal transplant recipient. *Transpl Infect Dis* 2014; **16**(1): 115-8.
451. Stretz C, Mook A, Modak JM, Rodriguez JM, Nouh AM. Gerstmann Syndrome in a Patient With Aggressive Mucormycosis. *Neurohospitalist* 2017; **7**(2): 102-3.
452. Su YY, Chang TY, Wang CJ, et al. Disseminated *Cunninghamella bertholletiae* Infection During Induction Chemotherapy in a Girl with High-Risk Acute Lymphoblastic Leukemia. *Pediatr Neonatol* 2016; **57**(6): 531-4.
453. Sun M, Hou X, Wang X, Chen G, Zhao Y. Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient: A Case Report. *Medicine (Baltimore)* 2017; **96**(16): e6360.
454. Sunagawa K, Ishige T, Kusumi Y, et al. Renal abscess involving mucormycosis by immunohistochemical detection in a patient with acute lymphocytic leukemia: a case report and literature review. *Jpn J Infect Dis* 2013; **66**(4): 345-7.
455. Sunassee A, Muirhead DM. Gastric Zygomycosis in a Previously Healthy 56-Year-Old Male. *S D Med* 2017; **70**(4): 161-3.
456. Suthanathan AE, Koek SA, Sieunarine K. Cutaneous mucormycosis in an immunocompromised patient: a case report. *J Surg Case Rep* 2017; **2017**(3): rjx056.
457. Suzuki D, Kobayashi R, Hori D, et al. Stem cell transplantation for acute myeloid leukemia with pulmonary and cerebral mucormycosis. *Pediatr Int* 2016; **58**(7): 569-72.
458. Suzuki K, Sugawara Y, Sekine T, Nakase K, Katayama N. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. *Kansenshogaku Zasshi* 2014; **88**(6 Suppl 11): 11-4.
459. Tachamo N, Rajagopalan P, Nazir S, Lohani S, Le B, Patel N. Acute ischemia of bilateral lower extremities as a presenting feature of disseminated mucormycosis endocarditis: A case report. *J Community Hosp Intern Med Perspect* 2016; **6**(6): 33215.
460. Talebi-Taher M, Alavi Niakou SN, Javad-Mousavi SA, Vaziri M, Iranpour A, Dehghani M. Pulmonary Mucormycosis in a Patient with Chronic Rejection of Kidney Transplant: A Case Report. *Tanaffos* 2015; **14**(2): 149-52.
461. Tansir G, Rastogi N, Ramteke P, et al. Disseminated mucormycosis: A sinister cause of neutropenic fever syndrome. *Intractable Rare Dis Res* 2017; **6**(4): 310-3.
462. Tathe SP, Dani AA, Chawhan SM, Meshram SA, Randale AA, Raut WK. Gastric mucormycosis: Diagnosis by imprint cytology. *Diagn Cytopathol* 2016; **44**(10): 820-2.
463. Teal LJ, Schultz KM, Weber DJ, et al. Invasive Cutaneous Rhizopus Infections in an Immunocompromised Patient Population Associated with Hospital Laundry Carts. *Infect Control Hosp Epidemiol* 2016; **37**(10): 1251-3.
464. Teixeira CA, Medeiros PB, Leushner P, Almeida F. Rhinocerebral mucormycosis: literature review apropos of a rare entity. *BMJ Case Rep* 2013; **2013**.
465. Terry AR, Kahle KT, Larvie M, Vyas JM, Stemmer-Rachamimov A. A 43-Year-Old Man with Altered Mental Status and a History of Alcohol Use. *N Engl J Med* 2016; **374**(7): 671-80.
466. Timoteo CA, Correa AP, Zorzi Colete J, Marcondes Aranega A, Junior IR. Survival Without Neurological Impairment of a Patient With Rhino-Orbito-Cerebral Zygomycosis. *J Craniofac Surg* 2016; **27**(4): e376-8.

467. Torres-Damas W, Yumpo-Cardenas D, Mota-Anaya E. [Coinfection of rhinocerebral mucormycosis and sinus aspergillosis]. *Rev Peru Med Exp Salud Publica* 2015; **32**(4): 813-7.
468. Trabelsi H, Neji S, Sellami H, et al. Invasive fungal infections in renal transplant recipients: about 11 cases. *J Mycol Med* 2013; **23**(4): 255-60.
469. Trenker C, Dohse M, Metzelder SK, Rexin P, Mariss J, Goerg C. 71-Year-Old Patient with Chronic Lymphocytic Leukemia (CLL) and Hypochoic Nodular Spleen and Liver Lesions with Fatal Outcome: Presentation of Mucormycosis in B-Mode Imaging and Contrast-Enhanced Ultrasound (CEUS). *Ultrasound Int Open* 2016; **2**(3): E100-1.
470. Trief D, Gray ST, Jakobiec FA, et al. Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus. *Br J Ophthalmol* 2016; **100**(2): 184-8.
471. Tsai WC, Lee CH, Wu WM, et al. Cutaneous manifestations of subcutaneous and systemic fungal infections in tropical regions: a retrospective study from a referral center in southern Taiwan. *Int J Dermatol* 2017; **56**(6): 623-9.
472. Turan MN, Tatar E, Yaprak M, et al. A mucormycosis case presented with orbital apex syndrome and hemiplegia in a renal transplant patient. *Int Urol Nephrol* 2013; **45**(6): 1815-9.
473. Turnbull A, Chembo CL, Leikis M, et al. A Case of Pulmonary Mucormycosis in a Renal Transplant Recipient. *Nephrology (Carlton)* 2017; **22**(8): 657.
474. Tuysuz G, Ozdemir N, Senyuz OF, et al. Successful management of hepatic mucormycosis in an acute lymphoblastic leukaemia patient: a case report and review of the literature. *Mycoses* 2014; **57**(8): 513-8.
475. Tyll T, Lyskova P, Hubka V, et al. Early Diagnosis of Cutaneous Mucormycosis Due to *Lichtheimia corymbifera* After a Traffic Accident. *Mycopathologia* 2016; **181**(1-2): 119-24.
476. Urs AB, Singh H, Mohanty S, Sharma P. Fungal osteomyelitis of maxillofacial bones: Rare presentation. *J Oral Maxillofac Pathol* 2016; **20**(3): 546.
477. Vaideeswar P, Shah R. Zygomycotic infective endocarditis in pregnancy. *Cardiovasc Pathol* 2017; **28**: 28-30.
478. Vallabhaneni S, Walker TA, Lockhart SR, et al. Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement--Connecticut, 2014. *MMWR Morb Mortal Wkly Rep* 2015; **64**(6): 155-6.
479. Vallverdu Vidal M, Iglesias Moles S, Palomar Martinez M. Rhino-orbital-cerebral mucormycosis in a critically ill patient. *Med Intensiva* 2017; **41**(8): 509-10.
480. Vallverdu Vidal M, Iglesias Moles S, Palomera Fernandez M, Palomar Martinez M. [Isolated renal mucormycosis in a critically ill patient]. *Rev Iberoam Micol* 2017; **34**(1): 57-8.
481. Varghese R, Nair RM, Kavalakkat FJ. Fungal otomastoiditis: a case series in immunocompetent adults. *Indian J Otolaryngol Head Neck Surg* 2014; **66**(1): 110-3.
482. Vercillo MS, Liptay MJ, Seder CW. Early pneumonectomy for pulmonary mucormycosis. *Ann Thorac Surg* 2015; **99**(3): e67-8.
483. Verma A, Singh V, Jindal N, Yadav S. Necrosis of maxilla, nasal, and frontal bone secondary to extensive rhino-cerebral mucormycosis. *Natl J Maxillofac Surg* 2013; **4**(2): 249-51.
484. Verma R, Nair V, Vasudevan B, Vijendran P, Behera V, Neema S. Rare case of primary cutaneous mucormycosis of the hand caused by *Rhizopus microsporus* in an immunocompetent patient. *Int J Dermatol* 2014; **53**(1): 66-9.
485. Vidovic A, Arsic-Arsenijevic V, Tomin D, et al. Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report. *J Med Case Rep* 2013; **7**: 263.
486. Vijayabala GS, Annigeri RG, Sudarshan R. Mucormycosis in a diabetic ketoacidosis patient. *Asian Pac J Trop Biomed* 2013; **3**(10): 830-3.
487. Ville S, Talarmin JP, Gaultier-Lintia A, et al. Disseminated Mucormycosis With Cerebral Involvement Owing to *Rhizopus Microsporus* in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy. *Exp Clin Transplant* 2016; **14**(1): 96-9.
488. Vogt N, Hess K, Bialek R, et al. Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. *Ann Hematol* 2017; **96**(1): 151-3.
489. Vondran FW, Knitsch W, Krech T, et al. Intestinal mucormycosis with *Rhizopus microsporus* after liver transplantation--successful treatment of a rare but life-threatening complication. *Transplantation* 2014; **97**(2): e11-3.
490. Wang Q, Liu B, Yan Y. Disseminated mucormycosis (DM) after pneumonectomy: a case report. *BMC Infect Dis* 2016; **16**: 337.
491. Wang XM, Guo LC, Xue SL, Chen YB. Pulmonary mucormycosis: A case report and review of the literature. *Oncol Lett* 2016; **11**(5): 3049-53.
492. Wang Y, Zhao Z, Lu H, Zhang J, Huang F. Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases. *Exp Ther Med* 2017; **13**(2): 489-94.

493. Webb BJ, Blair JE, Kusne S, et al. Concurrent pulmonary *Aspergillus fumigatus* and mucor infection in a cardiac transplant recipient: a case report. *Transplant Proc* 2013; **45**(2): 792-7.
494. Williams KE, Parish JM, Lyng PJ, et al. Pseudomembranous tracheobronchitis caused by *Rhizopus* sp. After allogeneic stem cell transplantation. *J Bronchology Interv Pulmonol* 2014; **21**(2): 166-9.
495. Winstead M, Ozolek J, Nowalk A, Williams J, Vander Lugt M, Lin P. Disseminated Lichtheimia ramosa Infection After Hematopoietic Stem Cell Transplantation in a Child With Chronic Granulomatous Disease. *Pediatr Infect Dis J* 2017; **36**(12): 1222-4.
496. Wolkow N, Jakobiec FA, Stagner AM, et al. Chronic orbital and calvarial fungal infection with *Apophysomyces variabilis* in an immunocompetent patient. *Surv Ophthalmol* 2017; **62**(1): 70-82.
497. Wright AJ, Steiner T, Bilawich AM, English JC, Ryan CF. Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab. *Can J Infect Dis Med Microbiol* 2013; **24**(2): 67-8.
498. Xia XJ, Shen H, Liu ZH. Primary cutaneous mucormycosis caused by *Mucor irregularis*. *Clin Exp Dermatol* 2015; **40**(8): 875-8.
499. Xia ZK, Wang WL, Yang RY. Slowly progressive cutaneous, rhinofacial, and pulmonary mucormycosis caused by *Mucor irregularis* in an immunocompetent woman. *Clin Infect Dis* 2013; **56**(7): 993-5.
500. Xu L, Bao Y, Wang S, et al. [A clinical analysis of eight proven cases of pulmonary mucormycosis]. *Zhonghua Nei Ke Za Zhi* 2014; **53**(3): 206-9.
501. Xu S, Nambudiri VE, Tahan S, Seo SJ. Violaceous necrotic plaques on the leg of an immunosuppressed patient. Cutaneous mucormycosis. *JAMA Dermatol* 2014; **150**(1): 79-81.
502. Yamaguchi S, Okubo Y, Katano A, Sano A, Uezato H, Takahashi K. Primary cutaneous mucormycosis caused by *Mucor irregularis* in an elderly person. *J Dermatol* 2015; **42**(2): 210-4.
503. Yang C, Friess SH, Dehner LP. Hepatic Mucormycosis Mimicking Venous-occlusive Disease: Report of a Case and Review of the Literature. *Pediatr Dev Pathol* 2016; **19**(2): 150-3.
504. Yang H, Wang C. Looks like Tuberculous Meningitis, But Not: A Case of Rhinocerebral Mucormycosis with Garcin Syndrome. *Front Neurol* 2016; **7**: 181.
505. Yang YM, Fang BM, Xu XM, et al. [Pulmonary mucormycosis: report of 5 cases and review of 46 cases reported in China]. *Zhonghua Jie He He Hu Xi Za Zhi* 2013; **36**(8): 572-6.
506. Yasmeen S, Waqas O, Munir J, Sultan F, Hameed A. Hepatosplenic mucormycosis post autologous stem cell transplant. *Pak J Med Sci* 2017; **33**(3): 776-8.
507. Ye B, Yu D, Zhang X, et al. Disseminated *Rhizopus microsporus* infection following allogeneic hematopoietic stem cell transplantation in a child with severe aplastic anemia. *Transpl Infect Dis* 2013; **15**(6): E216-23.
508. Ye W, Wang Y, Wen Y, Li H, Li X. Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy. *Int Urol Nephrol* 2014; **46**(6): 1247-51.
509. Yuda J, Kato K, Kikushige Y, et al. Successful treatment of invasive zygomycosis based on a prompt diagnosis using molecular methods in a patient with acute myelogenous leukemia. *Intern Med* 2014; **53**(10): 1087-91.
510. Zafar S, Prabhu A. Rhino-orbito-cerebral mucormycosis: recovery against the odds. *Pract Neurol* 2017; **17**(6): 485-8.
511. Zahoor BA, Piercey JE, Wall DR, Tetsworth KD. A surgical approach in the management of mucormycosis in a trauma patient. *Ann R Coll Surg Engl* 2016; **98**(8): e173-e7.
512. Zaman K, Kaur H, Rudramurthy SM, Singh M, Parashar A, Chakrabarti A. Cutaneous mucormycosis of scalp and eyelids in a child with type I diabetes mellitus. *Indian J Dermatol Venereol Leprol* 2015; **81**(3): 275-8.
513. Zehani A, Smichi I, Marrakchi J, Besbes G, Haouet S, Kchir N. Aggressive infection following a dental extraction in a diabetic patient :Rhinocerebral mucormycosis. *Tunis Med* 2017; **95**(5): 378-80.
514. Zhai X, Zhang JL, Liu G. [One case of intracranial mucormycosis infection following endoscopic repair of cerebrospinal fluid rhinorrhea]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2013; **48**(10): 849-50.
515. Zhang D, Wang X, Lv J, Dong Y. Treatment of a patient with severe hemorrhagic fever accompanied by infection with methicillin-resistant *Staphylococcus aureus*, *Acinetobacter baumannii*, *aspergillus* and mucor: a case report. *Int J Clin Pharmacol Ther* 2015; **53**(12): 1028-34.
516. Zhang H, Liu G, Hang W, Zhang J. [Rhino-orbito-cerebral mucormycosis: report of 9 cases]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2014; **49**(6): 446-51.
517. Zhang J, Kim JD, Beaver HA, Takashima M, Lee AG. Rhino-orbital Mucormycosis Treated Successfully with Posaconazole without Exenteration. *Neuroophthalmology* 2013; **37**(5): 198-203.
518. Zhang Y, Wang T, Liu GL, Li J, Gao SQ, Wan L. Mucormycosis or extranodal natural killer/T cell lymphoma, similar symptoms but different diagnosis. *J Mycol Med* 2016; **26**(3): 277-82.
519. Zhu X, Liu H, Wang W, et al. Two cases of transplant renal artery thrombosis and spontaneous rupture caused by mucormycosis. *Transpl Infect Dis* 2015; **17**(3): 442-8.

520. Zimmerli S, Bialek R, Blau IW, Christe A, Lass-Flörl C, Presterl E. Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools. *Mycopathologia* 2016; **181**(7-8): 561-6.
521. Dadax. Countries in the world by population (2018). 2018. <http://www.worldometers.info/world-population/population-by-country/> (accessed June 20, 2018).
522. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of *Aspergillus*-active antifungal therapy: a case-control observational study of 27 recent cases. *J Infect Dis* 2005; **191**(8): 1350-60.
523. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. *Emerg Infect Dis* 2009; **15**(9): 1395-401.
524. Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. *Leuk Lymphoma* 2017; **58**(3): 586-93.
525. Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). *J Chemother* 2009; **21**(3): 322-9.
526. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. *Clin Infect Dis* 1998; **27**(5): 1138-47.
527. Bitar D, Che D. [Epidemiology of mucormycosis in metropolitan France, 1997-2010]. *Med Sci (Paris)* 2013; **29 Spec No 1**: 7-12.
528. Chakrabarti A, Singh R. Mucormycosis in India: unique features. *Mycoses* 2014; **57 Suppl 3**: 85-90.
529. Dolatabadi S, Ahmadi B, Rezaei-Matehkolaei A, et al. Mucormycosis in Iran: A six-year retrospective experience. *J Mycol Med* 2018; **28**(2): 269-73.
530. Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. *BMC Infect Dis* 2016; **16**(1): 730.
531. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. *Emerg Infect Dis* 2010; **16**(9): 1456-8.
532. Cuenca-Estrella M, Bernal-Martinez L, Isla G, Gomez-Lopez A, Alcazar-Fuoli L, Buitrago MJ. Incidence of zygomycosis in transplant recipients. *Clinical Microbiology and Infection* 2009; **15**: 37-40.
533. Corzo-Leon DE, Chora-Hernandez LD, Rodriguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. *Med Mycol* 2018; **56**(1): 29-43.
534. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 2005; **41**(5): 634-53.
535. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. *Int J Infect Dis* 2010; **14 Suppl 3**: e100-3.
536. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone Marrow Transplant* 2007; **40**(5): 451-6.
537. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. *N Engl J Med* 2004; **350**(9): 950-2.
538. Kim SB, Cho SY, Lee DG, et al. Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study. *Med Mycol* 2017; **55**(3): 237-45.
539. Aslani J, Eizadi M, Kardavani B, et al. Mucormycosis after kidney transplantations: report of seven cases. *Scand J Infect Dis* 2007; **39**(8): 703-6.
540. Godara SM, Kute VB, Goplani KR, et al. Mucormycosis in renal transplant recipients: predictors and outcome. *Saudi J Kidney Dis Transpl* 2011; **22**(4): 751-6.
541. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. *Clin Infect Dis* 2001; **32**(9): 1319-24.
542. Forrest GN, Mankes K. Outcomes of invasive zygomycosis infections in renal transplant recipients. *Transpl Infect Dis* 2007; **9**(2): 161-4.
543. Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. *Mycoses* 2016; **59**(7): 402-15.
544. Guimaraes LF, Halpern M, de Lemos AS, et al. Invasive fungal disease in renal transplant recipients at a Brazilian center: local epidemiology matters. *Transplant Proc* 2016; **48**(7): 2306-9.
545. Mitchell TA, Hardin MO, Murray CK, et al. Mucormycosis attributed mortality: a seven-year review of surgical and medical management. *Burns* 2014; **40**(8): 1689-95.
546. Schaal JV, Leclerc T, Soler C, et al. Epidemiology of filamentous fungal infections in burned patients: A French retrospective study. *Burns* 2015; **41**(4): 853-63.

547. Ezzatzadegan S, Chen S, Chapman JR. Invasive fungal infections after renal transplantation. *Int J Organ Transplant Med* 2012; **3**(1): 18-25.
548. Husain S, Silveira FP, Azie N, Franks B, Horn D. Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance(R) registry analysis. *Med Mycol* 2017; **55**(3): 269-77.
549. Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. *Transpl Infect Dis* 2013; **15**(3): 233-42.
550. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis* 2010; **50**(8): 1091-100.
551. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. *Emerg Infect Dis* 2011; **17**(10): 1855-64.
552. Einollahi B, Lessan-Pezeshki M, Pourfarziani V, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients. *Ann Transplant* 2008; **13**(4): 55-8.
553. Bavikar P, Mehta V. Rhino-Orbital-Cerebral Mucormycosis: A Fatal Complication of Uncontrolled Diabetes Mellitus. *Cureus* 2017; **9**(11): e1841.
554. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. *J Infect Dis* 2009; **200**(6): 1002-11.
555. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966; **64**(2): 328-40.
556. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. *Int J Clin Pract* 2009; **63**(1): 134-9.
557. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). *Br J Haematol* 1997; **99**(2): 331-6.
558. Wang X, Wang A, Wang X, Li R, Yu J. Cutaneous mucormycosis caused by *Mucor irregularis* in a patient with CARD9 deficiency. *Br J Dermatol* 2019; **180**(1): 213-4.
559. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. *Clin Microbiol Infect* 2019; **25**(1): 26-34.
560. Moreira J, Varon A, Galhardo MC, et al. The burden of mucormycosis in HIV-infected patients: A systematic review. *J Infect* 2016; **73**(3): 181-8.
561. Neblett Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. *N Engl J Med* 2012; **367**(23): 2214-25.
562. Warkentien T, Rodriguez C, Lloyd B, et al. Invasive mold infections following combat-related injuries. *Clin Infect Dis* 2012; **55**(11): 1441-9.
563. Rodriguez CJ, Tribble DR, Malone DL, et al. Treatment of Suspected Invasive Fungal Infection in War Wounds. *Mil Med* 2018; **183**(Suppl 2): 142-6.
564. Tilak R, Raina P, Gupta SK, Tilak V, Prakash P, Gulati AK. Cutaneous zygomycosis: a possible postoperative complication in immunocompetent individuals. *Indian J Dermatol Venereol Leprol* 2009; **75**(6): 596-9.
565. Tehmeena W, Hussain W, Zargar HR, Sheikh AR, Iqbal S. Primary cutaneous mucormycosis in an immunocompetent host. *Mycopathologia* 2007; **164**(4): 197-9.
566. Singla K, Samra T, Bhatia N. Primary Cutaneous Mucormycosis in a Trauma Patient with Morel-Lavallee Lesion. *Indian J Crit Care Med* 2018; **22**(5): 375-7.
567. Hay RJ. Mucormycosis: an infectious complication of traumatic injury. *Lancet* 2005; **365**(9462): 830-1.
568. Andresen D, Donaldson A, Choo L, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. *Lancet* 2005; **365**(9462): 876-8.
569. Tribble DR, Rodriguez CJ. Combat-Related Invasive Fungal Wound Infections. *Curr Fungal Infect Rep* 2014; **8**(4): 277-86.
570. Davoudi S, Graviss LS, Kontoyiannis DP. Healthcare-associated outbreaks due to Mucorales and other uncommon fungi. *Eur J Clin Invest* 2015; **45**(7): 767-73.
571. Duffy J, Harris J, Gade L, et al. Mucormycosis outbreak associated with hospital linens. *Pediatr Infect Dis J* 2014; **33**(5): 472-6.
572. Rammaert B, Lanternier F, Zahar JR, et al. Healthcare-associated mucormycosis. *Clin Infect Dis* 2012; **54**(Suppl 1): S44-54.
573. Antoniadou A. Outbreaks of zygomycosis in hospitals. *Clin Microbiol Infect* 2009; **15**(Suppl 5): 55-9.
574. Maravi-Poma E, Rodriguez-Tudela JL, de Jalon JG, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. *Intensive Care Med* 2004; **30**(4): 724-8.

575. Chemaly RF, Fox SB, Alkotob LM, et al. A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient. *Scand J Infect Dis* 2002; **34**(2): 149-51.
576. Holzel H, Macqueen S, MacDonald A, et al. Rhizopus microsporus in wooden tongue depressors: a major threat or minor inconvenience? *J Hosp Infect* 1998; **38**(2): 113-8.
577. Harper JJ, Coulter C, Lye GR, Nimmo GR. Rhizopus and tongue depressors. *Lancet* 1996; **348**(9036): 1250.
578. Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. *Lancet* 1996; **348**(9025): 441-3.
579. Levy E, Bia MJ. Isolated renal mucormycosis: case report and review. *J Am Soc Nephrol* 1995; **5**(12): 2014-9.
580. Sridhara SR, Paragache G, Panda NK, Chakrabarti A. Mucormycosis in immunocompetent individuals: an increasing trend. *J Otolaryngol* 2005; **34**(6): 402-6.
581. Shatriah I, Mohd-Amin N, Tuan-Jaafar TN, Khanna RK, Yunus R, Madhavan M. Rhino-orbito-cerebral mucormycosis in an immunocompetent patient: case report and review of literature. *Middle East Afr J Ophthalmol* 2012; **19**(2): 258-61.
582. Chakrabarti A, Das A, Sharma A, et al. Ten years' experience in zygomycosis at a tertiary care centre in India. *J Infect* 2001; **42**(4): 261-6.
583. Mignogna MD, Fortuna G, Leuci S, et al. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. *Int J Infect Dis* 2011; **15**(8): e533-40.
584. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). *Clin Infect Dis* 2012; **54** (Suppl 1): S35-43.
585. Nilesh K, Vande AV. Mucormycosis of maxilla following tooth extraction in immunocompetent patients: Reports and review. *J Clin Exp Dent* 2018; **10**(3): e300-e5.
586. Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, et al. Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. *Med Mycol* 2017; **55**(7): 691-704.
587. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. *J Infect* 2009; **59**(2): 134-8.
588. Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. *Medicine (Baltimore)* 2014; **93**(24): 395-404.
589. Uckay I, Chalandon Y, Sartoretti P, et al. Invasive zygomycosis in transplant recipients. *Clin Transplant* 2007; **21**(4): 577-82.
590. Harril WC, Stewart MG, Lee AG, Cernoch P. Chronic rhinocerebral mucormycosis. *Laryngoscope* 1996; **106**(10): 1292-7.
591. Nolan RL, Carter RR, 3rd, Griffith JE, Chapman SW. Subacute disseminated mucormycosis in a diabetic male. *Am J Med Sci* 1989; **298**(4): 252-5.
592. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. *Arch Intern Med* 1999; **159**(12): 1301-9.
593. Jundt JS, Wong MEK, Tataru AM, Demian NM. Invasive Cutaneous Facial Mucormycosis in a Trauma Patient. *J Oral Maxillofac Surg* 2018; **76**(9): 1930 e1- e5.
594. Barrak HA. Hard palate perforation due to mucormycosis: report of four cases. *J Laryngol Otol* 2007; **121**(11): 1099-102.
595. Downie ML, Alghounaim M, Davidge KM, et al. Isolated cutaneous mucormycosis in a pediatric renal transplant recipient. *Pediatr Transplant* 2018; **22**(4): e13172.
596. Becker BC, Schuster FR, Ganster B, Seidl HP, Schmid I. Cutaneous mucormycosis in an immunocompromised patient. *Lancet Infect Dis* 2006; **6**(8): 536.
597. Lu XL, Liu ZH, Shen YN, et al. Primary cutaneous zygomycosis caused by *Rhizomucor variabilis*: a new endemic zygomycosis? A case report and review of 6 cases reported from China. *Clin Infect Dis* 2009; **49**(3): e39-43.
598. Kaur H, Ghosh A, Rudramurthy SM, Chakrabarti A. Gastrointestinal mucormycosis in apparently immunocompetent hosts-A review. *Mycoses* 2018.
599. Vikum D, Nordoy I, Torp Andersen C, et al. A Young, Immunocompetent Woman with Small Bowel and Hepatic Mucormycosis Successfully Treated with Aggressive Surgical Debridements and Antifungal Therapy. *Case Rep Infect Dis* 2017; **2017**: 4173246.
600. Ismail MH, Hodkinson HJ, Setzen G, Sofianos C, Hale MJ. Gastric mucormycosis. *Trop Gastroenterol* 1990; **11**(2): 103-5.
601. Kwok M, Maurice A, Carroll J, et al. Gastrointestinal mucormycosis in an immunocompromised host. *ANZ J Surg* 2019; **89**(1-2): E26-E7.

602. Knoop C, Antoine M, Vachiere JL, et al. Gastric perforation due to mucormycosis after heart-lung and heart transplantation. *Transplantation* 1998; **66**(7): 932-5.
603. Deja M, Wolf S, Weber-Carstens S, et al. Gastrointestinal zygomycosis caused by *Mucor indicus* in a patient with acute traumatic brain injury. *Med Mycol* 2006; **44**(7): 683-7.
604. Gupta S, Jayashree M, Chakrabarti A, Sodhi KS, Kanojia RP, Mitra S. Invasive Gastrointestinal Mucormycosis: A Master Masquerader. *Pediatr Infect Dis J* 2018; **37**(10): 1067-70.
605. Marak RS, Misra R, Ansari MS, et al. Successful medical management of renal zygomycosis: a summary of two cases and a review of the Indian literature. *Med Mycol* 2010; **48**(8): 1088-95.
606. Thomas AJ, Shah S, Mathews MS, Chacko N. *Apophysomyces elegans* - renal mucormycosis in a healthy host: a case report from south India. *Indian J Med Microbiol* 2008; **26**(3): 269-71.
607. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. *Clin Infect Dis* 1998; **26**(3): 601-5.
608. Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. *Crit Rev Microbiol* 2016; **42**(1): 158-71.
609. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. *Clin Infect Dis* 2005; **41**(1): 60-6.
610. Marchiori E, Zanetti G, Escuissato DL, et al. Reversed halo sign: high-resolution CT scan findings in 79 patients. *Chest* 2012; **141**(5): 1260-6.
611. Sonnet S, Buitrago-Tellez CH, Tamm M, Christen S, Steinbrich W. Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography. *AJR Am J Roentgenol* 2005; **184**(3): 746-51.
612. Stanzani M, Vianelli N, Cavo M, Maritati A, Morotti M, Lewis RE. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. *Antimicrob Agents Chemother* 2017; **61**(9).
613. Sassi C, Stanzani M, Lewis RE, et al. The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. *Br J Radiol* 2018; **91**(1083): 20170220.
614. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of *Aspergillus* diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect* 2018; **24** Suppl 1: e1-e38.
615. Legouge C, Caillot D, Chretien ML, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? *Clin Infect Dis* 2014; **58**(5): 672-8.
616. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. *Clin Infect Dis* 2008; **46**(11): 1733-7.
617. Stanzani M, Sassi C, Lewis RE, et al. High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. *Clin Infect Dis* 2015; **60**(11): 1603-10.
618. Koc Z, Koc F, Yerdelen D, Ozdogu H. Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. *Int J Neurosci* 2007; **117**(12): 1677-90.
619. Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. *Mycoses* 2007; **50**(4): 290-6.
620. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. *Clin Infect Dis* 2008; **47**(3): 364-71.
621. Herrera DA, Dublin AB, Ormsby EL, Aminpour S, Howell LP. Imaging findings of rhinocerebral mucormycosis. *Skull Base* 2009; **19**(2): 117-25.
622. Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. *Curr Infect Dis Rep* 2012; **14**(4): 423-34.
623. Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. *Clin Infect Dis* 2007; **45**(7): e101-4.
624. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. *Clin Infect Dis* 2007; **44**(8): 1078-83.
625. Choo JY, Park CM, Lee HJ, Lee CH, Goo JM, Im JG. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. *Diagn Interv Radiol* 2014; **20**(1): 42-6.
626. Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. *Med Mycol* 2012; **50**(6): 611-8.
627. Centeno RS, Bentson JR, Mancuso AA. CT scanning in rhinocerebral mucormycosis and aspergillosis. *Radiology* 1981; **140**(2): 383-9.

628. Gamba JL, Woodruff WW, Djang WT, Yeates AE. Craniofacial mucormycosis: assessment with CT. *Radiology* 1986; **160**(1): 207-12.
629. Garcia-Romero MT, Garcia-Mendez J, Arenas R, Ferrari-Carballo T, Chanona-Vilchis J, Cervera-Ceballos E. Zygomycosis in two hematologic cases. *Case Rep Infect Dis* 2011; **2011**: 181782.
630. Chugh KS, Sakhuja V, Gupta KL, et al. Renal mucormycosis: computerized tomographic findings and their diagnostic significance. *Am J Kidney Dis* 1993; **22**(3): 393-7.
631. Sharma DS, Animesh, Deshpande SS, et al. Peripheral dose from uniform dynamic multileaf collimation fields: implications for sliding window intensity-modulated radiotherapy. *Br J Radiol* 2006; **79**(940): 331-5.
632. Dhaliwal HS, Singh A, Sinha SK, et al. Diagnosed only if considered: isolated renal mucormycosis. *Lancet* 2015; **385**(9984): 2322.
633. Piccoli GB, Priola AM, Vigotti FN, Guzzo G, Veltri A. Renal infarction versus pyelonephritis in a woman presenting with fever and flank pain. *Am J Kidney Dis* 2014; **64**(2): 311-4.
634. Sharma R, Shivanand G, Kumar R, et al. Isolated renal mucormycosis: an unusual cause of acute renal infarction in a boy with aplastic anaemia. *Br J Radiol* 2006; **79**(943): e19-21.
635. Douglas A, Lau E, Thursky K, Slavin M. What, where and why: exploring fluorodeoxyglucose-PET's ability to localise and differentiate infection from cancer. *Curr Opin Infect Dis* 2017; **30**(6): 552-64.
636. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. *Haematologica* 2004; **89**(2): 207-14.
637. Henzler C, Henzler T, Buchheidt D, et al. Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients. *Sci Rep* 2017; **7**(1): 4483.
638. Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. *Postgrad Med J* 2009; **85**(1009): 573-81.
639. Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. *J Antimicrob Chemother* 2010; **65**(2): 296-302.
640. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. *Clin Microbiol Infect* 2011; **17**(12): 1859-67.
641. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. *Arch Pathol Lab Med* 2001; **125**(3): 375-8.
642. Jensen HE, Salonen J, Ekfors TO. The use of immunohistochemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. *J Pathol* 1997; **181**(1): 100-5.
643. Jung J, Park YS, Sung H, et al. Using immunohistochemistry to assess the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis. *Clin Infect Dis* 2015; **61**(11): 1664-70.
644. Schwarz P, Bretagne S, Gantier JC, et al. Molecular identification of Zygomycetes from culture and experimentally infected tissues. *J Clin Microbiol* 2006; **44**(2): 340-9.
645. Lau A, Chen S, Sorrell T, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. *J Clin Microbiol* 2007; **45**(2): 380-5.
646. Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. *J Clin Microbiol* 2008; **46**(11): 3690-702.
647. Hrnčirova K, Lengerova M, Kocmanova I, et al. Rapid detection and identification of mucormycetes from culture and tissue samples by use of high-resolution melt analysis. *J Clin Microbiol* 2010; **48**(9): 3392-4.
648. Bernal-Martinez L, Buitrago MJ, Castelli MV, Rodriguez-Tudela JL, Cuenca-Estrella M. Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species. *Clin Microbiol Infect* 2013; **19**(1): E1-e7.
649. Buitrago MJ, Bernal-Martinez L, Castelli MV, Rodriguez-Tudela JL, Cuenca-Estrella M. Performance of panfungal- and specific-PCR-based procedures for etiological diagnosis of invasive fungal diseases on tissue biopsy specimens with proven infection: a 7-year retrospective analysis from a reference laboratory. *J Clin Microbiol* 2014; **52**(5): 1737-40.
650. Alanio A, Garcia-Hermoso D, Mercier-Delarue S, et al. Molecular identification of Mucorales in human tissues: contribution of PCR electrospray-ionization mass spectrometry. *Clin Microbiol Infect* 2015; **21**(6): 594.e1-5.
651. Springer J, Goldenberger D, Schmidt F, et al. Development and application of two independent real-time PCR assays to detect clinically relevant Mucorales species. *J Med Microbiol* 2016; **65**(3): 227-34.
652. Zaman K, Rudramurthy SM, Das A, et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. *J Med Microbiol* 2017; **66**(8): 1124-9.

653. Hayden RT, Qian X, Procop GW, Roberts GD, Lloyd RV. In situ hybridization for the identification of filamentous fungi in tissue section. *Diagn Mol Pathol* 2002; **11**(2): 119-26.
654. Nagao K, Ota T, Tanikawa A, et al. Genetic identification and detection of human pathogenic *Rhizopus* species, a major mucormycosis agent, by multiplex PCR based on internal transcribed spacer region of rRNA gene. *J Dermatol Sci* 2005; **39**(1): 23-31.
655. Bialek R, Konrad F, Kern J, et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. *J Clin Pathol* 2005; **58**(11): 1180-4.
656. Rickerts V, Just-Nubling G, Konrad F, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. *Eur J Clin Microbiol Infect Dis* 2006; **25**(1): 8-13.
657. Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL. Real-time PCR method for detection of zygomycetes. *J Clin Microbiol* 2008; **46**(7): 2353-8.
658. Dannaoui E, Schwarz P, Slany M, et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. *J Clin Microbiol* 2010; **48**(6): 2043-6.
659. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. *J Clin Microbiol* 2011; **49**(6): 2151-3.
660. Buitrago MJ, Aguado JM, Ballen A, et al. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. *Clin Microbiol Infect* 2013; **19**(6): E271-7.
661. Gade L, Hurst S, Balajee SA, Lockhart SR, Litvintseva AP. Detection of mucormycetes and other pathogenic fungi in formalin fixed paraffin embedded and fresh tissues using the extended region of 28S rDNA. *Med Mycol* 2017; **55**(4): 385-95.
662. Gholinejad-Ghadi N, Shokohi T, Seifi Z, et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples. *Mycoses* 2018; **61**(12): 909-15.
663. Salehi E, Hedayati MT, Zoll J, et al. Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays. *J Clin Microbiol* 2016; **54**(11): 2798-803.
664. Springer J, Lackner M, Ensinger C, et al. Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. *J Med Microbiol* 2016; **65**(12): 1414-21.
665. Drogari-Apiranthitou M, Panayiotides I, Galani I, et al. Diagnostic value of a semi-nested PCR for the diagnosis of mucormycosis and aspergillosis from paraffin-embedded tissue: A single center experience. *Pathol Res Pract* 2016; **212**(5): 393-7.
666. Ruangritchankul K, Chindamporn A, Worasilchai N, Poumsuk U, Keelawat S, Bychkov A. Invasive fungal disease in university hospital: a PCR-based study of autopsy cases. *Int J Clin Exp Pathol* 2015; **8**(11): 14840-52.
667. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. *Mycoses* 2013; **56**(6): 638-45.
668. Shimodaira K, Okubo Y, Nakayama H, et al. Trends in the prevalence of invasive fungal infections from an analysis of annual records of autopsy cases of Toho University. *Mycoses* 2012; **55**(5): 435-43.
669. Davoudi S, Kasraianfard A, Ahmadinejad Z, et al. Cytomegalovirus reactivation and preemptive therapy after liver transplant. *Exp Clin Transplant* 2014; **12** (Suppl 1): 72-5.
670. Borrás R, Rosello P, Chilet M, Bravo D, de Lomas JG, Navarro D. Positive result of the Aspergillus galactomannan antigen assay using bronchoalveolar lavage fluid from a patient with an invasive infection due to *Lichtheimia ramosa*. *J Clin Microbiol* 2010; **48**(8): 3035-6.
671. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. *Clin Infect Dis* 2005; **41**(9): 1242-50.
672. Sinko J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. *Transpl Infect Dis* 2008; **10**(2): 106-9.
673. Marty FM, Cornely OA, Mullane KM, et al. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. *Mycoses* 2018; **61**(7): 485-97.
674. Angebault C, Lanternier F, Dalle F, et al. Prospective Evaluation of Serum beta-Glucan Testing in Patients With Probable or Proven Fungal Diseases. *Open Forum Infect Dis* 2016; **3**(3): ofw128.
675. Chamilos G, Ganguly D, Lande R, et al. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. *PLoS One* 2010; **5**(9): e12955.
676. Egger M, Pruller F, Raggam R, et al. False positive serum levels of (1-3)-ss-D-Glucan after infusion of intravenous immunoglobulins and time to normalisation. *J Infect* 2018; **76**(2): 206-10.

677. Ibrahim AS, Bowman JC, Avanesian V, et al. Caspofungin inhibits *Rhizopus oryzae* 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. *Antimicrob Agents Chemother* 2005; **49**(2): 721-7.
678. Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-ss-D-glucan concentrations in blood products predict false positive post-transfusion results. *Mycoses* 2016; **59**(1): 39-42.
679. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. *Med Mycol* 2006; **44**(3): 267-72.
680. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis* 2005; **41**(5): 654-9.
681. Burnham-Marusich AR, Hubbard B, Kvam AJ, et al. Conservation of Mannan Synthesis in Fungi of the Zygomycota and Ascomycota Reveals a Broad Diagnostic Target. *mSphere* 2018; **3**(3).
682. Bacher P, Steinbach A, Kniemeyer O, et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. *Am J Respir Crit Care Med* 2015; **191**(3): 348-52.
683. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. *Blood* 2011; **118**(20): 5416-9.
684. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-Specific T Cells in Patients with Hematologic Malignancies. *PLoS One* 2016; **11**(2): e0149108.
685. Mery A, Sendid B, Francois N, et al. Application of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections. *J Clin Microbiol* 2016; **54**(11): 2786-97.
686. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. *Clin Microbiol Rev* 2005; **18**(3): 556-69.
687. Waldorf AR, Halde C, Vedros NA. Murine model of pulmonary mucormycosis in cortisone-treated mice. *Sabouraudia* 1982; **20**(3): 217-24.
688. Kennedy KJ, Daveson K, Slavin MA, et al. Mucormycosis in Australia: contemporary epidemiology and outcomes. *Clin Microbiol Infect* 2016; **22**(9): 775-81.
689. Kontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of Zygomycetes under physiologic temperature conditions. *Am J Clin Pathol* 2007; **127**(2): 208-12.
690. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. *Clin Microbiol Rev* 2000; **13**(2): 236-301.
691. Alvarez E, Garcia-Hermoso D, Sutton DA, et al. Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus *Saksena*. *J Clin Microbiol* 2010; **48**(12): 4410-6.
692. de Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of Clinical Fungi. 2 ed: CBS, Utrecht; 2001.
693. Garcia-Hermoso D, Alanio A, Lortholary O, dromer F. Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis. In: Jorgensen J, Pfaller M, Carroll K, et al., eds. Manual of Clinical Microbiology. Eleventh Edition ed. Washington, DC.; 2015: 2087-108.
694. Padhye AA, Ajello L. Simple method of inducing sporulation by *Apophysomyces elegans* and *Saksena* *vasiformis*. *J Clin Microbiol* 1988; **26**(9): 1861-3.
695. Walsh TJ, Hayden RT, Larone DH. Mucormycetes. Larone's Medically Important Fungi: A Guide to Identification. 6th ed. Washington, DC: ASM Press; 2018: 171-89.
696. McDermott NE, Barrett J, Hipp J, et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010; **109**(3): e64-9.
697. Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N. The role of BAL in the diagnosis of pulmonary mucormycosis. *Chest* 2000; **117**(1): 279-82.
698. Garcia-Hermoso D, Criscuolo A, Lee SC, et al. Outbreak of Invasive Wound Mucormycosis in a Burn Unit Due to Multiple Strains of *Mucor circinelloides* f. *circinelloides* Resolved by Whole-Genome Sequencing. *MBio* 2018; **9**(2).
699. Page L, Weis P, Muller T, et al. Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure. *Int J Med Microbiol* 2018; **308**(8): 1018-26.
700. Arendrup MC, Guinea J, Cuenca-Estrella M, et al. EUCAST DEFINITIVE DOCUMENT E.DEF 9.3: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. 2015. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_9_3_Mould_testing_definitive.pdf.
701. CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 3rd ed. CLSI Standard M38. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
702. Arendrup MC, Jensen RH, Meletiadis J. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. *Antimicrob Agents Chemother* 2015; **59**(12): 7735-42.

703. Chowdhary A, Kathuria S, Singh PK, et al. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. *Mycoses* 2014; **57 Suppl 3**: 97-107.
704. Chowdhary A, Singh PK, Kathuria S, Hagen F, Meis JF. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. *Antimicrob Agents Chemother* 2015; **59**(12): 7882-7.
705. Caramalho R, Maurer E, Binder U, et al. Etest cannot be recommended for in vitro susceptibility testing of mucorales. *Antimicrob Agents Chemother* 2015; **59**(6): 3663-5.
706. Lamoth F, Alexander BD. Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds. *J Clin Microbiol* 2015; **53**(10): 3176-81.
707. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against *Aspergillus* and *Rhizopus*, and synergy testing for *Rhizopus*. *Med Mycol* 2008; **46**(6): 567-73.
708. Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. *Antimicrob Agents Chemother* 2015; **59**(3): 1745-50.
709. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela JL. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. *Antimicrob Agents Chemother* 2009; **53**(4): 1686-9.
710. Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, et al. Species recognition and clinical relevance of the zygomycetous genus *Lichtheimia* (syn. *Absidia* pro parte, *Mycocladius*). *J Clin Microbiol* 2010; **48**(6): 2154-70.
711. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. *Antimicrob Agents Chemother* 2007; **51**(7): 2587-90.
712. Vitale RG, de Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. *J Clin Microbiol* 2012; **50**(1): 66-75.
713. Kaindl T, Andes D, Engelhardt M, Saulay M, Larger P, Groll AH. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. *J Antimicrob Chemother* 2019; **74**(3): 761-7.
714. Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes. *Clin Microbiol Infect* 2009; **15** (Suppl 5): 71-6.
715. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. *Apophysomyces elegans*: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. *J Clin Microbiol* 2010; **48**(12): 4580-5.
716. Dannaoui E, Meletiadiis J, Mouton JW, Meis JF, Verweij PE, Eurofung N. In vitro susceptibilities of zygomycetes to conventional and new antifungals. *J Antimicrob Chemother* 2003; **51**(1): 45-52.
717. Halliday CL, Chen SC, Kidd SE, et al. Antifungal susceptibilities of non-*Aspergillus* filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. *Int J Antimicrob Agents* 2016; **48**(4): 453-8.
718. Jain R, Singhal SK, Singla N, Punia RS, Chander J. Mycological Profile and Antifungal Susceptibility of Fungal Isolates from Clinically Suspected Cases of Fungal Rhinosinusitis in a Tertiary Care Hospital in North India. *Mycopathologia* 2015; **180**(1-2): 51-9.
719. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. *Mycoses* 2005; **48**(4): 246-50.
720. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against *Mucor* spp. in an immunosuppressed-mouse model. *Antimicrob Agents Chemother* 2002; **46**(7): 2310-2.
721. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. *Antimicrob Agents Chemother* 2007; **51**(3): 1126-9.
722. Dannaoui E, Mouton JW, Meis JF, Verweij PE, Eurofung N. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. *Antimicrob Agents Chemother* 2002; **46**(6): 1953-9.
723. Takemoto K, Yamamoto Y, Kanazawa K. Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model. *J Infect Chemother* 2010; **16**(6): 388-95.
724. Rodriguez MM, Pastor FJ, Calvo E, Salas V, Sutton DA, Guarro J. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against *Rhizopus microsporus* in a murine disseminated infection. *Antimicrob Agents Chemother* 2009; **53**(12): 5022-5.

725. Rodriguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against *Rhizopus oryzae* infection in mice. *Antimicrob Agents Chemother* 2010; **54**(5): 1665-9.
726. Spreghini E, Orlando F, Giannini D, Barchiesi F. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. *J Antimicrob Chemother* 2010; **65**(10): 2158-63.
727. Lamoth F, Damonti L, Alexander BD. Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. *J Clin Microbiol* 2016; **54**(6): 1638-40.
728. Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SC. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. *J Antimicrob Chemother* 2013; **68**(12): 2842-6.
729. Dannaoui E, Afeltra J, Meis JF, Verweij PE, Eurofung N. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. *Antimicrob Agents Chemother* 2002; **46**(8): 2708-11.
730. Clinical and laboratory Standards Institute (CLSI). Interpretive Criteria for Bacteria and Fungi Identification by DNA Target Sequencing; Approved Guideline MM-18A: Clinical and Laboratory Standards Institute, Wayne, Pa, 2008.
731. Baldin C, Soliman SSM, Jeon HH, et al. PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis. *J Clin Microbiol* 2018; **56**(10).
732. Bellanger AP, Berceanu A, Rocchi S, et al. Development of a quantitative PCR detecting *Cunninghamella bertholletiae* to help in diagnosing this rare and aggressive mucormycosis. *Bone Marrow Transplant* 2018; **53**(9): 1180-3.
733. Ino K, Nakase K, Nakamura A, et al. Management of Pulmonary Mucormycosis Based on a Polymerase Chain Reaction (PCR) Diagnosis in Patients with Hematologic Malignancies: A Report of Four Cases. *Intern Med* 2017; **56**(6): 707-11.
734. Kobayashi M, Togitani K, Machida H, Uemura Y, Ohtsuki Y, Taguchi H. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by *Cunninghamella bertholletiae*. *Respirology* 2004; **9**(3): 397-401.
735. Legrand M, Gits-Muselli M, Boutin L, et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment. *Clin Infect Dis* 2016; **63**(10): 1312-7.
736. Lengerova M, Racil Z, Hrcirova K, et al. Rapid detection and identification of mucormycetes in bronchoalveolar lavage samples from immunocompromised patients with pulmonary infiltrates by use of high-resolution melt analysis. *J Clin Microbiol* 2014; **52**(8): 2824-8.
737. Millon L, Herbrecht R, Grenouillet F, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). *Clin Microbiol Infect* 2016; **22**(9): 810 e1- e8.
738. Millon L, Larosa F, Lepiller Q, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. *Clin Infect Dis* 2013; **56**(10): e95-101.
739. Scherer E, Iriart X, Bellanger AP, et al. Quantitative PCR (qPCR) detection of Mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis. *J Clin Microbiol* 2018; **56**(8).
740. Shigemura T, Nakazawa Y, Matsuda K, et al. Serial monitoring of Mucorales DNA load in serum samples of a patient with disseminated mucormycosis after allogeneic bone marrow transplantation. *Int J Hematol* 2014.
741. Springer J, White PL, Kessel J, et al. A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. *J Clin Microbiol* 2018; **56**(2).
742. Millon L, Herbrecht R, Grenouillet F, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). *Clin Microbiol Infect* 2016; **22**(9): 810.e1-.e8.
743. Alvarez E, Stchigel AM, Cano J, et al. Molecular phylogenetic diversity of the emerging mucoralean fungus *Apophysomyces*: proposal of three new species. *Rev Iberoam Micol* 2010; **27**(2): 80-9.
744. Garcia-Hermoso D, Hoinard D, Gantier JC, Grenouillet F, Dromer F, Dannaoui E. Molecular and phenotypic evaluation of *Lichtheimia corymbifera* (formerly *Absidia corymbifera*) complex isolates associated with human mucormycosis: rehabilitation of *L. ramosa*. *J Clin Microbiol* 2009; **47**(12): 3862-70.
745. Walther G, Pawlowska J, Alastruey-Izquierdo A, et al. DNA barcoding in Mucorales: an inventory of biodiversity. *Persoonia* 2013; **30**: 11-47.
746. Alvarez E, Sutton DA, Cano J, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. *J Clin Microbiol* 2009; **47**(6): 1650-6.

747. Bonifaz A, Tirado-Sanchez A, Calderon L, et al. Mucormycosis in children: a study of 22 cases in a Mexican hospital. *Mycoses* 2014; **57 Suppl 3**: 79-84.
748. Yang M, Lee JH, Kim YK, Ki CS, Huh HJ, Lee NY. Identification of mucorales from clinical specimens: a 4-year experience in a single institution. *Ann Lab Med* 2016; **36**(1): 60-3.
749. Chakrabarti A, Ghosh A, Prasad GS, et al. *Apophysomyces elegans*: an emerging zygomycete in India. *J Clin Microbiol* 2003; **41**(2): 783-8.
750. Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of *Aspergillus*, *Fusarium*, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? *J Clin Microbiol* 2009; **47**(4): 877-84.
751. Hall L, Wohlfiel S, Roberts GD. Experience with the MicroSeq D2 large-subunit ribosomal DNA sequencing kit for identification of filamentous fungi encountered in the clinical laboratory. *J Clin Microbiol* 2004; **42**(2): 622-6.
752. Machouart M, Larche J, Burton K, et al. Genetic identification of the main opportunistic mucorales by PCR-restriction fragment length polymorphism. *J Clin Microbiol* 2006; **44**(3): 805-10.
753. Nyilasi I, Papp T, Csernetics A, Krizsan K, Nagy E, Vagvolgyi C. High-affinity iron permease (FTR1) gene sequence-based molecular identification of clinically important Zygomycetes. *Clin Microbiol Infect* 2008; **14**(4): 393-7.
754. Voigt K, Cigelnik E, O'Donnell K. Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data. *J Clin Microbiol* 1999; **37**(12): 3957-64.
755. Etienne KA, Gillette J, Hilsabeck R, et al. Whole genome sequence typing to investigate the *Apophysomyces* outbreak following a tornado in Joplin, Missouri, 2011. *PLoS One* 2012; **7**(11): e49989.
756. Schwarz P, Lortholary O, Dromer F, Dannaoui E. Carbon assimilation profiles as a tool for identification of zygomycetes. *J Clin Microbiol* 2007; **45**(5): 1433-9.
757. Becker PT, de Bel A, Martiny D, et al. Identification of filamentous fungi isolates by MALDI-TOF mass spectrometry: clinical evaluation of an extended reference spectra library. *Med Mycol* 2014; **52**(8): 826-34.
758. Chen YS, Liu YH, Teng SH, et al. Evaluation of the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Bruker Biotyper for identification of *Penicillium marneffei*, *Paecilomyces* species, *Fusarium solani*, *Rhizopus* species, and *Pseudallescheria boydii*. *Front Microbiol* 2015; **6**: 679.
759. De Carolis E, Posteraro B, Lass-Flörl C, et al. Species identification of *Aspergillus*, *Fusarium* and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clin Microbiol Infect* 2012; **18**(5): 475-84.
760. Dolatabadi S, Kolecka A, Versteeg M, de Hoog SG, Boekhout T. Differentiation of clinically relevant Mucorales *Rhizopus microsporus* and *R. arrhizus* by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). *J Med Microbiol* 2015; **64**(7): 694-701.
761. Lau AF, Drake SK, Calhoun LB, Henderson CM, Zelazny AM. Development of a clinically comprehensive database and a simple procedure for identification of molds from solid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2013; **51**(3): 828-34.
762. McMullen AR, Wallace MA, Pincus DH, Wilkey K, Burnham CA. Evaluation of the Vitek MS Matrix-Assisted Laser Desorption-Ionization-Time of Flight Mass Spectrometry System for Identification of Clinically Relevant Filamentous Fungi. *J Clin Microbiol* 2016; **54**(8): 2068-73.
763. Ranque S, Normand AC, Cassagne C, et al. MALDI-TOF mass spectrometry identification of filamentous fungi in the clinical laboratory. *Mycoses* 2014; **57**(3): 135-40.
764. Riat A, Hinrikson H, Barras V, Fernandez J, Schrenzel J. Confident identification of filamentous fungi by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry without subculture-based sample preparation. *Int J Infect Dis* 2015; **35**: 43-5.
765. Rychert J, Slechta ES, Barker AP, et al. Multicenter Evaluation of the Vitek MS v3.0 System for the Identification of Filamentous Fungi. *J Clin Microbiol* 2018; **56**(2).
766. Schrodler W, Heydel T, Schwartze VU, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. *J Clin Microbiol* 2012; **50**(2): 419-27.
767. Schulthess B, Ledermann R, Mouttet F, et al. Use of the Bruker MALDI Biotyper for identification of molds in the clinical mycology laboratory. *J Clin Microbiol* 2014; **52**(8): 2797-803.
768. Shao J, Wan Z, Li R, Yu J. Species Identification and Delineation of Pathogenic Mucorales by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. *J Clin Microbiol* 2018; **56**(4).
769. Chakrabarti A, Ghosh A, Prasad GS, et al. *Apophysomyces elegans*: an Emerging Zygomycete in India. *Journal of Clinical Microbiology* 2003; **41**(2): 783-8.
770. Sanguinetti M, Posteraro B. Identification of Molds by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. *J Clin Microbiol* 2017; **55**(2): 369-79.

771. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. *Am J Transplant* 2006; **6**(10): 2365-74.
772. Busca A, Marmont F, Locatelli F, et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. *Mycoses* 2010; **53**(3): 275-8.
773. Clark FL, Batra RS, Gladstone HB. Mohs micrographic surgery as an alternative treatment method for cutaneous mucormycosis. *Dermatol Surg* 2003; **29**(8): 882-5.
774. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. *Antimicrob Agents Chemother* 2006; **50**(1): 126-33.
775. Li KW, Wen TF, Li GD. Hepatic mucormycosis mimicking hilar cholangiocarcinoma: a case report and literature review. *World J Gastroenterol* 2010; **16**(8): 1039-42.
776. Schlebusch S, Looke DF. Intraabdominal zygomycosis caused by *Syncephalastrum racemosum* infection successfully treated with partial surgical debridement and high-dose amphotericin B lipid complex. *J Clin Microbiol* 2005; **43**(11): 5825-7.
777. Su H, Thompson GR, 3rd, Cohen SH. Hepatic mucormycosis with abscess formation. *Diagn Microbiol Infect Dis* 2012; **73**(2): 192-4.
778. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. *Ann Thorac Surg* 1994; **57**(4): 1044-50.
779. Vironneau P, Kania R, Morizot G, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. *Clin Microbiol Infect* 2014; **20**(5): O336-9.
780. Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. *Pediatr Infect Dis J* 2007; **26**(8): 723-7.
781. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. *Indian J Ophthalmol* 2003; **51**(3): 231-6.
782. Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. *Transplantation* 2010; **90**(1): 85-92.
783. Sun HY, Aguado JM, Bonatti H, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. *Am J Transplant* 2009; **9**(9): 2166-71.
784. Bonifaz A, Tirado-Sánchez A, Calderón L, Ponce RM. Cutaneous Mucormycosis: Mycological, Clinical, and Therapeutic Aspects. *Current Fungal Infection Reports* 2015; **9**(4): 229-37.
785. Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. *Postgrad Med J* 2004; **80**(949): 670-4.
786. Gurevich M, Levi I, Steinberg R, et al. Mucormycosis in a liver allograft: salvage re-transplantation and targeted immunosuppressive management. *Transpl Infect Dis* 2012; **14**(5): E97-101.
787. Chen X, Liu L, Nie W, et al. Vacuum Sealing Drainage Therapy for Refractory Infectious Wound on 16 Renal Transplant Recipients. *Transplant Proc* 2018; **50**(8): 2479-84.
788. Chander J, Singla N, Kaur M, et al. Saksena erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections - a study from a tertiary care hospital in north India(). *Infect Dis (Lond)* 2017; **49**(3): 170-7.
789. Wollstein R, Palekar A. Mucormycosis infection following intravenous access in the forearm. *Can J Plast Surg* 2010; **18**(2): e30-2.
790. Soman R, Gupta N, Sohanlal T, et al. Insect Bite Causing Mucormycosis - Report of Two Cases. *JIMSA* 2010; **23**(1): 57-8.
791. Moran SL, Ford KS, Wulf CA, Cooney WP. Outcomes of dorsal capsulodesis and tenodesis for treatment of scapholunate instability. *J Hand Surg Am* 2006; **31**(9): 1438-46.
792. Ayala-Gaytan JJ, Petersen-Morfin S, Guajardo-Lara CE, Barbosa-Quintana A, Morfin-Otero R, Rodriguez-Noriega E. Cutaneous zygomycosis in immunocompetent patients in Mexico. *Mycoses* 2010; **53**(6): 538-40.
793. Ingram PR, Suthanathan AE, Rajan R, et al. Cutaneous mucormycosis and motor vehicle accidents: Findings from an Australian case series. *Med Mycol* 2014; **52**(8): 819-25.
794. Patino JF, Castro D. Necrotizing lesions of soft tissues: a review. *World J Surg* 1991; **15**(2): 235-9.
795. Rodriguez CJ, Tribble DR, Malone DL, et al. Treatment of Suspected Invasive Fungal Infection in War Wounds. *Mil Med* 2018; **183**(suppl_2): 142-6.
796. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; **356**(4): 348-59.
797. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007; **356**(4): 335-47.

798. Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. *Clin Infect Dis* 2017; **64**(11): 1619-21.
799. Cho SY, Lee DG, Choi SM, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. *Mycoses* 2015; **58**(9): 565-71.
800. Lerolle N, Raffoux E, Socie G, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. *Clin Microbiol Infect* 2014; **20**(11): O952-9.
801. Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. *Clin Infect Dis* 2012; **55**(11): 1515-21.
802. Duarte RF, Lopez-Jimenez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. *Antimicrob Agents Chemother* 2014; **58**(10): 5758-65.
803. Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. *J Antimicrob Chemother* 2016; **71**(6): 1747.
804. Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. *J Antimicrob Chemother* 2017; **72**(12): 3501.
805. Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. *Antimicrob Agents Chemother* 2014; **58**(7): 3610-7.
806. Cornely OA, Helfgott D, Langston A, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. *Antimicrob Agents Chemother* 2012; **56**(5): 2652-8.
807. Chin A, Pergam SA, Fredricks DN, Hoofnagle AN, Baker KK, Jain R. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections. *Antimicrob Agents Chemother* 2017; **61**(10).
808. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis* 2016; **16**(7): 828-37.
809. Nosari A, Ravini M, Cairoli R, et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. *Bone Marrow Transplant* 2007; **39**(10): 631-5.
810. Hoover M, Morgan ER, Kletzel M. Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. *Med Pediatr Oncol* 1997; **28**(4): 268-73.
811. Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. *Clin Infect Dis* 2018; **67**(10): 1610-3.
812. Gebremariam T, Alkhazraji S, Baldin C, Kovanda L, Wiederhold NP, Ibrahim AS. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. *Antimicrob Agents Chemother* 2017; **61**(5).
813. Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. *J Antimicrob Chemother* 2017; **72**(8): 2359-67.
814. Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. *Drugs* 2011; **71**(18): 2405-19.
815. Wu X, Clancy CJ, Rivosecchi RM, et al. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. *Antimicrob Agents Chemother* 2018; **62**(12).
816. Rivosecchi R, Clancy C, Shields R, Falcione B, Humar A, Nguyen M-H. Isavuconazole prophylaxis among solid organ transplant recipients: effectiveness and drug interaction with tacrolimus. ECCMID. Vienna, Austria; 2017.
817. Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. *Antimicrob Agents Chemother* 2011; **55**(3): 1308-11.
818. Walsh TJ, Tepler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. *N Engl J Med* 2004; **351**(14): 1391-402.
819. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. *Clin Infect Dis* 2008; **47**(4): 503-9.

820. Abidi MZ, Sohail MR, Cummins N, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. *Mycoses* 2014; **57**(11): 687-98.
821. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. *Clin Microbiol Infect* 2016; **22**(9): 811 e1- e8.
822. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Jr., Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. *Antimicrob Agents Chemother* 2008; **52**(4): 1556-8.
823. Jenks JD, Reed SL, Seidel D, et al. Rare Mold Infections Caused by Mucorales, Lomentospora Prolificans and Fusarium, San Diego: The Role of Antifungal Combination Therapy. *Int J Antimicrob Agents* 2018; **52**(5): 706-12.
824. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clin Infect Dis* 2007; **44**(10): 1289-97.
825. Lantermier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. *J Antimicrob Chemother* 2015; **70**(11): 3116-23.
826. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. *Clin Infect Dis* 1998; **26**(6): 1383-96.
827. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. *Infect Med* 2003; **20**: 201–6.
828. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clin Infect Dis* 2006; **42**(7): e61-5.
829. Vehreschild JJ, Birtel A, Vehreschild MJ, et al. Mucormycosis treated with posaconazole: review of 96 case reports. *Crit Rev Microbiol* 2013; **39**(3): 310-24.
830. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE, Jr., Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. *Antimicrob Agents Chemother* 2009; **53**(2): 772-5.
831. Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. *Haematologica* 2013; **98**(10): e127-30.
832. DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. *Mycoses* 2019; **62**(1): 81-6.
833. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. *Eur J Clin Microbiol Infect Dis* 2001; **20**(7): 460-6.
834. Kim JH, Benefield RJ, Ditolla K. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection. *Mycoses* 2016; **59**(11): 726-33.
835. Andrey DO, Kaiser L, Emonet S, Erard V, Chalandon Y, van Delden C. Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient. *Int J Infect Dis* 2017; **55**: 24-6.
836. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. *Antimicrob Agents Chemother* 2012; **56**(6): 2806-13.
837. Lewis RE, Albert ND, Kontoyiannis DP. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. *Antimicrob Agents Chemother* 2014; **58**(11): 6767-72.
838. Tverdek FP, Heo ST, Aitken SL, Granwehr B, Kontoyiannis DP. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. *Antimicrob Agents Chemother* 2017; **61**(8).
839. Mahmood M, Abu Saleh O, Sohail MR. Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels. *Antimicrob Agents Chemother* 2017; **61**(4).
840. Desai AV, Kovanda LL, Hope WW, et al. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. *Antimicrob Agents Chemother* 2017; **61**(12).
841. Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ. Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. *Antimicrob Agents Chemother* 2018; **62**(7).
842. Haidar G, Clancy CJ, Shields RK, Nguyen MH. Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. *IDWeek*. San Diego, CA; 2017.

843. Jeong W, Snell GI, Levvey BJ, et al. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. *J Antimicrob Chemother* 2018; **73**(3): 748-56.
844. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. *Clin Microbiol Rev* 2014; **27**(1): 68-88.
845. Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of Invasive Fungal Disease in Children. *J Pediatric Infect Dis Soc* 2017; **6**(Suppl 1): S3-s11.
846. Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. *BMC Infect Dis* 2016; **16**(1): 667.
847. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. *Clin Microbiol Infect* 2009; **15** (Suppl 5): 50-4.
848. Wattier RL, Dvorak CC, Hoffman JA, et al. A Prospective, International Cohort Study of Invasive Mold Infections in Children. *J Pediatric Infect Dis Soc* 2015; **4**(4): 313-22.
849. Prasad PA, Vaughan AM, Zaoutis TE. Trends in zygomycosis in children. *Mycoses* 2012; **55**(4): 352-6.
850. Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of Invasive Fungal Disease in Children. *J Pediatric Infect Dis Soc* 2017; **6**(suppl_1): S3-s11.
851. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK, Jr., Walsh TJ. Zygomycosis in neonates: an uncommon but life-threatening infection. *Am J Perinatol* 2009; **26**(8): 565-73.
852. King J, Pana ZD, Lehrnbecher T, Steinbach WJ, Warris A. Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. *J Pediatric Infect Dis Soc* 2017; **6**(suppl_1): S12-S21.
853. Dabritz J, Attarbaschi A, Tintelnot K, et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. *Mycoses* 2011; **54**(6): e785-8.
854. Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. *J Pediatr Hematol Oncol* 2009; **31**(12): 911-9.
855. Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). *Clin Microbiol Infect* 2012; **18**(10): E396-400.
856. Ardeshirpour F, Bohm LA, Belani KK, Sencer SF, Lander TA, Sidman JD. Surgery for pediatric invasive fungal sinonasal disease. *Laryngoscope* 2014; **124**(4): 1008-12.
857. Groll AH, Giri N, Petratis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental *Candida albicans* infection of the central nervous system. *J Infect Dis* 2000; **182**(1): 274-82.
858. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. *Eur J Clin Microbiol Infect Dis* 2003; **22**(10): 603-7.
859. Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. *J Antimicrob Chemother* 2009; **64**(2): 383-7.
860. Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. *Med Mycol* 2010; **48**(3): 511-7.
861. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. *Pediatr Infect Dis J* 1999; **18**(8): 702-8.
862. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. *Pediatr Infect Dis J* 2005; **24**(2): 167-74.
863. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. *Antimicrob Agents Chemother* 2005; **49**(12): 5092-8.
864. Chiou CC, Walsh TJ, Groll AH. Clinical pharmacology of antifungal agents in pediatric patients. *Expert Opin Pharmacother* 2007; **8**(15): 2465-89.
865. Lestner J, McEntee L, Johnson A, et al. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. *Antimicrob Agents Chemother* 2017; **61**(6).
866. Seibel NL, Shad AT, Bekersky I, et al. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. *Antimicrob Agents Chemother* 2017; **61**(2).
867. Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. *Antimicrob Agents Chemother* 2006; **50**(3): 935-42.
868. Doring M, Muller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. *BMC Infect Dis* 2012; **12**: 263.

869. Heinz WJ, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. *Med Mycol* 2016; **54**(2): 128-37.
870. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. *Antimicrob Agents Chemother* 2007; **51**(3): 812-8.
871. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. *Eur J Clin Microbiol Infect Dis* 2010; **29**(8): 1043-5.
872. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. *Clin Infect Dis* 2007; **44**(1): 2-12.
873. Welzen ME, Bruggemann RJ, Van Den Berg JM, et al. A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. *Pediatr Infect Dis J* 2011; **30**(9): 794-7.
874. Arrieta A, Sung L, Berthold F, et al. Safety, Tolerability, and Pharmacokinetics of Posaconazole Oral Suspension in Neutropenic Children. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO; 2013.
875. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. *Antimicrob Agents Chemother* 2009; **53**(4): 1450-6.
876. Phulpin-Weibel A, Rivier A, Leblanc T, Bertrand Y, Chastagner P. Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases. *Mycoses* 2013; **56**(3): 236-40.
877. Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. *Antimicrob Agents Chemother* 2009; **53**(3): 869-75.
878. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. *Antimicrob Agents Chemother* 2005; **49**(11): 4536-45.
879. Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. *Pediatr Infect Dis J* 2009; **28**(12): 1132-5.
880. Doring M, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. *Med Mycol* 2017; **55**(4): 375-84.
881. Groll A, Abdel-Azim H, Lehrnbecher T, et al. Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia. IDWeek. San Diego, CA; 2017. p. P827.
882. Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. *Pediatr Infect Dis J* 2016; **35**(2): 183-8.
883. Mesini A, Faraci M, Giardino S, et al. Alternate-day dosing of posaconazole tablets in children leads to efficient plasma levels. *Eur J Haematol* 2018; **101**(1): 127-8.
884. Ibrahim AS, Gebremariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. *J Clin Invest* 2007; **117**(9): 2649-57.
885. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. *J Clin Invest* 1993; **91**(5): 1979-86.
886. Ibrahim AS, Gebremariam T, Lin L, et al. The high affinity iron permease is a key virulence factor required for *Rhizopus oryzae* pathogenesis. *Mol Microbiol* 2010; **77**(3): 587-604.
887. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). *Kidney Int* 1989; **36**(6): 1061-8.
888. Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. *Antimicrob Agents Chemother* 2009; **53**(7): 3122-5.
889. Soman R, Gupta N, Shetty A, Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. *J Antimicrob Chemother* 2012; **67**(3): 783-4.
890. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. *Diabetes* 1982; **31**(12): 1109-14.
891. Zhao Z, Li S, Liu G, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. *PLoS One* 2012; **7**(7): e41641.
892. Calvaruso G, Vitrano A, Di Maggio R, et al. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. *Am J Hematol* 2015; **90**(7): 634-8.
893. Ibrahim AS, Edwards JE, Jr., Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. *J Antimicrob Chemother* 2006; **58**(5): 1070-3.
894. Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. *J Antimicrob Chemother* 2012; **67**(3): 519-20.
895. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. *Int J Clin Pract* 2007.

896. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. *Clin Infect Dis* 2000; **30**(6): 851-6.
897. Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. *Lancet Infect Dis* 2017; **17**(1): 18.
898. Rammaert B, Lanternier F, Poiree S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. *Diabetes Metab* 2012; **38**(3): 193-204.
899. Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. *J Clin Invest* 2010; **120**(6): 1914-24.
900. Gebremariam T, Liu M, Luo G, et al. CoH3 mediates fungal invasion of host cells during mucormycosis. *J Clin Invest* 2014; **124**(1): 237-50.
901. Gebremariam T, Lin L, Liu M, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *J Clin Invest* 2016; **126**(6): 2280-94.
902. Farina C, Marchesi G, Passera M, Diliberto C, Russello G, Favalli A. In vitro activity of Amphotericin B against zygomycetes isolated from deep mycoses: a comparative study between incubation in aerobic and hyperbaric atmosphere. *Med Mycol* 2012; **50**(4): 427-32.
903. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. *Clin Microbiol Infect* 2005; **11**(7): 515-7.
904. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. *Rev Infect Dis* 1988; **10**(3): 551-9.
905. Garcia-Covarrubias L, Barratt DM, Bartlett R, Van Meter K. [Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated in the same institution and review of the literature]. *Rev Invest Clin* 2004; **56**(1): 51-5.
906. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. *Cancer* 2006; **106**(12): 2664-71.
907. Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. *Clin Infect Dis* 2001; **32**(12): e145-50.
908. Schmidt S, Tramsen L, Perkhofer S, et al. Characterization of the cellular immune responses to *Rhizopus oryzae* with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. *J Infect Dis* 2012; **206**(1): 135-9.
909. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. *Lancet* 2003; **362**(9398): 1828-38.
910. Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: New Developments into a Persistently Devastating Infection. *Semin Respir Crit Care Med* 2015; **36**(5): 692-705.
911. Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. *Rev Esp Quimioter* 2013; **26**(2): 173-88.
912. Machicado JD, Younes M, Wolf DS. A rare cause of gastrointestinal bleeding in the intensive care unit. Healthcare-associated mucormycosis. *Gastroenterology* 2014; **146**(4): 911, 1136-7.
913. Poirier P, Nourrisson C, Gibold L, et al. Three cases of cutaneous mucormycosis with *Lichtheimia* spp. (ex *Absidia*/*Mycocladas*) in ICU. Possible cross-transmission in an intensive care unit between 2 cases. *J Mycol Med* 2013; **23**(4): 265-9.
914. Agger WA, Maki DG. Mucormycosis. A complication of critical care. *Arch Intern Med* 1978; **138**(6): 925-7.
915. Sipsas NV, Kontoyiannis DP. Invasive fungal infections in patients with cancer in the Intensive Care Unit. *Int J Antimicrob Agents* 2012; **39**(6): 464-71.
916. Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. *J Antimicrob Chemother* 2017; **72**(suppl_1): i39-i47.
917. Blazquez R, Pinedo A, Cosin J, Miralles P, Lacruz C, Bouza E. Nonsurgical cure of isolated cerebral mucormycosis in an intravenous drug user. *Eur J Clin Microbiol Infect Dis* 1996; **15**(7): 598-9.
918. Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. *Curr Opin Infect Dis* 2016; **29**(4): 340-5.
919. Dayal D, Bakshi J. Early Diagnosis and Surgery is Crucial to Survival Outcome in Rhinocerebral Mucormycosis. *Indian J Otolaryngol Head Neck Surg* 2016; **68**(2): 261-2.
920. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). *Haematologica* 2013; **98**(4): 492-504.
921. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med* 2017; **45**(3): 486-552.

922. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. *N Engl J Med* 2014; **370**(17): 1583-93.
923. Mer M, Schultz MJ, Adhikari NK. Core elements of general supportive care for patients with sepsis and septic shock in resource-limited settings. *Intensive Care Med* 2017; **43**(11): 1690-4.
924. Asfar P, Schortgen F, Boisrame-Helms J, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. *Lancet Respir Med* 2017; **5**(3): 180-90.
925. Girardis M, Busani S, Damiani E, et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. *Jama* 2016; **316**(15): 1583-9.
926. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999; **340**(6): 409-17.
927. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med* 2014; **371**(15): 1381-91.
928. Hanba C, Svider PF, Lai W, et al. An investigation of operative outcomes: Pediatric invasive fungal sinusitis. *Int J Pediatr Otorhinolaryngol* 2017; **102**: 142-7.
929. Bagshaw E, Kuessner D, Posthumus J, et al. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. *Future Microbiol* 2017; **12**: 515-25.
930. Baldin C, Soliman S, Jeon HH, et al. Identification of specific Targets for early Diagnosis of Mucormycosis. 8th Advances Against Aspergillosis. Lisbon, Portugal; 2018.
931. Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. *J Antimicrob Chemother* 2016; **71**(12): 3599-606.